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Resumo  
A asma é um problema de saúde pública com impacto significativo na população 
pediátrica que tem apresentado um crescimento notável ao longo dos anos. O desafio proposto 
para esta tese de doutoramento foi o desenvolvimento de metodologias avançadas para o 
estabelecimento de padrões metabolómicos em urina e ar exalado associados à asma, cuja 
aplicabilidade foi posteriormente explorada para avaliar o estado da doença, a adesão ou 
efeito da terapia e para fins de diagnóstico.  
A composição volátil do ar exalado foi estudada combinando a microextração em fase 
sólida em modo espaço-de-cabeça (HS-SPME) com cromatografia de gás acoplada a 
espectrometria de massa ou com a cromatografia gasosa bidimensional abrangente acoplada à 
espectrometria de massa com analisador de tempo de voo de alta resolução (GC×GC- 
TOFMS). Estas metodologias permitiram identificar centenas de compostos de diferentes 
famílias químicas. A análise multivariada (MVA) permitiu concluir que o perfil 
metabolómico de indivíduos com asma é caracterizado por teores mais elevados de compostos 
associados à peroxidação lipídica, eventualmente associado a stress oxidativo e inflamação 
(alcanos e aldeídos). Com vista a futuras aplicações em contexto clínico, foi definido um 
conjunto de 9 metabolitos, cuja aplicabilidade foi comprovada na monitorização do estado da 
doença e avaliação do efeito e/ou adesão à terapia.  
O metaboloma volátil global de urina também foi explorado usando um método HS-
SPME/GC×GC-TOFMS, tendo sido identificados cerca de 200 compostos. Foi realizada uma 
análise-direccionada usando 78 metabolitos relacionados com a peroxidação lípidica e 
consequentemente com os níveis de stress oxidativo e inflamação. O padrão metabolômico 
não volátil urinária de asma foi estabelecido usando ressonância magnética nuclear de protão 
(1H NMR). Esta análise permitiu identificar vias metabólicas, como o stress oxidativo, 
metabolismo dos amino ácidos e lipídico e alterações da microflora intestinal, alterações no 
ciclo do ácido tricarboxílico, no metabolismo da histidina, acidose láctica, e a modificação de 
resíduos de tirosina livre após a estimulação de eosinófilos. 
Os resultados obtidos permitiram explorar e demonstrar a potencialidade da análise do 
perfil metabolómico do ar exalado e urina na asma. Além do desenvolvimento bem sucedido 
das metodologias de análise, foi possível explorar através do ar exalado e da urina vias 
metabólicas afetadas pela asma observando-se complementaridade entre as matrizes, bem 
como verificar a aplicabilidade clínica dos métodos desenvolvidos. 
Palavras-chave 
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Abstract 
Asthma is a significant health issue in the pediatric population with a noteworthy 
growth over the years. The proposed challenge for this PhD thesis was the development of 
advanced methodologies to establish metabolomic patterns in urine and exhaled breath associated with 
asthma whose applicability was subsequently exploited to evaluate the disease state, the therapy 
adhesion and effect and for diagnostic purposes.  
The volatile composition of exhaled breath was studied combining headspace solid 
phase microextraction (HS-SPME) with gas chromatography coupled to mass spectrometry or 
with comprehensive two-dimensional gas chromatography coupled to mass spectrometry with 
a high resolution time of flight analyzer (GC×GC–ToFMS). These methodologies allowed the 
identification of several hundred compounds from different chemical families. Multivariate 
analysis (MVA) led to the conclusion that the metabolomic profile of asthma individuals is 
characterized by higher levels of compounds associated with lipid peroxidation, possibly 
linked to oxidative stress and inflammation (alkanes and aldehydes) known to play an 
important role in asthma. For future applications in clinical settings a set of nine compounds 
was defined and the clinical applicability was proven in monitoring the disease status and in 
the evaluation of the effect and / or adherence to therapy.  
The global volatile metabolome of urine was also explored using an HS-
SPME/GC×GC–ToFMS method and c.a. 200 compounds were identified. A targeted analysis 
was performed, with 78 compounds related with lipid peroxidation and consequently to 
oxidative stress levels and inflammation. The urinary non-volatile metabolomic pattern of 
asthma was established using proton nuclear magnetic resonance (1H NMR). This analysis 
allowed identifying central metabolic pathways such as oxidative stress, amino acid and lipid 
metabolism, gut microflora alterations, alterations in the tricarboxylic acid (TCA) cycle, 
histidine metabolism, lactic acidosis, and modification of free tyrosine residues after 
eosinophil stimulation. 
The obtained results allowed exploring and demonstrating the potential of analyzing 
the metabolomic profile of exhaled air and urine in asthma. Besides the successful 
development of analysis methodologies, it was possible to explore through exhaled air and 
urine biochemical pathways affected by asthma, observing complementarity between 
matrices, as well as, verify the clinical applicability. 
Keywords 
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1.1 Asthma 
 
1.1.1 Asthma: definition, symptoms and clinical diagnosis 
 
Asthma is a complex chronic disorder of the airways characterized by variable 
and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an 
underlying inflammation1. These characteristics interact and determine the clinical 
manifestations, asthma severity and treatment response. The symptomatology associated 
with asthma is coughing, wheezing, breathlessness and chest tightness that varies from 
person to person in severity and frequency (Figure 1.1). 
 
 
Figure 1.1 – The interaction between airway inflammation and clinical symptoms1. 
  
Asthma severity is divided into four groups: intermittent, persistent-mild, 
persistent-moderate and persistent-severe. Asthma control can also be classified as well, 
not well and poorly controlled2. Both asthma severity and control are assessed by 
criteria, such as symptoms presence, nighttime awakenings, normal activity impairment 
and peak flow among others. Asthma severity classification is highlighted when 
initiating therapy whereas asthma control is emphasized to monitor and change therapy 
as needed. Actually, asthma control is weighted equally with asthma severity to 
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establish the adequate therapy. Nevertheless, asthma severity can change over time and 
therefore continuing care is highly recommended3. 
Asthma complexity leads to an evolving concept. Previously, asthma emphasized 
the duality of allergic asthma and non-allergic asthma. More recently, research in this 
field led to separate into subgroups based upon clinical, physiologic, and pathologic 
characteristics. Thus, an array of phenotypes and endotypes arose. Asthma phenotypes 
include allergic asthma, severe steroid-resistant asthma and asthma induced by exposure 
to air pollution, cigarette smoke, diesel exhaust particles, obesity, aspirin and exercise4. 
Eighty percent of childhood asthma has been reported to be allergic5. The triggers that 
cause allergic asthma are known as allergens. These comprise a large array of 
substances that two important characteristics: (1) they are almost always organic and (2) 
are always harmless to non-allergic individuals. Common sources include animal 
proteins (cat and dog allergens), dust mites, cockroaches, fungi and pollens. 
Asthma symptoms can manifest at any time in life, although many people develop 
asthma as children. In this PhD thesis, the focus was on pediatric asthma. Diagnosing 
asthma in children can be a difficult task to perform differing from pre-school children, 
school-aged children, adolescents and adults in several ways. In early life, asthma is 
quite variable and not fully grasped. Early childhood wheezing and symptoms related to 
asthma are heterogeneous disorders with several phenotypes and variable expressions 
during infancy. Another issue is related to the use of objective lung function tests in 
children, as these procedures poses a challenge for children to perform. Asthma control 
in children is also a complex issue due to the anatomic differences, as for example the 
smaller size of airways and lower inspiratory flow rate, affecting medication deposition 
in the affected airways. In addition to these aspects, there are a number of comorbidities 
that have similar symptoms to the ones caused by asthma, as well as, asthma is also 
associated with other pathologies such as rhinitis, hay fever, atopic eczema and 
rhinosinusitis. These comorbidities have a role in asthma clinical expressions and are 
documented to influence asthma management and control6. 
In children younger than 6 years old, lung function tests lack accuracy and the 
physician relies on the information that the parents and even the child give. The 
diagnosis may be in a halt until months have passed of symptom observation. Children 
younger than age 3 that have asthma symptoms the physician doctor may use a wait-
and-see approach as the effects of medication are still not clear. In children 6 years old 
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and older, pulmonary function tests are performed: auscultation, spirometry and 
bronchodilator response test1. 
Spirometry is a relatively simple and non-invasive method to measure the full 
lung inflation air volume and flow using forced manoeuvres7. It plays an important role 
in diagnosis and managing respiratory diseases; nevertheless there is no standard 
reference tests to accurate determine the sensitivity or specificity of spirometry to 
establish airflow limitation8. Gender, age, height, weight and ethnic group are factors 
that influence the obtained values9. The volume of air exhaled forcefully in 1 second is 
denominated forced expiratory volume 1 (FEV1) and the forced vital capacity (FVC) is 
the volume that can be maximally forcefully exhaled, so FVC contains FEV1. To detect 
an obstruction the ratio FEV1/FVC has to be lower than 0.7 and FEV1 less than 80% of 
the predicted value. FVC is highly dependent on the effort and collaboration of the 
subject and to complete a maneuver subjects must expel air forcefully and completely at 
least three times. This is extremely difficult for elderly subjects, children and those with 
severe airflow limitation. Another disadvantage in spirometry is that it is not 
recommended for asymptomatic individuals, being used for those with respiratory 
symptoms and there is no benefit in using spirometry to monitor disease status. This 
limitation leads to underdiagnosis in younger subjects and overdiagnosis in elderly 
subjects, which leads to false positives and false-negatives depending on age10.  
The determination of nitric oxide (NO) levels in exhaled breath is also an 
available tool that may complement asthma diagnosis. NO induced by inflammatory 
mediators in the airways are reportedly increased in asthmatic patients11. Several reports 
have been published to demonstrate its clinical value. NO is produced when L-arginine 
is catalyzed by nitric oxide synthases (NOS) into L-citrulline12. NO can be measured 
online allowing the evaluation with a real-time display. In the offline mode exhaled 
breath is collected into containers for posterior analysis. NO values are affected by 
several factors such as age, race, gender, atopy, diet, nasal NO contamination, 
measurement techniques, exhalation flow rate, among others. Although a connection 
between NO levels and eosinophils in blood, bronchoalveolar lavage fluid (BALF), 
sputum, and bronchial biopsies may correlate to eosinophilic inflammation, there are 
confounders that might result in higher eosinophilic content. Other pathologies that 
cause inflammation other than asthma, as atopic eczema reported by Zinelli and co-
authors13, increase the levels of NO found in exhaled breath. Recently, Hastie et al.14 
reported that NO levels, among other biomarkers, are poor surrogates in the accurate 
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prediction of sputum eosinophil and neutrophil percentages. The link between NO and 
treatments remain unclear, nevertheless lower values of NO are reported with the 
administration of short acting β-agonists15. Using NO in the clinical practice is still 
debated due to the inconsistencies and due to the large number of factors that can affect 
the outcome. 
Whenever the doctor suspects that asthma is related to allergens evaluation can be 
performed by skin prick tests. This test is performed by pricking the skin with a pin that 
contains a small dosage of the allergen, and if an immune-response arises in the form 
rash or urticaria the conclusion is that the patient has a hypersensitivity to that allergen 
(Figure 1.2).  
 
Figure 1.2 – Skin prick test16 
 
The advantage of this method is the quick interpretation (15-20 minutes) after pricking 
the skin, accompanied with visual indication of the results. Nevertheless, this test is not 
practical with patients with extensive eczema, dermographism, urticaria, and moreover 
cannot be applied in subjects that are consuming anti-histamines or other medications 
that may interfere with the results and lacks procedure worldwide standardization and 
allergen panels17. Although there was a considerable progress in asthma diagnosis, 
management and treatment, in the past years the development of new methods that 
allow standardization, more reliable results, and the follow-up of therapy, to yield better 
asthma controlled status, led to considerable research that take into consideration 
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important parameters such as airway inflammation, instead of symptoms and lung 
function. 
 The invasive method of obtaining samples such as BALF, bronchoscopy or 
bronchial biopsy are normally used to measure airway inflammation and to give more 
detailed information of asthmatic patients. Sputum induction is performed by inhaling 
isotonic or hypertonic solutions by nebulisation to induce airway secretion that can be 
expectorated18. BALF is an important tool in the diagnosis of several lung diseases in 
which a bronchoscope is passed through the mouth or nose into the lungs and a liquid is 
squirted in and collected for examination. The use of lung tissue in asthma is also a 
possibility using samples obtained during the bronchoscopy procedure yielding 
important information on tissue resident cells19. Although these procedures indicate 
airway inflammation more accurately, the invasiveness impairs their regular use in the 
clinical practice creating the necessity to assess the inflammation status in a less 
invasive manner. Blood is a less invasive method than sputum induction and 
bronchoscopy. It can be assumed that it can be used to indirectly measure the state of 
asthma as the inflamed tissue releases chemoatratractants and cytokines, which recruit 
activated immune cells from peripheral blood. Another possibility for atopy evaluation 
is the determination of allergen specific Immunoglobulin E (IgE) from blood samples. 
IgE antibodies are detected and measured by allergen-specific IgE antibody assays. The 
amount of bound allergen-specific IgE is interpolated from a standard calibration curve 
linked to WHO IgE standard20.  
 
1.1.2 Costs, incidence and prevalence 
According to the Global Initiative for Asthma (GINA) it is reported that 300 
million individuals suffer from asthma, and is the most chronic disease among 
children21. Asthma represents a substantial burden on society and is considered an 
important public health issue. Asthma is associated with high direct and indirect costs, 
being between 1-3% of the total medical expenditures in most countries. Around 30 
million people in Europe suffer from asthma22. In Europe, it is projected that these cost 
represent about €18 billion23,24 (Figure 1.3). 
Chapter I - Introduction 
 
6 
 
  
Figure 1.3 – Cost of care for asthma in Europe (data from 2003)24. 
These elevated costs are related to disease severity, poor illness control and 
underdiagnosis (direct costs) in addition to the costs related to time off work or school 
(indirect costs). It can be observed from Figure 1.3 that more than 50% of the costs are 
due the indirect costs of asthma not only of those affected by the pathology but also the 
caregivers. In England, up to 69% of parents had to miss working days due to their child 
asthma and 13% have been reported to quit their jobs25. The direct costs have also 
increased in the primary and secondary care, in addition to hospital admissions and 
treatment costs. The expenses associated with asthma drugs represent about 20% of the 
total costs in Europe25. Asthma, therefore, has a significant socioeconomic impact not 
only on patients, but on the whole family and consequently reducing life quality26.27   
Incidence and prevalence are two important concepts. Incidence is the risk 
evaluation to develop a new condition in a specific period of time whereas prevalence is 
the population portion that has the said condition28. Over the last years, it has been 
observed a striking increase in asthma incidence mainly in the urban areas of developed 
countries. It is thought that urbanization and industrialization are the main contributors 
to this tendency. Developing countries have also shown signals in following this 
pathway. Nevertheless, globally in the past 5-10 years data suggests stabilization of 
asthma incidence29. Asthma prevalence, despite of hundreds of reports, is difficult to 
determine as there is a lack of a precise and well-defined definition of asthma that 
makes the comparison of reported prevalence rather difficult30 (Figure 1.4). Globally the 
prevalence of asthma for different countries varied between 1 and 18%31 accordingly to 
the data listed in 2012 GINA report.  
Outpatient 
care €3.8 
Billion
Drugs € 3.6 
Billion
Inpatient care 
€0.5 Billion
Productivity 
Losses €9.8 
Billion
 Figure 1.4 
There is a sharp increase in global prevalence over the last 40 years, increasing by 
50% each decade.  The data from hospitalization due to asthma reflects an increase in 
asthma severity and poor disease management, especially in young children
In Portugal, the latest asthma 
Portuguese population has asthma currently whilst 10.5% had lifetime asthma
this, and according to the International Study of Asthma and Allergies in Childhood 
(ISAAC) performed in 4 different Por
Porto),  children between the ages of 6
teenagers (13-14 years old) varied between 9% (in 1995) and 12% (2002)
 
1.1.3 Disease management
After diagnosing asthma a
The control is focused in decreasing the risk of asthma attacks, the impairment, the 
symptoms frequency and intensity and whatever functional restrictions that the patient 
may possess - such as lung function decline
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The control of asthma symptoms can be achieved by either a non-
pharmacological and/or a pharmacological management (Figure 1.5). The non-
pharmacological management can be performed before or after the disease onset being 
designated primary and secondary prophylaxis, respectively. House dust mite, animal 
allergens (dog or cat fur, for example), tobacco smoke, pollen, specific foods (for 
example, eggs or milk) are some examples of triggers if avoided can help in controlling 
asthma symptoms. 
 
 Figure 1.5 – Non-pharmacological and pharmacological asthma management36 
 
Asthma treatment is an intricate pathway involving several steps that aims to 
achieve asthma control (Figure 1.5). The objective is to promote the decrease on 
medication intake to the lowest possible whilst the asthma condition remains stable. 
Nevertheless, treatment is approached in a step wise fashion, i.e., if the asthma severity 
increases the frequency and medications increases or if it diminishes the opposite is 
observed36. Asthma is treated with two types of medicines: controller asthma (long-term 
control) and rescue asthma (quick-relief) medications. Long-term control medicines 
help reduce airway inflammation and prevent asthma symptoms. Quick-relief, or 
"rescue," medicines alleviate asthma symptoms that may flare up. The initial treatment 
will depend on the asthma severity. In case of allergic asthma, many triggers can set off 
or worsen your asthma symptoms.  
The pharmacological management aims to control the disease, which entails 
several parameters to be achieved such as no daytime or nighttime symptoms, no need 
for rescue medications, no exacerbations, normal lung function, no limitation in activity 
and all with minimal medication side effects. Asthma medication can be divided into 
two main classes: medication for long-term control that includes inhaled corticosteroids 
(ICS), leukotriene modifiers (LTMs) and long acting beta2-agonists (LABAs). For quick 
relief of airflow obstruction and symptoms there are available short-acting beta2-
Asthma management
Non-pharmacological Pharmacological
Primary prophylaxis Secondary prophylaxis
CorticosteroidsLeukotriene 
receptor 
antagonist
Inhaled 
anticholinergic
Long-acting
beta2-agonist
Rescue asthma medication Controller asthma medication
Short-acting 
beta2-agonist
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agonists (SABAs), anticholinergics and systemic corticosteroids. ICS are the most 
effective long term control medication for asthma that reduces inflammation in the 
airways and clinically there is a reduction of symptom severity, improvement of asthma 
control, diminished airway hyperresponsiveness, hospitalization reduction and 
prevention of exacerbation, among others. Moreover, ICS suppresses cytokine 
generation and the release of inflammatory mediators37. LTMs are divided into two 
classes: leukotriene-receptor antagonists (LTRA) and leukotriene-receptor inhibitors 
(LTRI). Leukotrienes are potent biochemical mediators that contract airway smooth 
muscle, increase vascular permeability, increase mucus secretions and activate 
inflammatory cells in airways of patients with asthma. LTRA prevents leukotriene 
binding whilst LTRI focus on synthesis inhibition38. As for inhaled LABAs, their 
actions is to relax airway smooth muscle by stimulating beta2-receptors and are used as 
an adjunct to inhaled CCS to provide long-term control of asthma symptoms39. SABAs 
provide quick relief of symptoms relaxing the muscles lining the airway within 5 
minutes, increasing the airflow thus relieving asthma symptoms. Nevertheless, SABAs 
do no control the inflammation. Asthma management is a continuous appreciation of the 
patient’s asthma status as shown in Figure 1.6. 
 
Figure 1.6 – Asthma management continuum40 (ICS- Inhaled Corticosteroid; LABA- long 
acting beta2-agonists; LTRA- Leukotriene Receptor Antagonist). 
Environmental Control
Controlled Uncontrolled
Fast-acting bronchodilator on demand
Inhaled Corticosteroid
Second line: Leukotriene Receptor Antagonist
≥ 12 years: Add LABA
6-11 years: Increase ICS
≥ 12 years: Add LTRA
Prednisone
6-11 years: Add LABA or LTRA
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Allergen-specific immunotherapy (AIT) is a treatment used whenever asthma 
symptoms cannot be controlled by medication and environmental control, who cannot 
tolerate the medication, or do not comply with the medication regimen. AIT entails the 
administration of allergen extracts to provoke clinical and immunologic tolerance to the 
allergen. AIT can be administered subcutaneously or sublingually. This therapy 
stimulates desensitization and allergen specific tolerance in addition to the inhibition of 
allergic inflammation in affected tissues41. Several disadvantages limits a broader 
applicability, as for example, unwanted secondary effects, and poor efficacy/specificity 
that are mainly related to a poor quality of natural allergen extracts and the treatment 
takes several years42. 
For those suffering from the severe type of asthma and that have allergies 
Omalizumab® can be considered. This drug is a humanized, monoclonal anti-IgE 
antibody that stops the allergy cascade by binding to the circulating IgE. This 
medication is subcutaneously injected every 2 to 4 weeks usually related to the total IgE 
levels. This therapy is used whenever in patients 6 years of age or older with severe, 
persistent allergic asthma and elevated serum IgE levels whose symptoms cannot be 
controlled with ICS. This drug lowers the IgE levels regardless allergen specificity 
preventing free IgE from interacting with mast cells, basophils, macrophages, dendritic 
cells, among other cells43. 
 
 1.1.4 Asthma Pathophysiology 
Sensitization to the allergen has to occur in order for an individual to develop 
allergic asthma. This process can happen years before any clinical symptoms begin. 
Allergic sensitization is the result of a intricate interaction between the allergen and the 
host. After the allergen has been inhaled antigen-presenting cells as dendritic cells, 
which are present in ephithelium lining of the airways and nose, internalise, process and 
expresses the allergen on their surface. Afterward, the allergens are presented to 
immune response cells as T-lymphocytes that differentiate into T-helper (Th) 2-type 
cells. The activation of these cells produce inflammatory cytokines and consequently 
allergen-specific B-cells propagate and IgE-antibodies that are able of binding to a 
particular allergen are produced. Allergen-specific antibodies are produced whenever 
stimulation occurs by different allergens. IgE then connects to high affinity receptors on 
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mast cells so that the allergen specific receptor site is potentially accessible for the 
allergen. The process is completed with the production of allergen specific IgE-
antibodies (Figure 1.7).  
 
 Figure 1.7 – Allergic asthma pathophysiology representation of sensitization and re-
exposure44(CD- Cluster of Differentiation; IL- Interleukin; TCR- T-cell receptor ).  
 
Allergen re-exposure makes the immune system react more agressively and in a 
rapid memory response way. The allergen connects to the allergen-specific IgE on mast 
cells that leads to the release of the previously formed mediators. Whenever a sufficient 
number of mast cell/basophil- bound IgE antibodies are bound to the allergen cell 
degranulation occurs, leading to the release of inflammation mediators such as 
histamine chemokines, lymphokines, eicosanoids, proinflammatory cytokines and 
growth factors is initiated in an intra-cellular signalling process. The TH2 lymphocyte is 
very important in asthma pathogenesis as it produces cytokines involved in the initiation 
and maintenance of the inflammation cascade. Cytokines, such as interleukin (IL) 3, 
granulocyte macrophage colony-stimulating factor (GMC-SF) and IL-5, play a critical 
role in the differentiation, proliferation, survival and activation of eosinophils45. 
Eosinophils secret cytotoxic granule proteins and produce lipid-derived pro-
inflammatory mediators such as leukotriene C4 (LTC4), mediate the damage to the 
airway epithelium46. IL-3 and to a lesser extent IL-4, are critical in the development of 
mast cells47, which play a prominent role in the acute-phase response. IL-4 and IL-13 
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are required for isotype switch to IgE. IL-1 and tumor necrosis factor alpha (TNF-α) are 
potent pro-inflammatory cytokines that are involved in the upregulation of adhesion 
molecules on vascular endothelium, an essential step in the migration of leukocytes to 
sites of inflammation48. 
The response of the immune system is usually split in two phases: early and late 
phase reaction. Early phase reaction is the immediate hypersensitivity where the 
chemical mediators, as histamine, prostaglandins, leukotrienes and thromboxane, are 
released by mast cells producing characteristic allergic reaction responses.  Some 
examples are edema, mucus secretion and sneezing in the respiratory tract, vasodilation 
in the nose and bronchoconstriction in the lung that leads to wheezing. In the late phase 
reaction, that usually occurs 4-6 hours after the early phase reaction, the continued 
allergic response leads to cellular infiltration, fibrin deposition and tissue destruction. 
This reaction increases bronchial reactivity, edema and  extra inflammatory cell 
recruitment. Eosinophils, T lymphocytes and macrophages, as well as, the epithelial, 
endothelial and smooth muscle cells support the airway inflammation chronic 
symptoms. These cells are also thought to play an important role in the formaiton of 
inflammatory mediators like chemokines, cytokines, and leukotrienes44. IgE plays an 
important tole in the response that the immune systems yields to allergens as it triggers 
mas cell mediator release that directs to early and late phase reactions49. 
The role of oxidative stress in asthma pathogenesis is still in debate. Oxidative 
sress is observed on asthma patients and it may be derived from the inflammation or it 
may a contributory factor to asthma pathogenesis as several reports have been made on 
the role of oxidative stress in the immulogic diseases. ROS act as transfer stimulating 
signals as a critical intracellular second menssenger modulating immune responses. 
Oxidative stress increases airway inflammation as it induces pro-inflammatory 
mediators, which in its turn enhaces bronchial hyperresponsiveness, stimulates 
bronchspasm and increases mucus secretion. In fact, intracellular ROS, whenever 
NADPH oxidase activity occurs, increases temporarily in many types of cellular stimuli 
that include antigens, infections, chemical mediators and growth factors50,51. 
 
 
Asthma metabolic disorders 
Asthma produces alterations on a person’s physiology and hypothetically the 
metabolic profile of an asthmatic is different from a healthy individual. Therefore, the 
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metabolic signature would be different for differentiated conditions52. The asthma 
complexity is reflected in the myriad of biochemical pathways involved, as shown in 
Figure 1.8.  
 
 Figure 1.8 – Main altered biochemical pathways in asthma53. 
Compounds and the inherent metabolic pathways have been identified, such as 
oxidative stress (that damages lipids, proteins and DNA), lactic acidosis, tricarboxylic 
acid (TCA) cycle, the amino acids and energy metabolisms.   
Oxidative stress and lipid peroxidation (LPO) is a lipid metabolism dysfucntion 
54
 and asthma is characterized by sistemic and localized oxidative stress and subsequent 
LPO. Inflammatory cells (activated eosinophils, neutrophils, macrophages and 
monocytes) and epithelial/smooth muscle cells can generate reactive oxygen species50. 
Free radicals reactive oxygen species (ROS) and reactive nitrogen species (RNS) are 
generated in the body by various endogenous systems, exposure to different 
physiochemical conditions or pathological states. A free radical can behave as an 
oxidant or reductant as they can accept or donate an electron from other molecules. 
Table 1.1 shows the three phases of the LPO mechanism 
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Table 1.1 - LPO mechanism phases 
Phase Description 
1 Initiation: formation of free radicals 
2 Propagation: free radical chain reactions 
3 Termination: formation of non radical products 
 
The initiation can begin in a single event that can convert hundreds of fatty acids 
into lipid hydroperoxides. The length of the propagation depends on many factors as the 
lipid-protein ratio, the fatty acid composition, oxygen concentration and the presence of 
antioxidants within the membrane that might interrupt the chain reaction55. Propagation 
takes place by the reaction of lipid radical with a methylene group of a non-oxidized 
unsaturated fatty acid molecule to yield another lipid hydroperoxide and another fatty 
acid radical, which can react with oxygen to start a chain reaction56. These reactions 
occur until termination that occurs when there is a combination of two radicals forming 
a non radical product or by the presence of hydrogen or electron donor57.  Some 
examples of important oxygen-containing free radicals in several disease states are for 
example superoxide anion, hydroxyl, hydrogen peroxide and peroxynitrite. Free radical 
formation occurs continuously in the cells as a consequence of both enzymatic and non-
enzymatic reactions. Figure 1.9 shows the link of allergens and ROS in asthma. 
 
 Figure 1.9 – Allergens and reactive oxygen species linked in asthma58 (DEP- Diesel Exhaust 
Particles; GM-CSF- granulocyte macrophage colony-stimulating factor; MCP- Monocyte chemotactic 
protein; TNFα- tumor necrosis factor alpha). 
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If an imbalance between the free radicals and the antioxidant defenses is 
observed, a condition known as oxidative stress arises. Free radicals alter lipids, 
proteins and DNA and are known to generate a number of human diseases. Oxidative 
stress is thought to have a role in the development of human diseases such as cancer, 
cardiovascular disorders and immunologic diseases59.  
Lipid metabolism is also affected by asthma pathology as shown in the reports 
by Ho53, Saude et al.77 and Jung et al.81 (Table 1.2). Lipid metabolism has shown to 
contribute to asthma pathophysiology in childhood60.  
Table 1.2 - Lipid Metabolism related compounds by Nuclear Magnetic Ressonance 
Author Compound ↑ Biofluid 
Jung et al.81 
methionine Asthma 
Serum 
choline Healthy 
Saude et al.77 
carninitine Asthma 
Urine 
O-acetylcarnitine Asthma 
 
The latter author has demonstrated that there is a strong and direct influence of 
metabolic pathways on the immune mechanisms. Saude et al.77 has described that the 
urinary levels of carnitine are high in asthma patients with unstable status. This 
compound has a role in oxidative metabolism in mitochondrial and hypoxemic stress. 
The identified compounds in lipid metabolism pathways are identified in Table 1.1. 
Oxidative stress has been proven to affect smooth muscle contraction, induce 
airway hyperresponsiveness and increase mucus secretion and epithelial shedding 
within respiratory cells. Excessive ROS production in asthma can trigger key enzymatic 
and non-enzymatic reactions, leading to an antioxidant-oxidant imbalance in respiratory 
airways which promotes state of oxidative stress in asthma61. 
There is evidence that free radicals are influential components of the molecular 
mechanisms involved in the pathogenesis of asthma, namely airway inflammation, and 
determinant of asthma severity61. Inflammatory cells and resident cells (epithelial and 
smooth muscle cells) can generate ROS that can attack proteins to form carbonyls and 
react with nitrogen species and tyrosine to form nitrotyrosine. It has been shown that 
nitrotyrosine formation is increased after allergen exposure50. ROS also reacts with 
lipids to release isoprostane. 8-isoprostane has been reported to be elevated in the 
exhaled breath condensate of asthma patients62. ROS excess production also correlates 
with airway hyperresponsiveness, as for example, in the immediate formation of O2- 
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when an asthma attack occurs being high at the sites of antigen challenge that persists 
through the late asthmatic phase63. NO also plays an important role in asthma. There is 
evidence that the autoxidation of NO results in nitrite, which is a substrate for 
eosinophil peroxidase and myeloperoxidase64. NO reacts with superoxide that yields 
ONOO- and consequently can nitrate tyrosine residues and damage enzymes, structural 
and functional proteins65. ROS production by neutrophils also correlates with asthma 
severity as demonstrated by the levels of 3-bromotyrosine, a product of eosinophil 
peroxidase and eosinophil, which was 3 times higher in the bronchoalveolar lavage fluid 
in individuals with asthma when compared with control subjects66. 
Beside the previously identified compounds, volatile organic compounds 
(VOCs) have also been associated with asthma (Figure 1.10).  
 
Figure 1.10 – Secondary products formation in LPO (ALEs - advanced lipoxidation end products)67. 
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VOCs are generated during pulmonary physiologic and pathologic processes, 
such as LPO and inflammation68. The production of secondary compounds constitutes a 
minor degradation pathway and they comprise an array of chemical families, from 
aldehydes, ketones and alkanes with the latter being more stable not reacting with 
proteins. Dallinga et al.69 and Ibrahim et al.70 have reported C13 alkanes in the 
characterization of asthmatic population through exhaled breath (Table 1.3). Although 
the mechanism by which these alkanes are formed (namely, ramified alkanes) is still not 
well understood there are been reports on the volatile composition of lung cancer cell 
lines where these metabolites have an important role71. 
 
Table 1.3 - Oxidative stress and LPO secondary compounds in asthma studies analysing exhaled breath 
by GC-MS 
Author Compound 
Dallinga et al.69  
(branched) hydrocarbon (C13H28) 
(branched) hydrocarbon (C13H28) 
unsaturated hydrocarbon (C15H26) 
(branched) hydrocarbon (C11H24) 
Ibrahim et al.70 2,6,11-trimethyl-dodecane 
(branched) hydrocarbon (C13H28) 
 
Increased ROS is known to damage DNA, lipids, proteins and carbohydrates 
affecting cellular functions and increase inflammation (Figure 1.11). 
 
Figure 1.11  – Possibilities of the damage caused by ROS 72. 
 
The oxidative damage to DNA is known to affect nuclear or mitochondrial DNA 
leading to mutation, gene expression changes73. For example, it has been shown that 
hydrogen peroxide induces DNA strand breaks in airway epithelial cells that leads to 
modifications in the epithelial cell-specific gene expression74. DNA strand breaks also 
showed to influence type 2 alveolar epithelial cells and shows a relationship to the 
development of lung disease73 (Figure 1.12).  
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Figure 1.12 – Reactive oxygen species damage nuclear and mitochondrial DNA75. 
 
ROS’s protein modification affects their biological function that in several 
occasions are important to initiate and maintain inflammation. An example is the loss of 
antioxidant capacity of the superoxide dismutases known to catalyze superoxide to 
hydrogen peroxide and subsequently to water. Moreover, inflammatory cells can secrete 
enzymes that damages oxidatively the protein by producing reactive brominating, 
chlorinating and nitrogen species76. 
Other metabolic pathways are affected by asthma like the TCA and urea cycles. 
The TCA cycle is the central metabolic hub of the cell, which is the final common 
pathway for the oxidation of amino acids, fatty acids and carbohydrates. It is a 
fundamental metabolic pathway for energy production through aerobic respiration that 
takes place in the mitochondria. Saude et al.77 analyzed human urine from asthmatic 
individuals using proton nuclear magnetic resonance (1H-NMR) and found compounds 
related to the TCA that were critical for the discrimination attained between healthy 
individuals, outpatient asthmatics and even asthmatics from emergency department. Ho 
et al.53 studied in sensitized mice BALF that also identified compounds that are related 
to the TCA cycle.  
Succinate, fumarate, lactate and cis-acotinate concentrations were higher in 
asthmatics when compared to the healthy children whilst threonine and α-oxoglutarate 
levels are higher for the healthy children. Ho et al.53 found increases in malate, lactate 
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and creatinine mice BALF that are energy metabolism related compounds. The behavior 
of these energy-related compounds may be explained by an increased burden and 
subsequent demand of a higher energy intake by the inflammatory cells. Higher levels 
of lactate are a consequence of poor oxygenation (hypoxia), in which the mitochondria 
are unable to produce adenosine triphosphate in a sufficient rate to supply the cell. 
Subsequently, glycolysis is increased and the pyruvate excess is converted in lactate that 
is released to the bloodstream. For example, lactate was also found to be elevated in 
patients with lung cancer78. Malate is a TCA cycle intermediate and there are no reports 
that describe this compound to be altered in asthma or any lung related pathology with 
the exception of Ho et al.53. Nevertheless, other intermediates of the TCA cycle 
succinate, fumarate and cis-aconitate, have been reported by Saude et al.77 to be altered 
in asthmatics which supports the evidence that TCA cycle is affected by this pathology.  
Creatine takes part in the energy supply to muscles, as for example airway smooth 
muscles79 and as shown by Saude et al.77 the levels of this compound is increased in the 
asthmatic patients. This behavior is also attributed to the increased respiratory burden77. 
Creatinine is a downstream compound of creatine, and according to Ho et al.53, it has 
higher values in sensitized mice which corroborate the hypothesis of the promotion of 
energy metabolism, but by the urea cycle. The information is compiled in Table 1.4. 
Pyruvate is an end product of glycolysis and is converted to acetyl CoA involved 
in the TCA cycle80. Pyruvate has been identified in asthmatic sera81, nevertheless there 
is no reference of asthma influencing this particular compound but compounds that arise 
from different pathways have been reported. Lactate levels were increased in the sera of 
asthma patients81, as well as, in urine77. 
Table 1.4 - Energy metabolism affected by asthma 
Author Metabolites ↑ Metabolic 
pathways 
Analytical 
technique 
Biofluid 
Saude et al.77 
α-oxoglutarate Healthy 
TCA Cycle NMR 
Human 
Urine 
 
succinate Asthma 
fumarate Asthma 
threonine Healthy 
lactate Asthma 
cis-conitate Asthma 
Ho et al.53 
malate Asthma TCA Cycle 
GC-MS 
LC-MS 
Mice  
BALF 
lactate Asthma  
creatinine Asthma Urea cycle 
creatine Asthma 
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 Lactate concentration rises whenever lactic acidosis occurs82, that typically 
occurs when cells receives too little oxygen (hypoxia)83 and it is considered as a distinct 
form of metabolic acidosis. Lactic acidosis is more frequent in adult patients with severe 
asthma84, nevertheless it does occur in the pediatric population to a lower extent85. 
Lactate levels are also increased in lung cancer patients, as reported by Rocha et al.78.  
Glucose results from non-carbohydrate carbon substrate, such as pyruvate and lactate86, 
and the concentration of this compound has been reported to be higher in urine of 
asthmatic patients when compared to the healthy control levels77. Nonetheless, in sera 
glucose has decreased levels81, but in this study lactate levels, as previously mentioned, 
are increased which could explain this result. Ho et al.53 has also demonstrated lower 
levels of carbohydrate related compounds (mannose, galactose and arabinose) and 
suggested that these compounds could be used to yield lactate and malate to provide 
extra energy. Formate can also be formed from pyruvate and in serum the concentration 
is lower for asthmatics than in children81, nevertheless in exhaled breath condensate the 
levels of formate are 40% higher in asthmatic samples when compared to children 
considering this result as an indication of the airway S-nitrosothiol depletion87. 
The protein and amino acid metabolisms are reportedly changed by the asthma 
pathology. Ho et al.53 and Saude et al.77 also noticed the alteration in the protein and 
amino acid metabolism and the compounds that supported this hypothesis are shown in 
Table 1.5. 
Table 1.5 - Amino acid metabolism affected by asthma 
Author Metabolites ↑ Analytical 
technique 
Biofluid 
Saude et al.77 
2-hydroxyisobutyrate Asthma 
NMR Human Urine 
3-OH-3-methylglutarate Asthma 
1-methylhistamine Asthma 
tryptophan Asthma 
threonine Healthy 
kynurenine Asthma 
Jung et al.81 methionine Asthma NMR Human sera 
histidine Asthma 
 
 The protein metabolism is a set of biochemical processes (Figure 1.13) that 
comprise the protein and amino acid synthesis, as well as, protein breakdown by 
catabolism. 
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Figure 1.13 – Example of amino acid involvement in other biochemical pathways88 ( AAs – Amino 
Acids; Ala- Alanine; Arg- Arginine; Asp- Aspartic acid; ASA- Argininosuccinate; Cit- Citrulline; Cys-
Cysteine; Ser-Serine; Gly- Glycine; His- Histidine; KGA- α-Ketoglutaric Acid; Leu- Leucine; Ile- 
Isoleucine; Lys- Lysine; Met- Methionine; OAA- Oxaloacetic Acid; Phe – Phenylalanine; Orn- Ornithine; 
Pro- Proline;  Succinyl CoA- Succinyl Coenzyme A; Thr-Threonine; Trp-Tryptophan; Tyr- Tyrosine; 
Val- Valine)  
 
Another reported alteration is related to the histidine metabolism. Histamine is 
formed by decarboxylation reaction catalyzed by the enzyme histidine decarboxylase. 
Jung et al.81 have shown that histidine is elevated in the sera of asthmatic patients 
showing that this biochemical pathway may be influenced by asthma. A downstream 
compound of histamine (Figure 1.14), 1-methylhistamine, was reportedly increased in 
urine of asthmatic patients81. 
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Figure 1.14 - Role of histamine in allergic reaction93. 
Histamine is a known airway constrictor and influences the cells types that play a 
role in immune and inflammatory reactions. In asthmatics BALF, the histamine 
concentration has been shown to be higher89. The release of histamine, during allergic 
reactions, is activated by immunologic and non-immunologic triggers from cytoplasmic 
granules of mast cells and basophils90. Upon antigen challenge, histamine levels 
increase as well as IgE stimulated mast cells. Depending on the location, histamine 
release causes symptoms as acute rhinitis, bronchospasm, and flare responses, among 
others. The majority of acute symptoms in allergic asthma are the result of fast activity 
of histamine on vascular endothelium and bronchial and vascular smooth muscle cells91. 
Histamine elicits such responses as vasodilation, smooth muscle contraction, 
mucus hypersecretion, and edema as part of the immediate-phase allergic reaction92,93. It 
has also a significant immune/pro-inflammatory properties that are mediated by 
numerous cell types, including macrophages, T lymphocytes, epithelial and endothelial 
cells and their products, and other key regulatory molecules94.  
 Kynurenine pathway is a major route for tryptophan catabolism. Tryptophan is a 
precursor of several biochemical pathways, such as kynurenine, serotonin, melatonin 
and protein synthesis95. The kynurenine pathway exists in varying extents in most cell 
types, among them infiltrating macrophages and endothelial cells. The first stable 
intermediate in the tryptophan catabolism is kynurenine. Subsequently, several free-
radical generators can be formed96. The evidence that the kynurenine pathway is 
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important in the immune system regulation has been increasing in the past years97. The 
up-regulation of the kynurenine pathway has been associated to several pathologies, 
which include lung and breast cancer98. Kynurenine was found in higher concentrations 
in asthmatics than in healthy children77. Its concentration was also reported for 
interstitial lung disease to be higher when compared to normal subjects99. 
 Phenylalanine is an essential amino acid and it reportedly has adverse effects on 
asthma100 as phenylketonuria is associated with increased plasma IgE and atopic 
dermatitis101. It has also been associated with the production of tyrosine and 
catecholamines, as for example epinephrine102. Tyrosine residues react with ROS, as 
peroxynitrite to form a stable product nitrotyrosine that reportedly induces 
hyperresponsiveness in airways of guinea pigs, inhibits pulmonary surfactant  and 
damages pulmonary epthilelial cells103. Tyrosine can also be catabolized to fumarate 
and acetoacetate80, which are intermediaries of the TCA cycle  which may be influenced 
by asthma77.  
 Methionine is involved in several processes such as the biosynthesis of cysteine, 
taurine, lecithin, phosphatidylcholine and other phospolipids (Figure 1.15). Methonine 
is reported to be elevated in asthmatic sera81. It has been apparently involved in the 
DNA methylation phenomena104.  
 
Figure 1.15 – Methionine pathway to cysteine and glutathione105 (AMP- Adenosine monophosphate 
SAH- S-adenosyl-homocysteine; SAM- S-adenosyl methionine). 
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 Asthma also affects the leucine metabolism77. 3-Hydroxy-3-methylglutarate, 
which arises from leucine catabolism, is reported to be in higher concentration in 
unstable asthmatics when compared to the levels obtained with healthy children. 3-
Hydroxy-3-methylglutarate converts to 3-hydroxy-3-methylglutaryl-CoA and 
acetoacetate that can be converted to acetyl-CoA which plays a role, for example, in the 
TCA cycle and the urea cycle. This means that 3-hydroxy-3-methylglutarate may have 
an indirect role in these cycles influencing the normal outcome in these metabolic 
pathways. It has also been shown that 3-hydroxy-3-methylglutarate induces lipid and 
protein oxidative damage106.  
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1.2 Metabolomics 
1.2.1 Concept 
Metabolomics is an extensive measurement of the overall compounds in a 
biological system. This allows uncovering a wide range of endogenous and exogenous 
compounds and has a significant role in investigating physiological status, diagnosing 
diseases, pattern discovery for disease characterization and identification of affected 
biochemical pathways due to diseases or treatment. These small compounds play a 
significant part in the biological systems and are candidates to understand disease 
phenotypes107. 
These compounds are downstream products of numerous biochemical processes 
and can be a sensitive measure of an organism’s environment-gene interactions, in the 
identification of disease biomarkers and drug discovery108. The metabolome is 
complementary to transcriptomics and proteomics, nevertheless it has advantages since 
it reflects more closely the activities of the cells at a functional level, and the changes it 
reflects are expected to be amplified relative to the changes in the transcriptome and 
proteome109 (Figure 1.16). 
 
Figure 1.16 – The interactions between the different omics fields110. 
 
The environmental, developmental stimuli and/or genetic mutation can lead to 
alterations in cells, biofluids or even cell media. With these changes, the amount of the 
intermediate pathway metabolites and/or even the terminal metabolites may vary. The 
metabolites typically range from pmol to mmol and all compounds, if possible, should 
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be analyzed in a single analysis. Nevertheless this is unlikely to occur due to 
technological issues and a holistic approach is employed111. This approach, instead of 
identifying and quantifying each compound of the biological fluid, treats the obtained 
spectra as a unique classifiable metabolic fingerprint. With the use of an array of 
statistical tools, the spectral profiles of blood, tissue, urine or exhaled breath are 
classified in specific categories, conditions or disease states. All compounds are looked 
at once and a pattern of compounds may be formed for a determined status of the 
biological system understudy112. 
Figure 1.17 shows the workflow of the main steps involved in the metabolomic 
analysis for this PhD thesis. The experimental metabolomic workflow included the 
selection of the biological material to be studied. Direct analysis would be ideally 
performed; nevertheless it is an infrequent option. It was followed by sample 
preparation and subsequent measurement using the selected analytical chemistry 
methods and instrumentation. The raw data obtained was processed and normalized to 
yield a data matrix for statistical analysis. The compounds that discriminated the groups 
were identified and this information was biochemically interpreted and biological 
insights were achieved113. 
 
Figure 1.17 – Metabolomic analysis workflow (adapted from Zhang et al.114). 
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1.2.2 Analytical techniques in metabolomics: MS or NMR based 
methodologies 
Several analytical techniques are applied to profile the diverse compounds of a 
given biofluid or tissue, which makes metabolomic an interdisciplinary field of science 
that may combine analytical chemistry, NMR115, Fourier transform-infrared 
spectroscopy (FT-IR)116 and MS coupled to separation techniques, including GC-MS117, 
GC×GC-ToFMS118, liquid chromatography-mass spectrometry (LC-MS)119, FT-MS120 
and ultra high pressure liquid chromatography-mass spectrometry (UPLC-MS)121 with 
sophisticated multivariate data analysis107. For a comprehensive metabolome study the 
parallel application of several techniques followed by data integration should be sought 
to have a broader perspective and the most complete information. 
MS techniques, often coupled with other techniques, is extensively used in 
metabolomics offering high selectivity and sensitivity in the identification of several 
metabolites that are known end-products of cellular processes. The combination with 
chromatographic separation due to compound separation on a time dimension reduces 
spectra complexity and offers information on the analytes physicochemical properties. 
GC-MS has been widely used for metabolomics and can provide efficient and 
reproducible results122. The coupling of powerful separation and detection systems 
enables unbiased analysis of thousands of known and unknown compounds that can 
provide novel insights into the biological system under study. It is possible to analyze 
both volatile and nonvolatile compounds after derivatization. The MS electron 
ionization energy of 70 eV yields reproducible mass spectra and highly transferable 
electron ionization MS spectral libraries (as the National Institute of Standards and 
Technologies library) allowing the identification of compounds match to the spectral 
library. Retention indices are another tool useful to confirm compound identification on 
compounds that have similar mass spectra but are separated with chromatography.  
Although GC-MS provides adequate information for a variety of analytical tasks, 
it does not resolve the numerous components present in complex biological samples. 
Technological advances led to development of comprehensive two-dimensional gas 
chromatography (GC×GC). One dimensional GC in most cases provides adequate 
resolution, however does not resolve the numerous components present in biological 
samples118. In GC×GC two capillary columns with different stationary phases are 
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connected through a modulator and this setup increases separation efficiencies and peak 
capacities123. GC×GC has superior resolving power, which is suited for the analysis of 
low-molecular weight analytes in complex samples; sensitivity is enhanced due to 
solute band re-concentration and provides a two-dimensional chromatogram with 
chemically similar compound patterns124. The use of GC×GC coupled with a time of 
flight mass spectrometer (ToFMS) has been used in the analysis of the volatile profile 
for diabetes biomarker discovery125 or in the analysis of specific compounds, as 
reported by Snyder et al.126 for l-β-methylamino-alanine. GC×GC-ToFMS has also been 
applied in the metabolic footprinting of tumorigenic and nontumorigenic uroepithelial 
cells revealing the advantages that this technique presents and the potentiality that it 
demonstrated in the analysis of bladder cancer127. Hartonen et al.128 characterized 
cerebrospinal fluid and serum samples using GC×GC which led to distinct metabolomic 
profiles mainly identifying sugar and amino acid derivatives. 
NMR has been extensively used in providing unbiased information about 
compound profiles as it is a straight forward technique, largely automated and non-
destructive. Extensive research has been performed using NMR because this technique 
allows analyzing the pattern of compounds in a target matrix instead of all individual 
compounds making it a more realist and suitable approach. In addition, it permits the 
identification of primary and secondary compounds. In the NMR spectrum the signals 
are proportional to their molar concentration which makes the direct comparison 
possible, without the need to construct calibration curves for each compound. 
Nevertheless, the NMR application has a major drawback, the low sensitivity. Another 
limitation is the considerable signal overlap in the NMR spectra as it has hundreds of 
overlapping signals that may amper signal identification and accurate peak 
integration129. Nevertheless, several studies have been performed using NMR in a wide 
range of pathologies and have been extensively reviewed such as in HIV-infected 
biofluids130, cancer131, neurological diseases132, cardiac133, paediatric respiratory 
diseases and bronchiolitis134, among others.  
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1.2.3 Metabolomics in asthma 
Asthma is complex with several biochemical pathways affected. Additionally, 
this complexity translates to the clinical practice. Therapy responsiveness is not 
identical for each patient or even consistent in individual patients over time. There is 
considerable variability when it comes to asthma control that can be related to known 
asthma triggers (for example, allergen exposure) or unknown triggers. Nevertheless, a 
non-controlled status asthmaticus is associated to increased levels of airway 
inflammation and the objective measurement of this phenomenon would be of 
significant value in the clinical practice. This knowledge would result in selecting the 
right therapy, adjust medication dose, possibly separate asthma phenotypes and offer an 
objective classification of asthma. Figure 1.18 summarizes what is available in the 
clinical practice and under development.  
 
Figure 1.18 – Asthma biomarkers overview: present and future?135 (ECP- Eosinophil Cationic 
Protein; FeNO- Fractional exhaled nitric oxide;  uLTE- Urinary Leukotriene;) 
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As previously verified, asthma diagnosis and management is based on asthma 
symptoms combined with lung function tests and normally these do not reflect 
accurately airway inflammation136. Bronchoscopy and bronchoalveolar lavage (BAL) 
are the used tests to assess airway inflammation, but are generally too invasive. With 
this in mind, it is necessary to find asthma biomarkers or pattern of biomarkers that deal 
with the issues of identifying clinical asthma phenotypes, optimize diagnosis, guide 
treatment and eventually enlighten the biochemical pathways that are affected by 
asthma.  
 
Exhaled breath 
Exhaled breath is a rich source of information from a molecular point-of-view 
due the thousands compounds that are comprised in this biofluid. Over the past years 
exhaled breath has emerged as a new endpoint yielding useful biomarkers. The 
composition of exhaled breath has been correlated to several disease statuses. Exhaled 
breath has been extensively studied for the cancer (lung, breast, colorectal), asthma, 
cystic fibrosis, chronic pulmonary disease, interstitial lung diseases, among others. The 
identified compounds in exhaled breath have been classified as inorganic compounds 
(carbon dioxide, oxygen and nitric oxide), non-volatile compounds (isoprostanes, 
leukotrienes) and VOCs (hydrocarbons, aldehydes, ketones, sulphur compounds, 
alcohols)137. 
Thomas et al.138 reviewed the potential of exhaled breath condensate (EBC) in 
the diagnosis and evaluation of the inflammation of asthmatic children. Several markers 
are reported such as pH, nitric oxide products, glutathione and aldehydes, hydrogen 
peroxide, eicosanoids, leukotrienes and cytokines. EBC is obtained by cooling using a 
collection device, which allows collecting different respiratory particles, droplets and 
water vapor.  
Murata et al.139, using a cohort of 29 asthmatics and 33 healthy individuals, 
showed that pH had lower levels in the asthma group and that the hydrogen peroxide 
values were elevated. Nevertheless, it was also found out that these values did not 
correlate with the asthma control test scores, the fractional exhaled nitric oxide (FeNo) 
or even with the pulmonary function. Similarly to NO, a single marker is unlikely to 
reflect various pathologies present in a heterogeneous disease such as asthma and 
additional markers of airway inflammation would be necessary.  
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EBC is also composed by other compounds that may be helpful asthma markers 
such as leukotrienes and isoprostanes that are considered inflammation biomarkers. 
Balanzá140 has shown that LTB4, as well as, 8-isoprostane concentrations were 
increased in asthmatic children when compared with healthy individuals and were able 
to differentiate two degrees of asthma severity. EBC methodologies remain 
controversial due to standardization issues and a high intra-individual variability141. 
The measurement of VOCs in exhaled breath is a metabolomic approach to 
study molecular signatures of respiratory disease as it contains a complex mixture of 
potentially thousands of VOCs. These compounds derive from the metabolic processes 
in the airways and the presence and/or concentration of the different compounds may be 
influenced by airway inflammation. It is the least invasive method to obtain information 
about airway inflammation and oxidative stress (Figure 1.19). 
 
Figure 1.19 – Representation of non-invasive to invasive sampling techniques142. 
 
To determine the VOCs, two different methods can be applied: the use of a 
polymer-based gas sensor array (electronic nose) or GC-MS. The electronic nose 
represents a total expired VOC profile in which individual compounds cannot be 
identified and mimics the human nose. Dragonieri et al.143 has shown that an electronic 
nose has the ability to differentiate asthma patients from controls; however 
distinguishing different asthma severity degrees was not possible.  
The use of GC-MS or any related techniques is considered the gold standard in volatile 
analysis and the use of these techniques have been applied in analysis of exhaled breath 
in asthma populations. Recently, the reports of VOCs in asthma have increased and an 
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example is the study made by Gahleitner et al.144 attaining discrimination between 
asthmatic and healthy children using a panel of 8 compounds, namely 1-
(methylsulfanyl)propane, ethylbenzene, 1,4-dichlorobenzene, 4-isopropenyl-1-
methylcyclohexene, 2-octenal, octadecyne, 1-isopropyl-3-methylbenzene and 1,7-
dimethylnaphtalene. Robroeks et al.145 using a pattern of 6 volatile compounds (p-
xylene, 3-methylpentane, 2-ethyl-4-methyl-1-pentanol, an unknown compound, 1-
phenyl-1-butene and 4,6,9-nonadecatriene) were able to predict exacerbations of 
childhood asthma. Ibrahim et al.146 built a model using 15 compounds (2,6,10-
trimethyldodecane, 2,6,11-trimethyldodecane, benzyl alcohol, 3,4-dihydrobenzonitrile, 
2-methyldecane, 1-methyl-4-(1-methylethylidene)cyclohexene, 2,2,-dimethyl-3-oxo 
butanoic acid ethyl ester, 4-nitroso ethylester benzoic acid, 2-butylcyclohexanol, 5,5-
dibutylnonane, 4-ethenyl-1,2-dimethylbenzene, 2,6-bis(1,1-dimethylethyl)-2,5-
cyclohexadiene, 2-butanone, pentadecanal and allyl methyl sulphide)  with an accuracy 
of 86% and were able to classify clinically relevant disease phenotypes. Dallinga et 
al.147 developed a diagnostic tool for asthmatic children with a 92% classification rate 
and relatively high specificity (95%) and sensitivity (89%) with a total of ten 
compounds (two branched hydrocarbons (C13H28), carbon disulphide, 1-penten-2-one, 
butanoic acid, 3-(1-methylethyl)-benzene, an unsaturated hydrocarbon, (C15H26), 
benzoic acid,  p-xylene, and a branched hydrocarbon (C11H24)). 
 
Urine 
Urine is non-invasive, accessible, “informative”, stable body fluid. Bouatra et 
al.108 have compiled the information on the studies that have been performed to identify 
asthma biomarkers using urine as biofluid/matrix. The premise relies in the fact that 
asthma affects the body as a whole and alterations in the metabolism may be reflected in 
urine. 
Cysteinyl leukotrienes (CLTs) are major eicosanoids products released from 
various cells including eosinophils, neutrophils and mast cells. CLT4 and D4 are quickly 
catabolized to LTE4 and this compound appears in urine providing an indication of LTs 
production135.  Misso et al.148 measured LTE4 in urine showing that there was no 
statistical difference between the asthmatics and the controls and it varied widely both 
in the control group, as well as, in the asthmatics. More recently, Balgoma et al. 149 
developed a method using LC-MS/MS to quantify eicosanoid compounds in urine of 
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atopic asthmatics and discovered increases in compounds of prostaglandin D2, CLTs 
and isoprostanes after allergen provocation. 
A study performed by Saude et al.77 using urine of stable and unstable asthmatic 
patients/healthy children and 70 compounds were measured. Multivariate tools were 
used in the discrimination of the tree groups with high classification rates.  The obtained 
results allowed extrapolating some biochemical pathways affected by asthma. 
Mattarucchi et al.150 characterized urine of asthmatic and healthy groups by LC-MS 
attaining discrimination between both groups and identified compounds that are 
supposedly correlated with inflammatory diseases. 
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1.3 Biofluid Analysis: breath and urine 
1.3.1 Methodological aspects of sampling procedures 
Several reports have been made with highly promising results using exhaled 
breath and urine with an assortment of compounds characterizing asthma. Nevertheless, 
the regular use of these discoveries have not been introduced in the clinical practice due 
to technical obstacles such as a sampling, preconcentration and analysis, as well as, 
methodological issues such as normalization and data expression151. A brief discussion 
will be made addressing the studied matrices, exhaled breath and urine. 
 
Exhaled breath 
Exhaled breath is largely composed by nitrogen, oxygen, carbon dioxide, water 
vapor and inert gases. Several hundred volatile compounds of exogenous and 
endogenous sources comprise a small portion of exhaled breath. Exhaled breath 
potential to determine normal or abnormal physiology has been used for centuries 
beginning with Hippocrates. Subjective impressions of exhaled breath odor has been 
used to distinguish uncontrolled diabetes, liver, renal or dental diseases152. In the 
1970’s, Linus Pauling showed that exhaled breath was a complex gas containing more 
than 200 VOCs153. Since then, the identification and quantification of compounds in 
exhaled breath has been gained interest.  
The collection of exhaled breath is one of the most important steps in breath 
analysis (Figure 1.20) and can be made in one of two ways: 
• Mixed expiratory sampling 
• Alveolar sampling 
Mixed expiratory sampling is an easy and commonly used sampling method as it 
only requires spontaneously breathing by the subjects to a collection system and 
requires no additional sampling equipment. In this sampling procedure total breath, 
which included dead space air, is collected and a disadvantage can arise and be 
attributed to inaccuracy as the sample is diluted by dead space air. In order to 
circumvent this disadvantage, a breath capture system can be used, and adding a 
capnograph to the system only alveolar breath can be sampled. 
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Figure 1.20 – Capnograph waveforms with mixed expiratory and alveolar sampling (Phase I- Respiratory 
baseline, Phase II- Expiratory Stroke, Phase III- Expiratory Plateau; PetCO2- partial pressure of end-tidal 
carbon dioxide 
 
The main advantage of sampling alveolar exhaled breath relates to accuracy as the 
sample is not diluted in dead space air, nevertheless the complexity and expenses of the 
collection apparatus are two important disadvantages154. In dead space air no exchange 
is made, comes from the mouth, trachea and bronchioles, and averages about a third of 
the tidal volume. The remaining fraction is denominated alveolar air. Analyzing exhaled 
breath directly would be ideal; however in many situations this is not feasible and breath 
has to be stored in appropriate containers.  
The breath container where exhaled breath is captured into also plays an important 
role in exhaled breath analysis. Breath can be collected into several containers such as 
transparent or black Tedlar® bags (PTFE-polytetrafluoroethylene), BIOVOCS®, 
flexfoil bags PET/NY/AL/CPE-polyethylene terephthalate/nylon/aluminium 
foil/chlorinatedpolyethylene), nalophan bags, thermal desorption tubes, micropacked 
sorbent traps and metal canisters.  The most employed breath container is an inert bag, 
for example Tedlar® or Teflon. The volunteer is asked to breath into the bag that is 
taken to the laboratory for analysis. The ease in which the volunteer performs this task 
and the ability of reusing the container after appropriated cleansing are two big 
advantages. Nevertheless, there are some disadvantages in these bags. There is a risk of 
decomposition/loss of the compounds due to the interaction of sample constituents 
(reactive chemistry of the sample) modifying the sample composition and consequently 
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altering the outcome. Storage is also an important parameter in breath analysis as most 
chemical compounds found in breath are highly reactive and perishable. This 
disadvantage can be overcome by experimentally determine the most adequate bag 
158,155
  or determine how long exhaled breath can be maintained in the container without 
any significant loss156. The use of pre-concentration methods can be applied, as for 
example sorbent traps or solid-phase microextraction (SPME) which can diminish the 
decomposition issues. Stability assays have been performed to determine the 
compounds stability in the polymer bags157,158. Condensation also presents as a problem, 
namely in water-soluble compounds. It has been shown that there are differences 
between dry and wet samples by 10% and this number has risen up to 40% in heavier 
compounds. The volume of breath in the Tedlar® bag is also a parameter of interest as 
it has been shown that smaller volumes may affect the stability of the sample due to 
permeation problems. The actual recommendation by Mochalski and co-authors158 is to 
store breath for a maximum of 6 hours filling the maximum volume of the Tedlar® 
bag159.  
Another issue with polymer bags is related with the possible chemical 
contamination from the bag itself. Appropriate cleaning procedures must be adopted to 
circumvent these issues.  Tedlar® bags often release N,N-dimethylacetamide and 
phenol, septa may release compounds such as carbon disulfide or 3-methylpentane and 
plasticizers from tubings and/or valves may contaminate breath samples. Another 
approach is to collect breath directly to a trapping system avoiding the use of containers 
or even into glass vials or metal canisters, nevertheless this adds complexity to the 
design and also increases the expenses. 
Another issue that has to be addressed in exhaled breath analysis is the 
background contamination and the decision whether the identified compound are 
endogenous or exogenous. To overcome this drawback, room air volatile composition 
can be determined and taken into account as high concentrations of substances that can 
be inspired can impact the concentration of endogenous compounds. Another parameter 
that influences the possible outcomes of exhaled breath is the intra-individual variability 
that represents a possible issue in breath analysis. The intra-individual variability 
represents the variability associated with replicate exhaled breath samples from the 
same subject, and it is verified that natural biological intra-individual variability can be 
expected, as well as, related to diet or lifestyle changes 160,161. 
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Urine 
The primary route of removing water-soluble waste products is urination. Urine 
is a transparent, amber-colored fluid that contains high amounts of urea, inorganic salts, 
creatinine, ammonia, organic acids, various water-soluble toxins and pigmented 
products of hemoglobin breakdown. The kidneys also remove excess water, sugars and 
numerous other compounds.  Currently, urine is analyzed to evaluate urinary glucose, 
bilirubin, ketone bodies, nitrates, leukocyte esterase, specific gravity, hemoglobin, 
urobilinogen and protein. Other more detailed urine analysis can be used to verify renal 
diseases such as bladder, ovarian and kidney diseases. 
The use of urine for medical purposes dates back to ancient Egypt and 
throughout time the examination of color, cloudiness, smell and even taste was used to 
help in the identification of a wide range of diseases. As an important biological fluid, 
urine has been subjected to a detailed chemical analysis over the last 100 years and 
normal reference values have been documented for more than 100 urine ions and 
compounds. In addition to this information, several research groups have studied urine 
using a myriad of technologies and more than 3000 metabolites have been identified.108 
Urine is biofluid collected in a non-invasive way with great information potential to add 
to standardized studies that may be performed. So, there are been several studies that 
analyzed this matrix using an assortment of analytical techniques for several 
pathologies. In asthma, one can argue that urine is not directly linked to the lung tissue, 
yet urine is an integrated biofluid and it can reflect localized and systemic changes; 
nevertheless, this also is a disadvantage as this can difficult the determination of the 
origin of the metabolic changes. Another concern is the possible alteration of the 
compounds excretion by kidney or any liver diseases. 
After weighing the advantages and disadvantages of the matrix itself, strategies 
have to be employed to minimize variability and remove sample bias. A number of 
factors can influence considerably the obtained metabolome and this encompasses 
sampling time, diet, age, environment, exercise, among others.  Beside these factors, 
other parameters may also influence the possible outcome such as collection method, 
collected volume, collection time, processing and storage. Harmonizing urine 
collection, handling and storage is determinant to yield meaningful discoveries and 
outcomes. 
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Urine samples can be obtained in a random fashion, in timed sampling and/or 24-
h sampling. The random sampling can take place at any time of the day but does not 
take into account the excretion variation and usually a correction is necessary, as for 
example the ratio to a compound such as creatinine162. The 24-h sampling is 
burdensome but yields a more complete depiction of the excretion. The recovery of the 
first morning urine is also frequently used163.  
Another methodological issue with urine collection is the type of container used. 
The use of a container designed to facilitate the collection, ensure an optimal transport, 
free of interfering agents and made of non-absorbing materials is also a factor that has 
to be taken into consideration163.The use of high throughput and sensible MS and NMR 
based technology requires just a few microliters to milliliters of urine to proceed to a 
full metabolomic analysis. 
 Urine stability during storage is an important consideration so that it provides 
valid data and reliable information. The effects of freezing urine have been performed: 
at -80ºC immediately or stored at 4ºC for 24-h before being frozen. In general there 
were no statistical differences between the metabolic profiles of the samples stored in 
the two conditions164. Klein and co-authors studied the stability of selenium compounds 
in urine and reached to the conclusion that urine samples can be stored at -80ºC up to 4 
weeks without measurable changes165. Urine contains components that precipitate when 
cooled in refrigerators and centrifugation is necessary as non-centrifuged samples have 
shown different metabolomic profiles163.  
Despite the influence that the previous factors that may affect the urine 
metabolome outcome, an approach that is common to several groups is to consider that 
these possible confounding factors may not be controlled and that the compounds that 
allow the discrimination between a group with a determined pathology and the control 
groups is sufficient and intra-individual variability is supplanted.  
 
 1.3.2 Breath and urine characterization based on solid phase 
microextraction combined with gas chromatography analysis 
Sample preparation is often a necessary step and the main purpose is to extract 
the analytes from complex biological matrices, which removes matrix components that 
may interfere with the analysis. In the case of low-level compounds a pre-concentration 
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step is necessary to achieve the detection limits of the chosen analytical technique. 
Conventional sample preparation techniques, such as liquid-liquid extraction (LLE) and 
solid-phase extraction (SPE) (Figure 1.21) are often not feasible as analytes might be 
incompletely extracted and losses occur if the extract is concentrated. Solvent can 
interfere with analytes during gas chromatography process, for example compounds can 
be cut off with solvent delay, and solvent-free preparation techniques are often chosen. 
Traditional extraction techniques, such as LLE and SPE, have been extensively used in 
the preparation of biological samples. These techniques have some disadvantages, 
which include complicated and time-consuming operations, being difficult to automate, 
require solvents, usually involving large quantities of sample and usually the sample 
amount is limited. These multi-step procedures are prone to analyte losses. Therefore, 
the use of sample preparation techniques that can be easily automated, miniaturized, 
with a high throughput performance, using little or no solvent and with the possibility to 
couple on-line with analytical equipment has been subject of interest in metabolomic 
analysis166.  
 
Figure 1.21 – Comparison between liquid-liquid and solid phase extraction167. 
 
Liquid -liquid extraction
Solid -phase extraction 
(1) (2) (3)
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SPME is an example used in the analysis of volatile and semi-volatile 
compounds in metabolomics168. SPME, an extraction technique, introduced by 
Pawliszyn in 1990s169, convenes these characteristics and has been extensively used in 
the metabolomics extraction procedures. The first report using SPME as the extraction 
technique occurred in 1997 with the analysis of ethanol, isoprene and acetone in healthy 
volunteers170 whilst the analysis of urine by SPME was first reported in 1995 in the 
analysis of thinner components171. Since then, SPME has been used in urine analysis for 
potential cancer biomarkers172,173,174, in the analysis of cell cultures of cancer175, in the 
comparison of volatile compounds from melanoma and benign skin176, lung cancer 
chemotherapy control by breath profile177, determination of acetone in human breath178, 
among many other studies in the investigation of several pathologies. In spite of the 
technique simplicity, there are parameters that have to be optimized before analyzing 
exhaled breath and/or urine that will be discussed subsequently. 
 SPME was developed to facilitate sample preparation, reduce solvent use, easy 
to operate and to be field compatible. There are several phase geometries: fiber, disk, 
thin film, stirrer, suspendend particles and vessel. The most used is the fiber, a modified 
syringe that contains a stainless steel microtubing within its syringe needle with a fused-
silica fiber tip with about 1cm coated with an organic polymer. Sampling can be made 
by immersion/direct extraction (DI-SPME) or by headspace extraction (HS-SPME). In 
DI-SPME the fiber is put directly in the sample whereas in HS-SPME the compounds 
are extracted from the gas phase that is in equilibrium with the sample. On HS-SPME, 
the fiber has no direct contact with the sample, therefore the matrix effect and 
background effect are reduced, increasing the lifetime of the SPME fibers and 
increasing the selectivity by extracting volatile and semi-volatile compounds179. In this 
PhD thesis, HS-SPME mode was chosen. After the coated fiber is exposed using the 
pre-determined SPME conditions it is inserted in the injection port of the 
chromatograph to release the analytes, and in GC this is performed resorting to thermal 
desorption. 
The SPME extraction is non-exhaustive, which means that a small fraction of 
compounds are extracted representing the compounds overall composition. In this PhD 
thesis, it was decided to select the conditions that promoted greater extraction 
efficiency, i.e., a compromise between the number of extracted compounds, an 
acceptable chromatographic intensity and time. 
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 Upon exposure the fiber enters in a mass-transfer process driven by the second 
law of thermodynamics and the amount of analyte sorbed are expressed by: 
n =
C × V × V × K
K × V + V
 
Where C0 is the initial concentration of analyte, Vf is the fiber volume, Vs is 
sample volume (or headspace) and K is equal to Kf × K (Kfh is the partition 
coefficient between the fiber coating and headspace and Khs the partition coefficient 
between the headspace and the sample).  
The aforementioned SPME parameters namely fiber coating, temperature and 
extraction time, stirring effect, salt addition, sample pH among others, are  usually 
experimentally optimized.  
There are several commercially available SPME coating fibers with different 
polarities, film thicknesses and with different type of interaction with the compounds. 
There are liquid and solid coatings and the performance is quite different. Initially, 
extraction begins by analyte adsorption at the extraction phase-matrix interface followed 
by analyte diffusion into the bulk of the extraction-phase. If the diffusion coeficient of 
the analytes is high, absorption occurs with the analytes fully partitioning between the 
two phases. However if the diffusion coeficient is low, the analyte remains in the 
interface and adsorption occurs.The fibre coatings consist of one, two or three polymers. 
The fibers with two or three polymers have a synergetic effect of adsorption and 
absorption. When compared to the fibers with one polymer, a higher retention capacity 
and a higher sensitivity are achieved. Some examples are shown in Table 1.6. 
 
Table 1.6 – Commercially available SPME coatings 
Coating type Film thickness (µm) Polarity 
Polydimethylsiloxane (PDMS) 
7 
Nonpolar 30 
100 
Polyacrylate (PA) 85 Polar 
Polydimethylsiloxane/ divinylbenzene (PDMS/DVB) 65 Polar 
Carbowax/divinylbenzene (CW/DBV) 65 Polar 
Carboxen / polydimethylsiloxane(Car/PDMS) 85 Bipolar 
Divinylbenzene/carboxen/polydimethylsiloxane (DVB/CAR/PDMS) 55/30 Bipolar 
 
Temperature has a significant effect on the kinetics of the SPME process as it 
determines the vapour pressure of the analytes above the condensed phase, as well as, 
the compounds solubility on liquid samples. The increase of temperature results in an 
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increase of the analyte’s Henry’s constant, an increase in the the diffusion coefficient, 
and a decrease in the extracted amount at equilibrium (as the distribution constant 
decreases with temperature increase) 180. Consequently, increasing temperature will lead 
to the improvement of the extraction time. Nevertheless, a compromisse has to be 
achieved as elevated sampling temperatures decrease the fibre/sample partition 
coefficients leading to the decrease of the amount extracted in equilibrium. 
Another highly important parameter is the extraction time. Theoretically, if the 
period of time is long enough a concentration equilibirum can be reached between the 
extraction phase and the matrix and exposing the fiber longer will not result in the 
accumulation of more analytes. However, in a practical point-of-view the equilibrium 
time is defined as the time required to extract 95% of the analyte181.  The optimum 
extraction time is independent of sample concentration and is a compromisse between 
the desired length, sensitivity and repeatability and reaching equilibrium provides the 
highest sensitivity. However, equilibrium extraction times tend to be long182.  This is 
not convenient in laboratory assays and a compromisse should be reached. 
In liquid samples, such as urine, an optimizable parameter is ionic strength. 
Adding salt to a sample solution increases the constant Kfs improving sensitivity in 
most applications. The analytes mass transport from the aqueous phase to the headspace 
is improved and consequently the extraction efficiency is increased. Sodium chloride 
with high purity is usually added and this addition changes the properties of the 
boundary phase. Also the compound solubility decreases in the aqueous phase, a 
process known as salting-out where the water molecules form hydration shperes around 
the salt molecules. The water content that dissolve the analytes molecules is reduced 
and the compounds pass to the headspace. At the saturation point the compounds may 
interact with the salt ions in solution and this reduces the extraction efficiency183. 
Agitation can also improve extraction efficiency and increase extraction efficiency. This 
is provided by the use of a magnetic stirring bar and the compounds are transported 
from the solution to the proximity of the fiber. The effect caused by the depletion zone 
that is produced close to the fiber is reduced and the analytes diffusion coefficients is 
decreased. pH adjustment can also improve method sensitivity converting analytes that 
might be present in the sample into the neutral forms, so it is another parameter that can 
be optimized in sample such as urine182. 
After the extraction procedure is completed the exhaled breath and urine volatile 
and semi-volatile compounds are generally analyzed using gas chromatographic 
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techniques. GC-MS is the powerful combination of two analytical tools: gas 
chromatography for the gas-phase separation of the components in complex mixtures, 
and mass spectrometry that allows the identification of these components. GC-MS was 
developed in the 1950’s and it has been considered a highly valuable tool in any 
analytical chemistry laboratory184. Since its development the technique had numerous 
advances that allowed an in-depth sample characterization. The main advantages of GC-
MS are sensitivity, compound identification, and widely available instrumentation at 
relatively low cost (compared to other equipments)185. This analytical technique has 
been extensively used in exhaled breath186, 187, 188 and urine analysis189, 190, 191.  
Briefly, in GC-MS the components of a mixture are physically separated and 
selectively distributed between the mobile phase (which is an inert carrier gas) and a 
stationary phase present in inner column wall or as column packing particles. 
Nowadays, the majority of used columns are capillary with the stationary phase coated 
in the inner wall. The separation occurs due to different distribution coefficients of the 
single components of the mixture and the chromatographic process is a result of 
repeated sorption and desorption processes as the analytes move through the stationary 
phase carried by the inert gas. The GC instrumentation consists of a sample introduction 
device, a column housed in a temperature programmable oven, an interface, a mass 
spectrometer and a data collecting system. There are several detection systems 
available; nevertheless as the quadrupole mass analyzer was used in this study a more 
detailed description will be made. The quadrupole is a powerful analyzer for GC-MS 
systems as it presents several advantages such as the simplicity, size, reasonable cost 
and rapid scanning. This analyzer uses the ions trajectories stability in oscillating 
electric fields separating ions according to their m/z ratios. Quadrupole analyzers are 
constituted by four rods with circular, or ideally, hyperbolic section having a fixed 
direct current (DC) and alternating radio frequency (RF) voltages applied to the ions. 
These ions, produced in the source, are focused and passed in the middle of the rods and 
the motion depends on the electric fields, so the ions of a particular m/z will be in 
resonance and pass through to the detector. The ion motion is directly proportional to 
the mass, voltage on the quadrupole and RF. The RF voltages are varied, thus bringing 
different m/z ions to the detector forming a mass spectrum. Before entering the 
analyzer, the ions go through a potential to give the ions a determined speed to pass 
along the center of the quadrupole192.  
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As for compound identification, standard injection and mass spectrum inspection 
are normally used. In addition, another strategy to improve identification confidence 
may employed, as for example retention indices (RI) values. After the injection of an n- 
alkane series, usually ranging from C6 to C20, in the same GC column and 
chromatographic method the RI values can be calculated using the van den Dool and 
Kratz equation193. The obtained values can then be compared with literature values 
obtained in equal or similar chromatographic columns used experimentally. The RI 
values are relatively independent from individual chromatographic system conditions 
such as column length/diameter, film thickness, carrier gas velocity, and pressure. These 
values are obtained by normalizing the retention times to an adjacent n-alkane which 
makes RI values based on carbon number of the molecule. 
Although GC-MS yields significant analytical results, the matrices complex 
nature usually requires longer GC runs. It has also been shown that some peaks are 
formed by two or more compounds, a process denominated co-elution. For these 
reasons, in the last decades, research has been performed to overcome these issues and 
increase resolving power. The overall resolving power of 1D GC can be described by 
the peak capacity that is the maximum number of peaks that can be place, side by side, 
into the available one-dimensional separation space at a given resolution. In 1D GC, 
values of peak capacity of 1000 are very difficult to obtain194. A trustworthy option that 
has emerged is multidimensional gas chromatography (MDGC), namely GC×GC. 
MDGC is a robust and reliable technique that exceeds the separation capacity of 
single dimensional chromatography. MDGC incorporates multiple sequential 
separations of different mechanisms (for example, different column selectivity) with a 
transfer process between dimensions that serve to effectively split individual 
retentions195.  
GC×GC is reported by Liu and Phillips196 for the first time in 1991. The authors 
incorporated a thermal modulator between two columns that traps, focus and injects 
small amounts from the first column to the second column. When compared to one 
dimensional (1D-GC) the GC×GC presents several advantages: 
 
1. higher peak capacity, the highest number of chromatographic peaks is 
significantly enhanced due to the product of the peak capacity of both 
dimensions;  
Chapter I - Introduction 
 
45 
 
2. signal enhancement due to analyte refocusing followed by fast 
chromatography avoiding band broadening and the signal to noise ratio is 
improved due to improved analyte separation and; 
3. the ability to produce structured chromatograms. The structuration 
obtained of the 2D chromatographic space can be highlighted. Due to the 
complementary separation mechanisms of the two columns, a spatial 
distribution of the analytes occurs in the 2D space according to their 
chemical properties allowing the separation in compound classes. This 
can be used to reduce analysis time and the identification is more 
trustworthy as characteristic patterns are formed in an ordered manner197. 
For example, the use of non-polar capillary column in 1D leads to 
separation by volatility whilst the use of a polar column in 2D separates 
the analytes by polarity. 
 
These advantages makes GC×GC a powerful tool that has been used in different 
applications that are not easily solved in 1D GC 198. For this purpose, multidimensional 
chromatography is a technology that uses two orthogonal separation mechanisms to 
increase resolution power and peak capacity199. The theoretical peak capacity of these 
systems is the sum of the peak capacities of the first and second dimensions multiplied 
by the number of heart-cuts200.  
In GC×GC, two separations based on different separating mechanisms are 
applied to originate orthogonality. Orthogonality in GC×GC is created using columns 
that provide independent separation mechanisms in the first and second dimension201. 
The separation on the GC system is based on two parameters: the analytes volatility and 
the interaction with the stationary phase. The use of a non-polar column, where 
volatility is the only parameter of interest, and a polar column that will separate the 
analytes by specific interactions; but also by volatility is a common column set-up. 
Usually, using this set-up a structure chromatogram is obtained and it is possible to 
perform group-type identification202. Ryan et al.203 studied separation orthogonality 
using different sets of 1D and 2D columns and concluded that if the columns used are 
very different the separation on the second dimension is maximized. The in-series 
connection is performed through an interface known as the modulator. An example of 
the interface is the cryomodulator. This interface cuts small fractions of the eluate from 
1D by cryofocusing and re-injecting into the second column. Nevertheless, to maintain 
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the 1D separation the interface cuts the fractions so that they are no larger than one 
quarter of peak width. Then each individual fraction is refocused and injected in the 
second column which is a very fast process when compared to the first column 
separation204. Large series of high-speed second-dimension chromatograms are 
transformed to form a two-dimensional chromatogram that is usually performed by 
laboratory-written program. The visualization can be made in a contour plot (colored or 
not) or in a 3D plot202 (Figure 1.22). 
 
 
Figure 1.22 - GC×GC generation and visualization202. 
 
There are several detectors that can be used in combination with GC×GC, as for 
example, the flame ionization detector (FID), electron capture detector or ToFMS. The 
detectors used in GC×GC have to be very fast due to the fast separation in the second 
dimension that lead to peaks with typical widths between 100-600ms205. In the 
developed study, the GC×GC was combined with a ToFMS. ToFMS separation relies in 
the mass separation principle with the determination, by time measurement, of ion 
mass-to-charge ratio. The ions velocity, attained by homogeneous electrostatic field 
acceleration, depends on the mass-to-charge ratio. So ions with the same charge will 
possess the same kinetic energy and heavier ions will have lower velocities and lighter 
ions will have higher velocities206. ToFMS is ideal in the characterization for fast gas 
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chromatographic separation due to two main attributes: high spectral acquisition rates (a 
few hundred full-mass-range spectra per second) and spectral continuity across the 
chromatographic peak profile for a single-component peak. Spectral continuity means 
that for all the points on a chromatographic peak the ion abundance ratios for the 
different masses are the same207. Using the ToF spectrometer, even though 
concentration changes during peak elution, spectral continuity is not affected. The use 
of quadrupole MS or other scanning instruments the analyte concentration changes 
which results in skewed spectra that is resolved by averaging spectra across the apex of 
the chromatographic peak208.  
The use of comprehensive two-dimensional gas chromatography coupled to 
mass spectrometry with a high resolution time of flight analyzer (GC×GC–ToFMS) has 
brought a significant advantage in research and in analytes identification in several 
fields. Over the past years the use of GC×GC–ToFMS in the analysis of exhaled breath 
and urine compositions has gained interest in the scientific community. In exhaled 
breath it has been used in the detection of breath metabolome demonstrating the added 
value of this technique. Much more analytes were identified than in the 1D GC-MS 
reports due to the improved separation and increased sensitivity209,210.The GC×GC–
ToFMS was also used in urine analysis in infant urine finding several organic acids that 
would not be possible using 1D GC211. Other applications using GC×GC–ToFMS 
concerned the bladder cancer metabotyping212 and in the analysis of anabolic agents in 
doping control213. 
 
1.3.3 Urine characterization based on proton based nuclear magnetic 
ressonance 
NMR to analyze biofluids goes back to early 1980s. Actually, NMR is applied in 
several areas as disease diagnosis, drug discovery, microbiology, nutrition, toxicology, 
plant and environmental sciences. NMR is widely used in metabolomics applications as 
this technique is resolute, reproducible, reliable, and the data obtained is easily 
quantified and robust. Additionally, NMR requires minimal or even no sample 
preparation/separation and is of non-destructive nature. A major advantage in using 
NMR to obtain a metabolomic profile in a biological sample is that the acquisition can 
take from 1-15 min with acceptable sensitivity to be able to differentiate subtle 
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biological differences214. The major drawback is related to the sensitivity level when 
compared with MS-base methods
NMR is able to detect a wide range of structurally different compounds in a 
single run in the micromole per liter range. The number of compounds in human fluids 
are estimated between 2000-3000 and a maximum of about 20 000 compounds. The 
smaller compounds, including sugars, amino acids and bioactive products that are 
paramount in several metabolic pathways, are of great interest to researchers. Usually 
these compounds act as signaling functions at very low concentrations. The complexity 
of the urine 1 H NMR spectrum can be observed with several resolved peaks (Figure 
1.23). 
Figure 1.2
Several 1H NMR urine studies have been performed and have been extensively 
reviewed. Bouatra and co-authors
human urine. These authors found out that by NMR several hundred compounds were 
reported in a study performed with 22 healthy children up to 209 unique compounds 
have been identified and each compound was indisputably
These high-dimensional datasets are attained by bucketing. A bucket is a small slice of 
the spectrum and the integral is calculated to obtain a variable for each bucket. This 
procedure reduces the total number of variables and c
215
. 
 
3– Example of a urine 1H NMR spectrum108 
108
 have built a database of detectable compounds in 
 identified and quantified. 
ompensates the possible 
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misalignments. Beside inorganic ions and gases, the most abundant constituents in a 
healthy individual are urea, creatinine, hippuric acid and citric acid. Other compounds 
include branched-chain amino acids, organic acids, N-acetylated amino acids, 
hydroxycarboxylic acids, aromatic signals (for example, indoxylsulfate, histidine, 
phenylacetylglutamine), sugars, phenylacetate derivatives, among others216. 
NMR and metabolomics have been mainly applied in the human disease 
diagnosis field. The metabolomic studies using urine have provided important 
information on several pathologies such as cancer217,218, inborn errors of metabolism219, 
prenatal disorders220, cardiovascular pathologies221, respiratory diseases222, neurological 
pathologies223 and kidney pathologies224, among others. 
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1.4 Data pre-processing and multivariate analysis 
Multivariate analysis (MVA) plays an exceptionally significant role in 
metabolomic analysis.  The several compounds found in the studied biofluid, the lack of 
reference NMR and MS spectra for all the compounds and the inherent variability in 
each sample due to the individuality of the each organism highlights the role of MVA. 
The identification of the chemical features that characterize the object of study against 
the large background of compounds that define the system, the variations attained by 
disturbing the studied system by experimental and environmental factors and even the 
fluctuation on data spectra due to instrument instability or sampling variability requires 
a robust MVA methodology to verify the trends in the data set. Principal component 
analysis (PCA) and partial least squares discriminant analysis (PLS-DA) are tools used 
in metabolomics do determine relative differences between two data sets225.  
A metabolomic data analysis consists in several steps: pre-processing, pre-
treatment, processing, post-processing, validation and interpretation. Data pre-
processing consists in the obtention of clean data from raw instrumental data. 
Deconvolution, peak-picking, target analysis, alignment, phasing, baseline correction 
and bucketing are pre-processing tools used in NMR spectra and MS chromatograms 
(the last three tools are NMR specific). Pre-treatment involves normalization 
procedures, centering or mean-centering, scaling (autoscaling, range or pareto scaling), 
transforming the data (using logaritm, square root or box-cox) and examining for 
outliers226.  
In this PhD thesis, the unsupervised method of PCA and supervised methods of 
PLS-DA were employed due to the multivariate nature of the obtained data The basic 
principles will be described. Previously the normalization is discussed as it is an 
intrinsic part of the adopted MVA for the performed studies. 
 
1.4.1 Data normalization in metabolomics 
Metabolomic data needs to be transformed  before proceding to MVA as the raw 
data varies due to experimental or biological reasons. This situation has to be previously 
dealt with so that the intended goals can be accomplished. The experimental verified 
Chapter I - Introduction 
 
52 
 
variation can be due to human error (sample preparation and/or extraction),  instrument 
variation (temperature alteration in the instrument, sample degradation or even loss in 
equipment sensibility in the runs), different sets, laboratories and even different 
analytical platforms. Another possibility are biological discrepancies, as for example 
different biofluid concentrations, which might be mistaken as possible features of 
interest. This unwanted variation can be detected as in weight or volume of biological 
samples or even cells number, or remains undetected as for instance the aferomentioned 
biofluid concentration or other factors that might influence as form/size of cells. 
With this in mind, normalization procedures can identifiy and eliminate the 
observed and unnoticed factors mentioned taking a central role in metabolomic data 
analysis, as MVA results depends on the adopted procedure. These features are 
identified and eliminated by the normalization procedure and the selection of the 
appropriate method has to take into account a number of factors. Usually normalization 
is data and experiment-dependent but should also depend on the goal of the statistical 
analysis. This procedure can be performed by using an internal standard or by applying 
scaling factors for the samples under study for the complete dataset such as 
normalization by average, median, maximum, standard deviation, among others. 
In the present work the most classical case of normalization, mean 
normalization, was chosen in exhaled breath and urine volatile data. This procedure 
consists in dividing each row of a data matrix by its average, thus neutralizing the 
influence of any hidden factor. In urine data obtained by 1H NMR three normalization 
techniques were tested, namely total area normalization, creatinine227 and probabilistic 
normalization quotient (PQN)228.  After the appropriate normalization method is 
selected, MVA tools are used to develop models and identify biologically revelant 
features for future analysis. 
 
1.4.2 Principal component analysis and partial least squares - 
discriminant analysis 
The most popular tools for MVA in metabolomics are PCA and PLS229. 
Essentially these techniques are used to distinguish the classes in highly complex 
datasets, although there are other factors that may cause class variability. Generally a 
data matrix X, which contains N observation row vectors of K variables each, is the 
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most common manner to depict the acquired data. The data matrix X inputed is the 
spectral data obtained by MS and/or NMR. 
PCA is widely applied in statistical analysis in chemometrics in general. PCA is 
a orthogonal linear transformation of the data preserving the variance of the original 
data. In metabolomics it is the starting point of MVA being used for exploratory 
purposes and to reduce the obtained data230. It may establish intrinsic class-related 
patterns or clusters although PCA is an unsupervised method and may enable the 
detection of outliers in the data set. PCA is desgined to extract and display the 
systematic variation in a data matrix X and the projection of each sample into a plane 
(defined by the first two components) makes it possible to visualize all samples231. 
Though the unsupervised PCA yields an unbiased dimensionality reduction, only 
when the within-group variation is sufficiently less than the between-group variation a 
group structure is revealed. As a result supervised MVA tools, such as PLS-DA, are 
applied in metabolomic experiments where class membership of each observation is 
inputted. Class memberships are usually coded in the matrix to Y component and this 
way forced to be orthogonal229. PLS-DA is a powerful tool in the metabolomic data 
classification232. The information may be quantitative or qualitative and the information 
is used to focus the model plane to capture the Y-related variation in X . PLS focus on 
maximizing the variance of the dependent variables explained by the idependent ones 
instead of reproducing the empirical covariance matrix233. When the information 
provided by Y is qualitative, the method is denominated by PLS-DA to make the 
distinction from the quantitative.  
 
1.4.3 Statistical models validation  
Validation is a crucial step to guarantee the reliability of any developed 
statistical models. For example, the most common method PLS-DA234 overfits models 
to data where completely random variables have excellent class separation.  
The categorical variable Y indicates class membership, meaning that values of -
1 and 1 represent the healthy and the asthmatics under study, respectively. Nevertheless, 
due to the properties of regression models, the prediction is not inevitably the exact 
value. The challenges of PLS-DA are classification procedure and precise estimation of 
the quality of the obtained models and thereby differences between two classes. To 
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verify the quality of the obtained discrimination models  several tools have been 
developed, among them cross validation235. Regression model validation determines the 
if the relationships between the variables, obtained from regression analysis, truly 
describes the data. In the present work , an out-of-sample evaluation were considered.  
 Cross validation is widely applied in chemometrics as the use of this tool is 
indispensable to validate data from supervisioned tests such as PLS-DA, and if not 
mentioned, it is simply referred as the leave-one-out cross validation (LOO-CV). LOO-
CV is a practical and reliable fashion to test the significance of the developed models. 
Briefly, LOO-CV uses one observation for validation purposes whilst the remaining 
observations are considered the training data and the process is repeated until each 
observation is used once for validation236. LOO-CV has the disadvantage of being 
computationally expensive and often causes overfitting, and on average, gave an under-
estimation of the true predictive error237. MCCV first reported by Cook238 and tested for 
chemometric purposes by Xu and Liang239, can avoid an unnecessary large model and 
therefore decreases the risk of over-fitting for the calibration model. MCCV splits the 
data into a learning set or a test set and the model developed on the learning set and the 
error evaluated in the test set. The test set estimates are averaged over the learning-
testing random splits and each case only appears in the learning set or the test set, but 
not in both240. MCCV substancially reduces the variance of the split-sample error 
estimate241. MCCV yields the statistical model classification rate, sensitivity and 
specificity.  The classification rate indicates the samples correctly identified, the 
sensitivity yields the percentage of positives that are correctly identified and specificity 
measures the percentage of negatives to be true negatives. Receiver operating 
characteristics (ROC) curves plot sensitivity versus (1-specificity). This graphical 
illustration gives the proportion of true positives against the false positives. Also, the 
values of R2 could be used to assess the the degree of the model to the data in spite not 
being a cross validation evaluation. However, if R2 is much higher that Q2 obtained in 
MCCV it possibly indicates model overfitting229. 
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1.5 Aims and outlines of this PhD thesis 
 Following several steps, the work developed in this PhD thesis ultimately 
intended the development simple methodologies in the analysis of non-invasively 
obtained samples for asthma regarding for their clinical applications. The matrices 
under study were exhaled breath and urine that are promising biofluids that over the 
years have attracted scientific and clinical interest. These matrices are rich sources of 
information, obtained in a non-invasive manner and effortlessly. Among several 
available analytical techniques, GC-MS, GC×GC-ToFMS and 1H NMR were chosen to 
obtain the most complete volatile and non-volatile information. The chosen extraction 
methodology for the study of exhaled breath and urine volatile composition was HS-
SPME. This technique has been widely used in research in the clinical context as it 
possesses several advantages that make this technique meritorious in the analysis of the 
aforementioned matrices. In metabolomics, the use of multivariate tools is essential. 
These tools are necessary as the datasets are of multivariate nature due to the 
instrumentation availability and the complexity of systems and processes. These tools 
allow the extraction of relevant data with several variables using all the variables 
simultaneously forming a metabolomic pattern that may characterize the pathology. 
 In Chapter 1, the state-of-the-art is described, namely asthma definition, the 
metabolomic alterations produced, definition of metabolomics and used analytical 
techniques and biofluid analysis. The results of this thesis are then presented as follows. 
Chapter 2 begins with the optimization of the SPME parameters, as well as, of exhaled 
breath sampling parameters with the use of GC-MS. The optimized conditions were 
then applied to a set of asthmatic and healthy children and multivariate tools were 
applied. A GC×GC–ToFMS method was then developed to confirm and enrich the 
previous information using a new cohort of children. To add robustness to the 
developed statistical models, an external validation method (MCCV) was applied. 
Subsequently, using prediction tools new exhaled breath samples were collected to 
verify the possibility to use the developed method in a clinical practice environment. 
Case studies were included to appraise the method response versus the clinical status of 
the subject under study. In Chapter 3, the analysis of the urine volatile composition was 
made using an in-lab developed method. The same strategy was used as in exhaled 
breath and multivariate/validation tools were used. To complement this study, the non-
volatile composition was accessed by 1H NMR. This allowed obtaining more 
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information on asthma using this matrix, in addition to the development of statistical 
models that could be certainly used for future endeavors. Chapter 4 has the general 
conclusions of this PhD thesis, as well, recommendations for future research. 
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2.1 Overview 
The use of odor, namely in breath, remounts to ancient Greece where physicians 
related odor of  a patient’s breath and a pathology (e.g., sweet acetonic breath indicating 
uncontrolled diabetes). Over the past years several reports in exhaled breath have surfaced in 
the analysis of an array of pathologies that inclusively led to the development of specific 
equipment for exhaled breath analysis. Exhaled breath is a rich source of information with 
several compounds from different chemical families being identified. The focus of our study 
in exhaled breath was ultimately develop a methodology able to differentiate asthmatic 
children from healthy ones using the exhaled volatile organic compounds or “breath-print” 
yielding insights into this heterogeneous pathology.  
To acomplish this goal a HS-SPME/GC-MS method was developed. First an 
experimental design was built to select the best conditions for HS-SPME using chemical 
standards previously reported in exhaled breath, followed by the study of parameters related 
to breath sampling (containers, cleaning procedures and intra-individual variability). The 
optimized methodology was then sucessfully applied to a set of 35 asthmatic and 15 healthy 
children and the first results showed that compounds such as the alkanes/aldehydes (linked to 
lipid peroxidation) characterized the pathology. To improve the obtained results a high 
throughput analytical technique, GC×GC–ToFMS was considered in a different set of 32 
asthmatic and 27 healthy children. Several hundreds compounds were identified and the 
model had high classification rate, sensitivity and specificity. A model with a set of 9 
compounds was built and discriminated asthmatic from healthy children. The role that EB 
may have in non-invasive diagnostic method and in monitoring the asthmatic therapy was 
then accessed by applying the developed method on a new cohort of 49 asthmatic children. 
The developed models were then tested to demonstrate the true value in the clinical practice in 
following up the evolution of three children in exarcebation with the prescribed therapy 
(during 3 months), as well, the follow the Omalizumab therapy effect on one patient with 
severe asthma throughout 20 months. 
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2.2.1 Abstract  
Allergic asthma represents an important public health issue with significant growth 
over the years, especially in the paediatric population. Exhaled breath is a non-invasive, easily 
performed and rapid method for obtaining samples from the lower respiratory tract. In the 
present manuscript, the metabolic volatile profiles of allergic asthma and healthy children 
were evaluated by HS-SPME/GC–qMS. The lack of studies in breath of allergic asthmatic 
children by HS-SPME led to the development of an experimental design to optimize SPME 
parameters. To fulfill this objective, three important HS-SPME experimental parameters that 
influence the extraction efficiency, namely fibre coating, temperature and time extractions 
were considered. The selected conditions that promoted higher extraction efficiency 
corresponding to the higher GC peak areas and number of compounds were: 
DVB/CAR/PDMS coating fibre, 22ºC and 60 min as the extraction temperature and time, 
respectively. The suitability of two containers, 1 L Tedlar® bags and BIOVOC®, for breath 
collection and intra-individual variability were also investigated. The developed methodology 
was then applied to the analysis of children exhaled breath with allergic asthma (35), from 
which 13 had also allergic rhinitis, and healthy children (15), allowing to identify 44 volatiles 
distributed over the chemical families of alkanes (linear and ramified) ketones, aromatic 
hydrocarbons, aldehydes, acids, among others. Multivariate studies were performed by PLS–
DA using a set of 28 selected compounds and discrimination between allergic asthma and 
healthy children was attained with a classification rate of 88%. The allergic asthma paediatric 
population was characterized mainly by the compounds linked to oxidative stress, such as 
alkanes and aldehydes. Furthermore, more detailed information was achieved combining the 
volatile metabolic data, suggested by PLS–DA model, and clinical data. 
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2.2.2 Framework 
As molecular diagnosis is the next generation of personalized medicine1 an objective 
of the purposed work is to contribute for the interdisciplinary link between physicians and 
biochemists, providing tools for a more efficient and precise diagnosis. Exhaled breath is a 
rich source, as found out by Pauling in the 1970s, with the identification of 250 metabolites 
beside nitrogen, oxygen and water vapour2. The development of new and more efficient 
extraction methods, as well as, more sensitive and efficient separation techniques led to a 
significant progress in this research area. The analysis and characterization of exhaled breath 
became a new approach with potential to provide valuable information about respiratory and 
systemic diseases that can lead to a deeper knowledge of human health status, in the 
identification of disease-related marker compounds and consequently a potential information 
source regarding the knowledge of these diseases metabolic pathways. Exhaled breath is a 
non-invasive, easily performed and rapid sampling, either in the gaseous or condensed state.  
The lack of a prominent HS-SPME study in allergic asthma exhaled breath led us to 
develop an experimental design by combining HS-SPME with GC-MS to assess information 
from allergic asthma metabolomic patterns. To fulfil these objectives three important HS-
SPME experimental parameters that influence the extraction efficiency, namely extraction 
temperature and time, and coating fibre were considered. A full factorial design was applied 
to determine the best extraction conditions using different chemical standards (hydrocarbons, 
aldehydes, ketones, aromatic and aliphatic alcohols) reported in literature to be present in 
exhaled breath3,4,5. Some exhaled breath sampling parameters were also optimized. Two 
different breath sampling containers were tested, Tedlar® gas sampling bags and BIOVOCS® 
and the washing procedure of the chosen container was optimized. Another important 
parameter, the intra-individual variability, was checked over a period of three weeks with 
sampling throughout a single day. After this optimization, the proposed methodology was 
applied to the analysis of children exhaled breath with allergic asthma and healthy children, 
used as control. 
 
Chapter 2 - Exhaled breath analysis 
 
76 
 
2.2.3 Experimental 
Standards and materials 
The reagents used were of analytical grade and from different chemical families: linear 
hydrocarbons (hexane (99.5%, Fluka, Madrid, Spain), undecane (99.8%, Fluka, Madrid, 
Spain)), aldehydes (hexanal (98%, Sigma-Aldrich, Madrid, Spain), (E)-2-nonenal (95%, 
Acros Organics, Geel Belgium)), ketones (acetone (99.5%, Fluka, Madrid, Spain), 3-
heptanone (97%, Sigma-Aldrich, Madrid, Spain)), and aromatic and aliphatic alcohols 
(phenol (99%, Merck, New Jersey, USA), 1-hexanol (98%, Sigma-Aldrich, Madrid, Spain)). 
Absolute ethanol was supplied by Panreac (99.5 %, analytical grade, Barcelone, Spain). Ultra 
pure water was obtained from a Milli-Q system from Millipore (Milford, MA, USA). Four 
different fibres from Supelco (Bellefonte, PA, USA) were used: 
divinylbenzene/carboxen/polydimetylsiloxane (DVB/CAR/PDMS, 50/30 µm), 
polydimetylsiloxane/divinylbenzene (PDMS/DVB, 65 µm), polydimetylsiloxane (PDMS, 100 
µm) and polyacrilate (PA, 85 µm). SPME fibres and SPME manual holder was obtained from 
Supelco (Bellenfonte, PA, USA). All the fibres were of the same length (1 cm) and 
conditioned prior to use, as recommended by the manufacturer. 1 L Tedlar® bags (SKC Inc., 
Eighty Four, PA, USA) and BIOVOCS® (Markes International, Llanstrisant, UK) were used 
for sampling. 
 
Breath samples  
A group of 35 children with allergic asthma, from which 13 had allergic rhinitis, and 
15 healthy children volunteered for this study. All parents signed an informed consent for 
participation in the study. The children with allergic asthma were recruited from the 
outpatient clinic of the department of paediatric immunoalergology of Hospital D. Pedro 
(Aveiro, Portugal) whilst the healthy children were recruited at the local facilities that 
presented no asthma episodes or symptoms. Asthma diagnosis was made based on clinical 
symptoms and exams (skin prick tests and IgE values). Appropriate therapy was prescribed by 
the patient’s own physician. All allergic asthma population represented a controlled asthma 
status. The characteristics of the patients and healthy children are presented in Table 2.1. No 
restrictions were applied regarding drugs or diet and all allergic asthma subjects were sampled 
in the same room at the local hospital. The study was approved by the local hospital ethics 
committee. 
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Table 2.1 Characteristics of the studied population: allergic asthma and healthy children. 
 
Allergic asthma 
(n=35) 
Healthy 
(n=15) 
Age in years (mean±SD) / (range)  8.5±2.5 / 4-13 8.0±3.1 / 4-13 
Gender (male/female) 13/22 7/8 
Pathology 
Allergic Asthma (AA) 22 (63%) - 
Allergic Asthma + Allergic Rhinitis (AA+AR) 13 (37%) - 
Allergensa 
Dust mite 19 (54%) - 
Dust mite + cat fur 3 (9%) - 
Dust mite + gramineae 3 (9%) - 
Dust mite + cat fur + gramineae 1 (3%) - 
Information not available 9 (25%) - 
Therapy 
Corticosteroid + leukotriene receptor antagonist 12 (34%) - 
Corticosteroid and anti-histamines 4 (12%) - 
Corticosteroid and bronchodilator 13 (37%) - 
No therapy 6 (17%) - 
a
 Results obtained by prick-tests 
 
Experimental design 
Different chemical standards were used to perform the full factorial design,: hexane, 
acetone, hexanal, 3-heptanone, undecane, 1-hexanol, (E)-2-nonenal and phenol. A stock 
solution of each standard (1 g/L) was prepared in absolute ethanol and made up to volume, 
and from this a solution of 100 mg/L was set up. A working solution was prepared to yield 
different concentrations from 0.4 mg/L (undecane) to 1.6 mg/L (hexanal). To reproduce a 
two-phase system (headspace and coating fibre), as in breath analysis, 50 µL was added to a 
120 mL SPME flask and sealed with an aluminium crimp cap with a vial was capped with a 
PTFE septum (Chromacol, Hertfordshire, UK) and concentrations ranged from 166.7 to 670.0 
ng/L. Three important SPME experimental parameters were considered on this study: coating 
fibre, extraction time and temperature. Four different fibres, DVB/CAR/PDMS, PDMS/DVB, 
PDMS and PA, were tested and compared. Before daily analysis each fibre was conditioned 
for 15 min at 250 ºC. Two different temperatures (5 and 22 ºC) and five different extraction 
times (5, 15, 30, 45 and 60 min) were evaluated. 
 
Breath analysis 
 
Breath sampling containers: The suitability of two breath sampling containers was 
tested and from the wide range available commercially Tedlar® gas sampling bags and 
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BIOVOC® were chosen. All tests were made using the exhaled breath of a child with allergic 
asthma and using the method developed in the experimental design. 
Tedlar® gas sampling bags were chosen and due to impurities, derived from the 
manufacturing process, the washing procedure was verified as the manufacturer suggests. 
Prior to this step, the purity of the compressed air/nitrogen available in the laboratory was 
verified and the main conclusion is that the used gases are adequate for this procedure as there 
is no further contamination by these washing agents (data not shown). The manufacturer 
recommends that before using Tedlar® bags three nitrogen/compressed air flushes should 
suffice, however the comparison was made between no flush, 3 and 10 flushes. 
Breath sampling: Exhaled breath was collected in 1 L Tedlar® bags with parallel 
ambient air extraction. Breath samples were obtained while children waited for consultation. 
Children were asked to cleanse their mouth with water before sampling. Subsequently, 
children were instructed to inhale and exhaled normally and then exhale deeply into the 
Tedlar® bag previously holding their breath for 5 seconds. The collection method was 
successfully done by all volunteers. Each subject provided one sample using a disposable 
mouthpiece. Before collecting exhaled breath, all bags were thoroughly cleaned to remove 
residual contaminants by flushing with high purity nitrogen gas allowing the re-use of the 
Tedlar® bags. The bags were transported to the laboratory and the analysis was performed to 
a maximum of six hours as recommended by Mochalski et al.6. On average, the analysis was 
performed two to three hours after sampling. The bags were storage at 22 °C. Parallel room 
air sampling was also performed using a large volume syringe to fill a Tedlar bag with room 
air. 
Intra-individual variability evaluation: There have been reports on the intra-individual 
variation of exhaled breath over a period of time7. This is an important parameter to be 
assessed for the developed methodology to verify if the individual profile is repeatable or 
consistent over time. Hence, the exhaled breath of a child with allergic asthma was collected 
over a period of three consecutive weeks, six replicates were performed and analysed in the 
same day. All sampling was performed in the same room. 
HS-SPME general procedure: Breath analysis was performed with the optimized 
conditions using the DVB/CAR/PDMS fibre in a 22 ºC termostated room for 60 min. 
Following the extraction procedure, the SPME fibre was retracted from the Tedlar® bag and 
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inserted in the GC system injection port for 5 min where the compounds were thermally 
desorbed and transferred to the GC column. 
 
GC-MS analysis 
The SPME coating fibre containing the volatile compounds from the standard working 
solution and exhaled breath was manually introduced into the GC injection port at 250 ºC and 
kept for 5 min for desorption. The injection port was lined with a 0.75 mm I.D. glass liner. 
The desorbed volatile compounds were analyzed in an Agilent Technologies 6890N Network 
gas chromatograph, equipped with a 60m×0.32mm I.D., 0.25 µm film thickness DB-FFAP 
fused silica capillary column (J&W Scientific, Folsom, CA, USA), connected to an Agilent 
5973 quadrupole mass selective detector. Splitless injections were used (5 min). The oven 
temperature program was set initially to 50 ºC, with a temperature increase of 5 ºC/min to 220 
ºC held (6 min). Helium carrier gas had a flow rate of 1.7 mL/min and the column head 
pressure was 12 psi. The mass spectrometer was operated in the electron impact mode (EI) at 
70 eV scanning the range 33–300 m/z in a 4.76-s cycle, in a full scan acquisition mode. The 
identification of the chromatogram peaks was done comparing all mass spectra with the 
library data system of the GC–MS equipment (NIST 05 MS Library). The spectra were also 
compared with spectra found in the literature. The identification of each volatile compound 
was confirmed by comparing its mass spectrum and retention time with those of the pure 
standard compounds, when available. The GC peak area data were used as an indirect 
approach to estimate the relative content of each volatile compound. All measurements 
concerning the chemical standards were made with three replicates and the reproducibility 
was expressed as Relative Standard Deviation (R.S.D., %). Each breath represents a single 
sample, and was analysed once. To verify the absence of any carry over, blanks, corresponding 
to the analysis of the coating fibre not submitted to any extraction procedure, were run between 
sets of three analyses. 
 
Statistical analysis 
Single factor ANOVA was performed in the evaluation of the intra-individual 
variability over a period of three weeks. A critical value of 0.05 was used as a criterion of 
significance and all calculations were performed using the Excel® software (Microsoft). PLS 
is a very important procedure for both regression and classification purposes. Concerning the 
classification application of PLS, known as PLS-DA8, the most common approach is to use a 
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Y matrix containing dummy variables which defines sample memberships to pre-defined 
groups and allow extracting relevant information/variability that could describe the reasons 
for the observed patterns (clusters). This methodology allows one to understand which 
variables (metabolites) contribute the most for the observed separation. The PLS-DA was 
applied to volatile metabolites compositional data (28) identified by HS-SPME/GC-qMS 
present in all the cases (50) and for classification purposes were used two groups (healthy and 
asthma). The classification model complexity (number of latent variables) and classification 
rate were estimated by internal cross-validation (7 blocks splits). 
 
2.2.4 Results and discussion  
Experimental design: HS-SPME optimization 
The first stage of this study addressed the HS-SPME parameters optimization that 
influences the extraction process. Different chemical standards reported in literature3,9 to be 
present in exhaled breath were used: hexane, acetone, hexanal, 3-heptanone, undecane, 1-
hexanol, (E)-2-nonenal and phenol. Experimental design allows estimating the effect of 
several variables simultaneously and the complete factorial design enabled the evaluation of 
three significant factors that greatly influences the vapour pressure and equilibrium of the 
target compounds in the headspace, therefore affecting the extraction efficiency: fibre coating 
(DVB/CAR/PDMS, PDMS/DVB, PDMS and PA), temperature (5 and 22ºC) and extraction 
time (5, 15, 30, 45 and 60min) with a total of 120 runs being performed. The obtained results 
can be seen in Figure 1, in which each bubble represents the total chromatographic area of the 
eight standards under study inherent to three different variables (extraction temperature, 
extraction time and SPME fibre coating). Through the bubble illustration, showed in Figure 
2.1, it is easy to evaluate the overall extraction efficiency, since a larger bubble represents a 
higher total chromatographic area. 
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Figure 2.1 - Full factorial design of solid-phase microextraction conditions for GC-MS analysis of exhaled 
breath. 
 
The comparison was made in terms of total extraction efficiency and reproducibility. 
The highest extraction efficiency was obtained using the DVB/CAR/PDMS fibre in all 
studied extraction times and temperatures while PA (22ºC) and PDMS (5ºC) showed the 
lowest sorptive capacity. The nature of the analytes influences the SPME fibre selection. 
Previous reports10,11 on exhaled breath analysis used PDMS because these studies were 
focused in alkanes and aromatic hydrocarbons. These compounds are non-polar, so it is 
preferable a PDMS phase. The methodology optimized in the present manuscript is to be used 
in a wide range of analytes, which explains that DVB/CAR/PDMS fibre obtained the best 
results, as its stationary phase has a synergistic effect between adsorption and absorption. The 
mutually synergetic effect of adsorption and absorption of the stationary phase promotes a 
high retention capacity and, consequently, a higher sensitivity than fibres based on absorption 
only. Therefore, as DVB/CAR/PDMS presents a wide range capacity of sorbing compounds 
and it is recommended by the producers in the analysis of compounds with different 
physicochemical properties within a molecular weight ranging from 40 to 275. 
The extraction time was studied by increasing the fibre exposure time from 5 to 60 
min. Higher extraction time promoted higher extraction efficiency for all the fibres under 
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study. Sorption time for the selected standards indicated an extraction time of 60 min. 
Although this is a long extraction time, maximum sensitivity is desirable, at this particular 
stage, so that the knowledge of exhaled breath is maximized. 
The SPME process is also influenced by temperature. Higher extraction temperature 
usually increases the analytes release, therefore increasing their concentration in the 
headspace, due to the enhanced mass transfer (kinetics). Two temperatures were studied: 5ºC 
and 22ºC (room air temperature). Higher temperatures were avoided because heating these 
containers could possibly release contaminants or produce artifacts to the headspace, therefore 
influencing the results. For all fibres and extraction times under study, 22ºC allowed higher 
extraction efficiency. 
The extraction at 22ºC for 60min with the SPME coating fibre DVB/CAR/PDMS was 
selected for further breath extractions. For the selected conditions, RSD was considered 
acceptable (10%). 
 
 Breath analysis 
Beside the HS-SPME optimization for breath analysis there are several factors that 
have to be considered and optimized. Among the factors, we optimized the type of breath 
sampling containers used, the cleaning procedure adopted to such containers as well as an 
important parameter such as intra-individual variability. After these optimization steps, the 
developed methodology was applied to a set of 50 children (35 with allergic asthma, among 
these 13 had also allergic rhinitis and 15 healthy children). 
 
Breath sampling containers 
  There are a wide range of methods for sampling exhaled breath, which can include 
canisters, cold trapping, adsorbing agents, BIOVOC®, Teflon and Tedlar® gas sampling 
bags. These containers should be easy to operate, easy to handle and be able to store a sample 
for a prolonged period of time ( in breath sampling the storage time is a major drawback). 
Cost, re-usability, durability, size and versatility are other important issues to take in 
consideration when choosing the adequate container. As a result, Tedlar® gas sampling bags 
and BIOVOC® were chosen for further studies. 
The suitability of two sampling containers Tedlar® gas sampling bags and BIOVOC® 
was investigated using the exhaled breath of a child with allergic asthma with the previously 
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developed HS-SPME methodology. Taking into consideration the obtained results (Figure 
2.2), Tedlar® bags are the best choice for sampling exhaled breath.  
 
Figure 2.2 - Total peak area and number of compounds comparison between two breath collection containers 
(Tedlar® gas sampling bags and BIOVOC®). a.u. – arbitrary units. 
 
There was a great difference between both containers with the identification of forty-
four compounds for samples stored in Tedlar® bags, while for samples stored in BIOVOC® 
twenty-two were identified  In terms of total peak area, the difference between BIOVOC® 
and Tedlar® bag was considerable as BIOVOC® total peak area only represented 10% of the 
obtained by using the Tedlar® bag. For follow-up procedures, the Tedlar® bag was chosen. 
Tedlar® bags are frequently used to collect exhaled breath12 as it fulfils the requisites 
for sampling and storing this type of samples. Nevertheless, Tedlar® bags have two main 
disadvantages: (1) impurities derived from the manufacturing process and (2) sample leakage 
due to adsorption or diffusion through the walls. The manufacturer recommends flushing the 
bag three times with compressed air or nitrogen before use so that the contaminants are 
eliminated. The effectiveness of this routine on Tedlar® bags was evaluated from no flush, 
flushing three and ten times using the previously HS-SPME/GC-MS developed methodology. 
Blank runs were made, filling the Tedlar® gas sampling bags with compressed air and several 
pollutants, a total of sixteen compounds, were identified (Table 2.2).  
 
 
 
 
44
22
0
5
10
15
20
25
30
35
40
45
50
0.0E+00
2.0E+07
4.0E+07
6.0E+07
8.0E+07
Tedlar Biovoc
N
u
m
be
r 
o
f C
o
m
po
u
n
ds
To
ta
l P
ea
k 
A
re
a
 
(a.
u
.
)
Chapter 2 - Exhaled breath analysis 
 
84 
 
 
 
Table 2.2 - Volatiles identified in Tedlar bags and cleansing procedure effects with rising number of nitrogen 
flushes 
Retention time (min.) Compounds CAS number 
Volatiles identified in Tedlar bags 
No nitrogen 
flushes 
3 nitrogen 
flushes 
10 nitrogen 
flushes 
Alkanes      
6.34 hexane* 110-54-3 x x x 
7.20 2,4-dimethyl-heptane 2213-23-2 x n.d. n.d. 
7.65 4-methyl-octane 2216-34-4 x n.d. n.d. 
11.40 undecane* 1120-21-4 x n.d. n.d. 
      
Carbonyl Compounds      
7.39 acetone* 67-64-1 x x n.d. 
26.48 benzaldehyde* 100-52-7 x x x 
21.10 acetic acid* 64-19-7 x x x 
      
Aromatic Compounds      
33.77 phenol* 108-95-2 x x x 
13.56 dMethEthBenza 1075-38-3 x x x 
14.32 m/z 105, 122, 91 - x x x 
      
Miscellaneous      
8.57 dichloromethane* 75-09-2 x x x 
10.20 α-pinene* 80-56-8 x x x 
10.10 chloroform* 67-66-3 x x n.d. 
25.23 (N,N-dimethyl)-acetamide 127-19-5 x x x 
35.18 diethyl phthalate 84-66-2 x x x 
36.71 phthalate isobutyrate 103-28-6 x x x 
n.d. – not detected 
*Compounds confirmed by chemical standards 
a1-(1,1-dimethylethyl)-3-methyl-benzene – dMethEthBenz 
 
Increasing the number of nitrogen flushes produces a positive result as the number of 
compounds diminishes. Nevertheless, a more detailed overview of these results is 
demonstrated taking into consideration two contaminants reported in literature12, (N,N-
dimethyl)acetamide and phenol. There is a significant reduction of the total peak areas with 
the increase of number of flushes. For (N,N-dimethyl)acetamide, the total peak area 
diminished 74% and 94% whereas for phenol the reductions were of 57% and 99% with three 
and ten flushes respectively, relatively to the initial composition (no flush) (Figure 2.3). For 
further analysis, Tedlar® bags were vacuumed and flushed ten times with nitrogen. With 
these results a standard cleaning protocol for the Tedlar® bags was established for the present 
study.  
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Figure 2.3 - Cleaning procedure effects with rising number of nitrogen flushes for two reported contaminants 
((N,N-dimethyl)-acetamide and phenol) in Tedlar bags. a.u. – arbitrary units 
 
Intra-individual variability evaluation 
 The intra-individual variability was examined, comparing the data per subject from 
day to day, and throughout each day, by repeating breath sampling for the same child with 
allergic asthma over a period of 3 weeks with six daily collections (n= 18). This is an 
important factor in the evaluation of the developed methodology to determine whether a 
breath sample is dependent on the period of time that it is collected. Figure 2.4 summarizes 
the results of six selected compounds that represent linear and ramified alkanes and 
aldehydes.  
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Figure 2.4 - Evaluation of the intra-individual variability over a period of three weeks for selected group of six 
compounds. – arbitrary units 
 
Single factor ANOVA was performed to evaluate data variability and there were no 
significant differences between days, and throughout each day, represented by weeks 1, 2 and 
3 (p < 0.05). However, accordingly to Figure 2.4, there are intra-individual variations between 
samples over different days of the three weeks as well as in the same day that can be 
explained by several factors, as for example the circadian rhythm, and diet (sampling were 
performed throughout the day, before and after meals with different daily diets). It was 
confirmed that the child asthma status was maintained during this experiment with no 
occurrence of an asthma crisis. This study was performed with a single subject, and the results 
obtained are similar to those reported in previous study that has used a larger number of 
subjects13. 
 
Exhaled breath analysis 
 The developed HS/SPME-GC-MS methodology was applied to exhaled children 
breath samples. Forty-four volatile compounds were identified belonging to different 
chemical families such as alkanes (linear and ramified), ketones, aromatic hydrocarbons, 
aldehydes, acids, among others (Table 2.3). The predominant group identified in exhaled 
breath were the alkanes (26 compounds). The identified compounds are also reported in other 
studies performed using exhaled breath3,14, 15. 
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Table 2.3 - Identified compounds in exhaled breath in both children with allergic asthma and healthy children 
and obtained from ambient air parallel sampling 
Peak 
Number 
R.T. (min.) Compounds CAS number m/z¥ Breath Ambient 
air 
 
 Hydrocarbons     
 
 Alkanes     
1 6.34 hexane* 110-54-3 57a, 43,41 x x 
3 7.20 2,4-dimethylheptane 2213-23-2 43,57,85 x - 
5 7.65 4-methyloctane 2216-34-4 43,41,85 x x 
6 8.94 2,2,4-trimethylhexane 16747-26-5 57,56,41 x x 
7 9.57 decane* 124-18-5 43,57,41 x - 
8 10.19 3,3-dimethylheptane 4032-86-4 43,57,71 x - 
10 10.29 2,4-dimethyloctane 4032-94-4 57,71,85 x - 
12 11.15 3-ethyl-3-methylheptane 17302-01-1 71,43,85 x - 
13 11.27 2,3,7-trimethyldecane 62238-13-5 43,71,57 x - 
14 11.40 undecane* 1120-21-4 71,43,57 x - 
16 11.61 2,3-dimethyldecane 17312-44-6 71,43,85 x - 
19 14.10 dodecane* 112-40-3 57,43,71 x x 
21 15.15 3,9-dimethylundecane 17301-31-4 71,57,43 x - 
25 16.56 3,6-dimethyldecane 13150-81-7 71,43,57 x - 
26 16.57 tridecane* 629.50-5 57,43,71 x - 
28 16.82 n.i. - 43,71,57 x - 
29 17.11 n.i. - 71,57,43 x - 
31 17.42 2,5,6-trimethyldecane 62108-23-0 71,57,43 x - 
33 19.35 tetradecane* 629-59-4 57,43,71 x x 
38 21.64 pentadecane* 629-62-9 71,43,85 x x 
39 21.90 n.i. - 43,85,71 x - 
41 22.50 n.i. - 57,71,85 x - 
42 22.73 n.i. - 71,43,57 x x 
47 24.30 hexadecane* 544-76-3 57,43,71 x - 
48 25.08 2-methyl-tridecane 1560-96-9 57,43,71 x - 
52 25.86 2,6,10-trimethyldodecane 3891-98-3 57,71,43 - x 
53 26.24 2-methylpentadecane 1560-93-6 57,43,71 x x 
59 28.26 n.i. - 57,71,85 - x 
       
 
 Aromatic     
11 10.93 toluene* 108-88-3 91,92,65 x x 
18 13.02 p-xylene* 106-42-3 91,106,65 x x 
24 16.21 styrene 100-42-5 104,103,78 x - 
60 28.72 napthalene* 91-20-3 128,120,102 - x 
76 37.23 2,6bmethnapthb 24157-81-1 197,212,155 - x 
    
 
  
 Ketones   
4 7.39 acetone* 67-64-1 43,58,42 x x 
30 17.27 cyclohexanone* 108-94-1 55,98,42 - x 
32 18.08 6-methyl-5-hepten-2-one* 110-93-0 43,41,69 x x 
54 26.48 acetophenone* 98-86-2 105,120,77 x x 
       
 
 Monoterpenic compounds   
 
 Hydrocarbon type   
9 10.20 α-pinene* 80-56-8 93,92,91 - x 
17 12.15 α-phellandrene* 99-83-2 93,77,79 - x 
20 14.39 limonene* 138-86-3 68,67,93 - x 
    
 
  
  Alcohol type  
 
  
51 25.61 menthol* 1490-04-6 71,95 - x 
    
 
  
  Ketone type  
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Peak 
Number 
R.T. (min.) Compounds CAS number m/z¥ Breath Ambient 
air 
63 30.48 neryl acetone* 3879-26-3 43,69,107 - x 
    
 
  
       
 Aldehydes   
15 11.51 hexanal* 66-25-1 44,56,41 - x 
34 19.55 nonanal 124-19-6 43,57,57 x x 
40 22.24 decanal* 112-31-2 41,43,57 x x 
44 23.46 benzaldehyde* 100-52-7 77,105,106 x x 
       
 Acids   
36 21.10 acetic acid* 64-19-7 43,45,60 x x 
43 23.20 propanoic acid* 79-09-4 74,45,73 x - 
57 27.83 pentanoic acid* 109-52-4 60,70,41 - x 
62 30.18 hexanoic acid* 142-62-1 60,73,41 - x 
66 32.24 2-ethylhexanoic acid 149-57-5 88,73,57 - x 
67 32.40 heptanoic acid* 111-14-8 60,73,87 - x 
72 34.49 octanoic acid* 124-07-2 60,73,43 - x 
       
 
 Miscellaneous   
2 6.48 2-methyl-1,3-butadiene 78-79-5 67,68,53 x - 
22 15.27 n.i. - 57,55,43 x x 
23 15.71 n.i. - 105,120,43 x - 
27 16.79 n.i. - 105,120,84 - x 
35 19.68 2-butoxy-ethanol 111-76-2 57,45,41 x x 
37 21.45 2,1meox2propc 20324-33-8 59,103,43 - x 
45 23.82 n.i. - 73,43,59 - x 
46 23.98 n.i. - 57,82,67 - x 
49 25.19 2etoxethd 111-90-0 45,59,72 - x 
50 25.50 phenylethyl acetate 103-45-7 94,43,136 x - 
55 26.63 n.i. - 71,57,43 x x 
56 26.77 4-tert-butylcyclohexyl acetate 32210-23-4 57,80,73 - x 
58 28.00 benzyl acetate 140-11-4 108,91,90 - x 
61 29.19 n.i. - 57,41,71 - x 
64 31.19 benzyl alcohol* 100-51-6 79,108,107 - x 
65 31.97 2-phenyldodecane 2719-61-1 91,73,122 - x 
68 32.51 1-undecanol* 112-42-5 55,43,69 - x 
69 33.19 2-methyl-1-undecanol 10522-26-6 58,43,69 - x 
70 33.77 phenol* 87-66-1 94,66,65 x x 
71 33.87 isopropyl tetradecanoate 110-27-0 228,102,229 - x 
73 35.19 β-ionone* 14901-07-6 177,119,135 - x 
74 35.66 2-methyl-β-ionone 127-43-5 191,121,105 - x 
75 36.78 β-phenoxyethyl alcohol 9004-78-8 94,138,77 - x 
n.i.: not identified 
*Compounds confirmed by chemical standards 
¥
 Identification of highest abundance m/z 
aUsed fragment for area determination 
b 2,6bmethnapth: 2,6-bis(1-methylethyl)naphthalene 
c 2,1meox2prop: 2,1-(2-methoxy-1-methylethoxy)-2-propanol 
d 2etoxeth: 2-(2-ethoxyethoxy)ethanol 
 
Parallel room air sampling was also performed by the reported fact that in the 
environment there are a whole range of volatiles from several sources, which may influence 
the obtained results. Room air analysis allowed the identification of fifty-three compounds 
that belong to several different chemical families: alkanes (linear and ramified ketones, 
terpenic compounds, aromatic hydrocarbons, aldehydes, acids, among others (Table 2.3). 
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From these, twenty one compounds were common to children exhaled breath. Compounds 
that were present in room air with higher areas than in breath were discarded for PLS-DA 
analysis, as hexane for example, among others. 
 
Multivariate analysis 
Twenty-five from the forty-four volatiles were selected for multivariate analysis. This 
selection was made taking account the compounds that were present in all children with 
allergic asthma and by disregarding compounds that are known as solvents and 
contaminations (for example, aromatic hydrocarbons).  
 
Figure 2.5 – (A) PLS-DA LV1xLV2 scores scatter plot and (B) loading weights plot of exhaled breath for 
allergic asthma (AA and AA+RA) and heatlhy children. Peak identification is presented in Table 2.3. 
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PLS-DA was applied to the GC chromatographic unit variance scaled areas to 
establish a preliminary classification model and assess the relationships between the 
compounds and the children under study. Figure 2.5 A shows the scores scatter plot of the 
first two Latent Variables (LV1xLV2), while Figure 2.5 B shows the corresponding loading 
weights plot which establishes the contribution of each volatile compound that promotes the 
observed discrimination. The classification model was assessed by internal cross-validation (7 
blocks) giving a model with 4 LVs with a classification rate of 88%. A limited number of 
compounds (28) were used to classify children with allergic asthma and healthy children 
using discriminant analysis, with special highlight to compounds linked to oxidative stress 
such as alkanes and aldehydes16. These compounds were not unique to children with allergic 
asthma and were also observed in healthy children in greater or lesser abundance as normal 
human metabolism generates a wide variety of compounds. Airway inflammation plays a 
central role in the pathophysiology of asthma and during this process a degradation of 
polyunsaturated fatty acids occurs due to the imbalance between oxidants and antioxidants. 
This imbalance is explained by the continuous production of ROS caused by an influx of 
leukocytes characteristic of lung inflammation in asthma. During this process volatile 
compounds are formed by LPO of ω-3 and ω-6 polyunsaturated fatty acids17. 
From Figure 2.5 A, there are two relatively defined clusters with a clear tendency for 
the healthy group being associated with LV1 and LV2 negative values explained by 2,4-
dimethylheptane, 4-methyloctane and acetone, whereas the allergic asthma group is dispersed 
most probably due to the distinct allergic asthma as well as different disease stages. There are 
clusters for allergic asthma children for example in LVI and LV2 positive values that seems 
to have contribution from decane, dodecane and tetradecane. Another region is LV1 negative 
and LV2 positive values influenced by 2-methyl-1,3-butadiene whereas the allergic asthma 
children that are clustered in LV1 positive region and LV2 negative values are mainly 
influenced by 2,2-dimethylhexane, 2,4-dimethyloctane and 2,3,6-trimethyldecane among 
others. C13 alkanes were previously used to discriminate asthma patients from children13, 
being more intense in asthmatic ones. 
Clinical data such as therapy, spirometry values, IgE values and prick test results were 
also available. The PLS-DA scores scatter plot was tentatively explained using clinical data. 
Allergic asthma is a condition associated to airspace inflammation with increasing evidence 
that LPO may have an important part in the differentiating the composition of exhaled breath 
between allergic asthma and healthy group. Compounds as the identified alkanes, and that 
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exerted statistical differences between allergic asthma and healthy group, might be an end-
product of LPO but other pathways cannot be excluded. Allergic rhinitis is symptomatic 
disorder of the nose induced after allergen exposure, an IgE mediated inflammation of the 
membranes lining of the nose. Both allergic asthma and rhinitis are systemic inflammatory 
conditions and usually over 80% of asthmatics have rhinitis and 10-40% of patients with 
rhinitis have asthma. In the studied population, 63% were diagnosed with allergic asthma 
(AA) whilst 37% with allergic asthma and allergic rhinitis (AA+AR) and from the PLS-DA 
we denote that AA+AR cases are predominantly in LV1 negative LV2 positive whereas for 
AA children there is a higher scattering throughout LV1 axis. Both diseases are inflammatory 
diseases; however inflammation in rhinitis is concentrated in the nose while in allergic asthma 
occurs in the airways modifying the volatile composition as observed in Figure 2.5 A. 
Prick tests were also available with 54% of the studied cases being allergic to dust 
mites, 9% dust mites and gramineae, 9% dust mites and cat fur and 3% to dust mite, 
gramineae and car fur. Due to a higher number of cases the cases with positive prick tests to 
dust mites are highlighted in the PLS-DA and from this data we observe a high dispersion 
through LV1 axis. As for the other possible combinations, a higher number of cases are 
necessary to exert any conclusions.  
Several medication combinations are prescribed by clinicians to control allergic 
asthma and rhinitis. Inhaled corticosteroids prevent asthma symptoms by blocking the late-
phase immune reaction to an allergen, reduce airway hyppersponsiveness and decreases 
inflammation and inhibit inflammatory cells such as mast cells, eosinophils and basophils. 
Leukotriene receptor antagonist or leukast are drugs that inhibit the leukotrienes receptors, 
compounds that are produced by the immune system that cause inflammation in asthma and 
that constrict airways whereas a histamine antagonist or antihistamine is an agent that inhibits 
the action of histamine that is released in excess by an allergic reaction. Bronchodilators are 
used to dilate the bronchi and bronchioles decreasing airway resistance and thereby 
facilitating airflow. In our population, the three most frequent combinations were: inhaled 
corticosteroids and leukotriene receptor antagonist, inhaled corticosteroids and anti-
histamines or inhaled corticosteroids and bronchodilator. As far as medication effects on 
breath volatile composition that should reflect the inflammation, we observed in the PLS-DA 
(highlighted with an asterisk in Figure 2.5 A differences between the exhaled breath of 
children that used a combination between corticosteroid and leukotriene receptor antagonist 
for asthma control as these individuals presented themselves closer to control subjects than 
other subjects that were under corticosteroid and anti-histaminic or corticosteroid and 
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bronchodilator therapy. This occurrence may be explained by the properties of the 
combination of inhaled corticosteroids and leukotriene receptor antagonist as both decrease 
inflammation consequently affecting the volatile composition of exhaled breath and thereby 
inflammation compounds such as linear and ramified alkanes. 
 
2.2.5 Concluding remarks 
In this study, we report the development of HS-SPME/GC-MS methodology using a 
full factorial design. Breath sampling related subjects such as breath sampling containers and 
their cleaning, as well as an important parameter like intra-individual variability were also 
determined. The optimization of SPME parameters was done with selected standards 
representative of different chemical families previously reported in human breath3,9 and the 
higher extraction efficiency was obtained with the mixed phase DVB/CAR/PDMS fibre with 
an extraction of 60min and a temperature of 22ºC. 
The comparison between 1 L Tedlar® gas sampling bags and BIOVOC®, for breath 
collection, showed Tedlar® gas sampling bags to be the most adequate containers for 
collecting breath samples. The cleaning protocol for the Tedlar® bags was also established 
and consists of flushing the bag with nitrogen ten times, preceded by vacuum. As for intra-
individual variability, results show that there was no statistical difference between sampling 
exhaled breath within the same day as well as sampling between different weeks, if the 
asthma status is maintained. 
The developed methodology was then successfully applied to breath samples of 
allergic asthma children and healthy children, allowing the identification of forty-four 
volatiles from different chemical families, namely: alkanes (linear and ramified) ketones, 
aromatic hydrocarbons, aldehydes, acids, among others. Multivariate studies were performed 
(PLS-DA) using a set of 28 selected compounds and the corresponding loadings suggested the 
compounds that promoted the observed distinction between allergic asthma and healthy 
children. The allergic asthma population was characterized mainly by the compounds possibly 
linked to oxidative stress, such as alkanes and aldehydes, which is a characteristic of airway 
inflammation. Furthermore, more detailed information can be achieved about the asthma 
metabolic volatile profile by the proposed approach. The advantage of the developed method 
was observed when the volatile metabolic data processed by PLS-DA was explained using the 
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clinical data. Further studies are being performed increasing the number of allergic asthma 
and healthy children. 
Although the number of cases studied is relatively small (50), the obtained results 
generated fundamental information which represents the scientific basis for the definition of a 
rapid and non-invasive diagnostic tool. The results of this study provided a novel 
methodological approach to characterize allergic asthma as a function of its metabolomic 
patterns, which will open new strategies to early diagnosis, therapy monitoring, and 
understanding the asthma pathogenesis that affects millions around the world. 
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2.3 Allergic asthma exhaled breath metabolome: A challenge for 
comprehensive two-dimensional gas chromatography 
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2.3.1 Abstract 
Allergic asthma represents an important public health issue, most common in the 
paediatric population, characterized by airway inflammation that may lead to changes in 
volatiles secreted via the lungs. Thus, exhaled breath has potential to be a matrix with relevant 
metabolomic information to characterize this disease. Progress in biochemistry, health 
sciences and related areas depends on instrumental advances, and a high throughput and 
sensitive equipment such as GC×GC–ToFMS was considered. GC×GC–ToFMS application 
in the analysis of the exhaled breath of 32 children with allergic asthma, from which 10 had 
also allergic rhinitis, and 27 healthy children allowed the identification of several hundreds of 
compounds belonging to different chemical families. Multivariate analysis, using PLS-DA in 
tandem with MCCV was performed to assess the predictive power and to help the 
interpretation of recovered compounds possibly linked to oxidative stress, inflammation 
processes or other cellular processes that may characterize asthma. The results suggest that 
the model is robust, considering the high classification rate, sensitivity, and specificity. A 
pattern of six compounds belonging to the alkanes characterized the asthmatic population: 
nonane, 2,2,4,6,6-pentamethylheptane, decane, 2-methyldecane, dodecane, and tetradecane. 
To explore future clinical applications, and considering the future role of molecular-based 
methodologies, a compound set was established to rapid access of information from exhaled 
breath, reducing the time of data processing, and thus, becoming more expedite method for 
the clinical purposes. 
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2.3.2 Framework 
Hundreds of different volatiles are present in human breath, and their relative 
concentrations may alter via the disease13. Exhaled breath has been studied using 1D-GC in 
lung diseases, such as asthma13, cystic fibrosis18 and lung cancer10,19. Although such approach 
often provides satisfying analytical results an in-depth chromatogram analysis frequently 
indicates that some peaks are the result of two or more co-eluting compounds. GC×GC 
employs two orthogonal mechanisms to separate the constituents of the sample within a single 
analysis, based on the application of two GC columns coated with different stationary phases, 
which increases peak capacity as a result of the product of the peak capacity of the two 
dimensions. For example, a non-polar / polar phase combination (NP / P), connected in series 
through a modulator interface achieves this goal. For instance, using a cryogenic modulator, 
the interface samples small (several seconds) portions of the 1D eluate by cryofocusing, and 
re-injects them into the second column (2D). Each 1D peak is modulated several times, largely 
preservating the 1D separation. Co-eluting compounds from 1D undergo additional separation 
on 2D20 Sensitivity and limits of detection are improved due to focusing of the peak in the 
modulator and separation of analytes from chemical background21 compared to 1D-GC. 
ToFMS brings several advantages such as full mass spectra acquisition at trace level 
sensitivity and mass spectral continuity, which allows for deconvolution of spectra of co-
eluted peaks22.  
Thus, this study aims to obtain a deeper knowledge of allergic asthma based on 
exhaled breath analysis using a previously developed HS-SPME extraction technique, as well 
as several other exhaled breath sampling parameters (Chapter 2.1), combined with GC×GC–
ToFMS system. The first step was to check the separation potential of GC×GC–ToFMS and 
sensitivity issues, important parameters in exhaled breath analysis, a complex matrix with 
several compounds in the micromolar to nanomolar range23. Secondly, PLS–DA and MCCV 
were performed to assess both the predictive power and classification models robustness. 
Moreover PLS-DA regression vectors were used to help understand metabolic variations 
important to class discrimination. 
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2.3.3 Experimental 
Standards and materials 
Several reagents were used to perform this study: linear alkanes (C8-C20) in hexane 
(99.5%, Fluka, Madrid, Spain), linear alkenes (C8-C20) (98%, Sigma-Aldrich, Madrid, Spain), 
aldehydes: hexanal (98%, Sigma-Aldrich, Madrid, Spain), (E)-2-nonenal (95%, Acros 
Organics, Geel Belgium), decanal (98%, Sigma-Aldrich, Madrid, Spain), ketones: 3-
heptanone (97%, Sigma-Aldrich, Madrid, Spain), 5-methyl-3-heptanone (94%, Sigma-
Aldrich, Madrid, Spain), 3-octanone (98%, Sigma-Aldrich, Madrid, Spain), absolute ethanol 
was supplied by Panreac (99.5 %, analytical grade, Barcelone, Spain). Ultra pure water was 
obtained from a Milli-Q system from Millipore (Milford, MA, USA). 
For the sensitivity studies, a stock solution of each standard (1 g/L) was prepared in 
absolute ethanol and made up to volume, and from this a solution of 100 mg/L was set up. A 
working solution was prepared to yield different concentrations and to reproduce a two-phase 
system (headspace and coating fibre), as in breath analysis, 5 µL was added to a 120 mL 
SPME flask and sealed with an aluminium crimp cap with a vial was capped with a PTFE 
septum (Chromacol, Hertfordshire, UK), and concentrations ranged from 20 to 200 ×103 pg/L. 
The SPME holder for manual sampling and fibre were purchased from Supelco 
(Aldrich, Bellefonte, PA, USA). The SPME device included a fused silica fibre coating 
partially cross-linked with 50/30µm divinylbenzene-carboxen-poly(dimethylsiloxane) 
(DVB/CAR/PDMS). Prior to use, the SPME fibre was conditioned at 270 ºC for 60 min in the 
GC injector, according to the manufacturer’s recommendations. Then, the fibre was daily 
conditioned for 10 min at 250 ºC. 
 
Samples 
A group of 32 children with allergic asthma, from which 10 had allergic asthma and 
allergic rhinitis, and 27 healthy children volunteered for this study (n=59). The characteristics 
of the patients and children are presented in Table 2.4. A naive patient was also included in 
this study. This patient was a 9 years old female child that had never taken an asthma drug 
and was diagnosed by physicians with allergic asthma based on symptoms history and skin 
prick tests were performed being positive for dust mites. After the first consult, this child was 
prescribed a combination of anti-histamine and a leukotriene receptor antagonist. The 59 
individuals correspond to a total of 69 exhaled breath samples. Usually, each individual 
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corresponds to one breath sample, except for an allergic asthma child that was collected up to 
6 times in different locations/time periods and for the naive exhaled breath was collected at 
four different moments. 
Table 2.4 Characteristics of the studied population: allergic asthma and healthy children. 
 Allergic asthma Healthy 
Age in years (range/median)  4-16/9 3-6/5 
Gender (male/female) 18/14 15/12 
Pathology 
Allergic Asthma (AA) 22 (69%) - 
Allergic Asthma + Allergic Rhinitis (AA+AR) 10 (31%) - 
Allergensa 
Dust mite 18 (56%) - 
Dust mite + gramineae 5 (16%) - 
Gramineae 4 (13%) - 
Dust mite + cat fur + gramineae 2 (6%) - 
Dust mite + cat fur 1 (3%) - 
Gramineae + cat fur 1 (3%) - 
Dust mite + cockroach  1 (3%) - 
Therapy 
Corticostero Leukotri Bronchodilato Anti- Nasal 
  
x x x - - 1 (3%) - 
x - x - - 9 (28%) - 
x x - - - 5 (16%) - 
- x - x x 2 (6%) - 
- - x x - 5 (16%) - 
- x x - - 1 (3%) - 
- - - x x 2 (6%) - 
- x - x - 1 (3%) - 
No therapy 6 (19%) - 
a
 Results obtained by prick-tests 
 
The allergic asthma population represented a controlled asthma status, with exception 
of a naive child. No restrictions were applied regarding drugs or diet, and each allergic asthma 
and healthy groups were sampled in two distinct locations (in a total of four collections sites). 
The study was approved by the hospital ethics committee and the daycare administration. 
 
Breath sampling  
The breath sampling parameters were previously optimized (Chapter 2.1). Exhaled 
breath was collected in 1 L Tedlar® bags. Children were asked to cleanse their mouth with 
water before sampling. Subsequently, children were instructed to inhale and exhaled normally 
and then exhale deeply into the Tedlar® bag previously holding their breath for 5s. The 
collection method was successfully done by all volunteers. Each subject provided one sample 
using a disposable mouthpiece. Before collecting exhaled breath, all bags were thoroughly 
cleaned to remove residual contaminants by flushing with high purity nitrogen gas. The bags 
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were transported to the laboratory and the analysis was performed to a maximum of six hours 
as recommended by Mochalski et. al.24. On average, the analysis was performed after two to 
three hours after sampling. The bags were stored at 22 °C. 
 
HS-SPME methodology 
The SPME coating fibre and the experimental parameters were adopted from a 
methodology previously developed in our laboratory (Chapter 2.1): DVB/CAR/PDMS fibre, 
and an extraction temperature and time of 22 ºC and 60 min, respectively. Following the 
extraction procedure, the SPME fibre was retracted from the Tedlar® bag and inserted in the 
GC system injection port. The HS-SPME methodology was also applied to selected standards 
to verify the GC×GC sensitivity as previously described in standards and materials section. 
Each breath represents a single sample, and was analysed once. To verify the absence of any 
carry over, blanks (that corresponds to the analysis of the coating fibre not submitted to any 
extraction procedure and Tedlar® bags) were performed. 
 
GC×GC–ToFMS analysis 
After the extraction/concentration step, the SPME coating fibre was manually 
introduced into the GC×GC–ToFMS injection port at 250 °C. The injection port was lined 
with a 0.75 mm I.D. splitless glass liner. Splitless injections were used (2 min). The LECO 
Pegasus 4D (LECO, St. Joseph , MI , USA ) GC×GC-ToFMS system consisted of an Agilent 
GC 7890A gas chromatograph (Agilent Technologies, Inc., Wilmington , DE ), with a dual 
stage jet cryogenic modulator (licensed from Zoex) and a secondary oven, and mass 
spectrometer equipped with a high resolution ToF analyzer. An HP-5  column (30 m × 0.32 
mm I.D., 0.25 µm film thickness, 5% Phenyl-methylpolysiloxane, J&W Scientific Inc., 
Folsom, CA, USA) was used as 1D column and a DB-FFAP (0.79 m × 0.25 mm I.D., 0.25 µm 
film thickness, nitroterephthalic acid modified polyethylene glycol, J&W Scientific Inc., 
Folsom, CA, USA) was used as 2D column. The carrier gas was helium at a constant flow rate 
of 2.50 mL/min. The GC×GC–ToFMS injection port was at 250 °C. The primary oven 
temperature program was: initial temperature 35 ºC (hold 1 min), raised to 40 ºC (1 ºC/min), 
and finally rose to 220 ºC (7 ºC/min) and hold for 1 min. The secondary oven temperature 
program was 15 ºC offset above the primary oven. The MS transfer line temperature was 250 
ºC and the MS source temperature was 250 ºC. A 6 s modulation time with a 30 ºC secondary 
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oven temperature offset (above primary oven) was chosen to be a suitable compromise as it 
maintained the 1D separation, maximized the 2D resolution, and avoiding wrap-around effect 
(the elution time of a pulsed solute exceeds the modulation period) for compounds that were 
late to elute from the 2D. Ideally, all peaks must be detected before the subsequent re-injection 
and, hence, 2tR must be equal or less than the modulation period25,26. The ToFMS was 
operated at a spectrum storage rate of 125 spectra/s. The mass spectrometer was operated in 
the EI mode at 70 eV using a range of m/z 35-350 and the detector voltage was -1695 V. Total 
ion chromatograms (TIC) were processed using the automated data processing software 
ChromaToF (LECO) at signal-to-noise threshold of 80. Contour plots were used to evaluate 
the separation general quality and for manual peak identification. In order to identify the 
different compounds, the mass spectrum of each compound detected was compared to those 
in mass spectral libraries of one home-made (using standards) and two commercial databases 
(Wiley 275 and US National Institute of Science and Technology (NIST) V. 2.0 - Mainlib and 
Replib). The identification was also supported by experimentally determining the retention 
index (RI) values that were compared, when available, with values reported in literature for 
chromatographic columns similar to that used as the 1D column and whenever available 
compared to RI values obtained by GC×GC27-62. For determination of RI values a C8-C20 n-
alkanes series was used, calculated according to the Van den Dool and Kratz equation63. The 
majority (> 90%) of the identified compounds presented similarity matches > 850. The 
GC×GC area data was used as an approach to estimate the relative content of each volatile 
component of exhaled breath. 
 
Multivariate Analysis 
A full dataset comprises 134 metabolites belonging to selected chemical families. A 
sub-set of 23 metabolites was also established by the compounds simultaneously identified by 
GC×GC–ToFMS, and those previously reported in Chapter 2.1 (indicated in Table 2.5). PLS 
is a widely used procedure for both regression and classification purposes. Concerning the 
classification application of PLS, PLS-DA8, the most common approach is to use a Y matrix 
containing dummy variables which defines sample memberships to pre-defined groups and 
allow extracting relevant information/variability that could describe the reasons for the 
observed patterns (clusters). This methodology allows one to understand which variables 
(metabolites) contribute the most for the observed separation. Each sample was mean 
normalized and UV (unit variance) scaled which is a data pre-treatment process that gives to 
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variables the same weight. The PLS-DA was applied to volatile metabolites (both datasets: 23 
and 134 metabolites) tentatively identified by HS-SPME/GC×GC-ToFMS in all exhaled 
breath samples (69) and for classification purposes two groups were used (healthy and 
asthma).The classification model complexity (number of latent variables) of the full dataset 
(134 metabolites) was computed, as well as classification rate and Q2 were estimated by 
cross-validation (7 blocks splits). Model robustness was assessed using MCCV with 1000 
iterations. For each of the 1000 randomly generated classification models, the number of 
Latent Variables (LV), the Q2 (expressing the cross-validated explained variability), and the 
confusion matrix was computed. The selection of model complexity was based on the most 
frequent list of model properties that maximizes the predictive power (i.e., lower LV and 
higher Q2). The sensitivity and the specificity of the model were then depicted from the 
confusion matrix resulting into a ROC map to further assess the results significance. Then, the 
same procedure was applied using permuted class membership. Sensitivity is calculated from 
the ratio between true positives (allergic asthma samples correctly predicted) and the total 
number of modelled breath samples, whereas specificity is determined from the ratio between 
true negatives (healthy samples correctly predicted) and the total number of modelled control 
GC×GC data. 
 
2.3.4 Results and Discussion 
 
The previous study reported the development of an HS-SPME/GC–MS methodology, 
as well as the optimization of important breath sampling parameters and its application to a 
group of children with allergic asthma and children. To increase the information obtained on 
exhaled breath, the HS-SPME technique was applied to exhaled breath of a different 
population (n= 59) using a powerful tool such as the GC×GC–ToFMS, that relatively to 1D 
GC analysis is more sensitive, has higher chromatographic resolution and a structured 
chromatogram is obtained, three relevant advantages. 
Structured chromatogram and sensitivity  
 GC×GC has proven to be a powerful technique in the analysis of complex samples and 
to detect trace components64,65. Automated processing of HS-SPME/GC×GC–ToFMS data 
was used to tentatively identify all peaks in the GC×GC chromatogram contour plots with 
signal-to-noise threshold > 80. The peak finding routine based on deconvolution method 
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allowed to identify ca. 350 compounds per sample comprising several chemical families: 
linear and ramified alkanes, cycloalkanes, alkenes, aldehydes, ketones, aromatic compounds, 
terpenoids and esters. One hundred and thirty four compounds belonging to linear, ramified 
and cycloalkanes, alkenes, aldehydes, ketones and a group of miscellaneous compounds, were 
selected for further studies. The remaining compounds were considered as possible 
contaminants, as for example, aromatic compounds from environmental cumulative 
exposure66, whereas terpenoids and esters can have its origin in ingested foods67. Otherwise, 
the linear, ramified and cycloalkanes, alkenes, aldehydes and ketones have been reported to 
be associated to several biochemical processes that may occur in humans68. 
The total number of compounds detected in allergic asthma exhaled breath substantially 
increased with the use of the GC×GC–ToFMS, approximately 8 times, when compared to the 
obtained results by 1D GC-MS. By 1D GC-MS a total of 44 compounds were identified 
whereas by GC×GC–ToFMS ca. 350 compounds were tentatively identified. For example, 
considering the alkanes, alkenes, aldehydes and ketones, the number of detected compounds 
increased by 66%, 96%, 67% and 56%, respectively. 
The compounds included in the selected dataset were tentatively identified based on 
comparison of their mass spectra to home-made and commercial databases, and by 
comparison of the RIs calculated (RIcalc) with the values reported in the literature (RIlit) for 
5% phenylpolysilphenylene-siloxane (or equivalent) column (Table 2.5). A range between 1 
and 30 was obtained for RIcal compared to the RIlit reported in the literature (|RIcalc-RIlit|) for 
1D-GC with 5%-phenyl-methylpolysiloxane GC column or equivalent. This difference in RI 
is considered minimal (on average lower than 0.5%), and is well justified if one takes into 
account that: (i) the literature data is obtained from a large range of GC stationary phases 
(several commercial GC columns are composed of 5% phenylpolysilphenylene-siloxane or 
equivalent stationary phases), and (ii) the literature values were determined in a 1D-GC 
separation system, and the modulation causes some inaccuracy in first dimension retention 
time65. 
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Table 2.5 - List of volatile compounds identified by GC×GC –ToFMS in exhaled breath of allergic asthma and 
healthy children 
Peak # 1tR a (s) 2tR a (s) Compounds CAS Number RIcalcb RIlit.c (GC) RIlit.
d  
(GC × GC) 
   Hydrocarbons     
   Alkanes     
1 138 0.48 hexane 110-54-3 600 600 600 
4 210 0.52 2,4-dimethylhexane 589-43-5 727 736 729 
7 252 0.54 octane 111-65-9 800 800 800 
11 276 0.55 2,2,4-trimethylhexane e 921-47-1 817 810 -* 
12 288 0.55 2,4-dimethylheptane e 2213-23-2 817 820 822 
13 318 0.56 4-ethyl-2-methylhexane 3074-75-7 831 833 - 
15 366 0.58 alkane isomer (m/z 43, 57, 85) - 853 - - 
20 468 0.56 nonane 111-84-2 900 900 900 
22 504 0.55 alkane isomer (m/z 43, 57, 85) - 919 - - 
23 516 0.55 2,4-dimethyloctane e 15869-93-9 925 924 - 
24 528 0.56 3-ethyl-3-methylheptane e 17302-01-1 932 - 942 
26 540 0.55 2,6-dimethyloctane 2051-30-1 938 936 933 
28 552 0.55 3-ethyl-2-methylheptane 14676-29-0 944 - 942 
30 558 0.55 alkane isomer (m/z 57, 43, 71) - 947 - - 
31 564 0.55 alkane isomer (m/z 43, 57, 71) - 950 - - 
33 576 0.56 4-ethyloctane 15869-86-0 957 956 - 
36 582 0.55 4-methylnonane 17301-94-9 960 962 956 
38 588 0.54 alkane isomer (m/z 57, 43, 85) - 963 - - 
40 594 0.55 alkane isomer (m/z 57, 43, 71) - 966 - - 
42 600 0.55 2-methylnonane 871-83-0 969 970 - 
43 606 0.55 alkane isomer (m/z 57, 43, 41) - 972 - - 
45 612 0.55 3-methylnonane e 5911-04-6 975 976 - 
52 636 0.54 2,2,4,6,6-pentamethylheptane 13475-82-6 988 997 - 
58 660 0.56 decane e 124-18-5 1000 1000 1000 
60 672 0.54 alkane isomer (m/z 57, 41, 71) - 1008 - - 
61 720 0.54 3,9-dimethylnonane e 17302-32-8 1039 1038  
64 756 0.54 2-methyldecane e 17301-30-3 1062 1063 - 
66 768 0.54 alkane isomer (m/z 57, 43, 85) - 1070 - - 
68 774 0.55 3-methyldecane e 13151-34-3 1073 1073 - 
72 786 0.55 alkane isomer (m/z 57, 43, 71) - 1081 - - 
74 798 0.55 2-methyldecane e 6975-98-0 1089 1073 - 
76 804 0.55 alkane isomer (m/z 43, 71, 57) - 1093 - - 
81 822 0.55 undecane e 1120-21-4 1100 1100 1100 
84 864 0.56 2,3-dimethyldecane e 1632-71-9 1135 1118 - 
86 876 0.56 alkane isomer (m/z 57, 43, 71) - 1144 - - 
87 894 0.55 5-methylundecane e 1632-70-8 1157 1154 - 
89 906 0.57 alkane isomer (m/z 57, 43, 71) - 1166 - - 
90 912 0.57 3,9-dimethylundecane e 7045-71-8 1170 1165 - 
95 948 0.57 dodecane e 112-40-3 1200 1200 1200 
96 960 0.58 alkane isomer (m/z 57, 71, 43) - 1206 - - 
99 966 0.57 alkane isomer (m/z 57, 43, 71) - 1211 - - 
100 972 0.56 2,5,6-trimethyldecane e 17301-28-9 1216 1206 - 
101 978 0.57 alkane isomer (m/z 57, 43, 71) - 1221 - - 
104 996 0.56 alkane isomer (m/z 57, 43, 71) - 1236 - - 
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Peak # 1tR a (s) 2tR a (s) Compounds CAS Number RIcalcb RIlit.c (GC) RIlit.
d  
(GC × GC) 
106 1002 0.57 alkane isomer (m/z 57, 43, 71) - 1241 - - 
107 1008 0.57 6-methyldodecane 6044-71-9 1246 1253 - 
108 1020 0.57 alkane isomer (m/z 43, 57, 71) - 1256 - - 
110 1044 0.55 alkane isomer (m/z 57, 43, 71) - 1276 - - 
111 1050 0.55 4-ethylundecane 17312-59-3 1281 - - 
112 1056 0.57 alkane isomer (m/z 57, 43, 71) - 1286 - - 
113 1062 0.55 alkane isomer (m/z 57, 71, 43) - 1291 - - 
115 1068 0.56 alkane isomer (m/z 43, 57, 71) - 1296 - - 
117 1074 0.57 tridecane e 629-50-5 1300 1300 1300 
120 1092 0.57 2,2-dimethyldodecane 49598-54-1 1316 1315 - 
121 1104 0.57 alkane isomer (m/z 57, 43, 71) - 1327 - - 
122 1110 0.57 alkane isomer (m/z 57, 43, 71) - 1332 - - 
123 1116 0.57 alkane isomer (m/z 57, 71, 43) - 1337 - - 
124 1128 0.57 3-ethyl-3-methylundecane e - 1348 1347 - 
125 1152 0.60 2-methyltridecane e 6418-41-3 1369 1371 - 
126 1158 0.59 alkane isomer (m/z 57, 43, 71) - 1374 - - 
127 1170 0.61 alkane isomer (m/z 57, 43, 71) - 1385 - - 
128 1188 0.61 tetradecane e 629-59-4 1400 1400 1400 
130 1284 0.58 alkane isomer (m/z 57, 43, 85) - 1489 - - 
131 1290 0.58 6,6-diethyldodecane - 1495 1498 - 
132 1296 0.64 pentadecane e 629-62-9 1500 1500 1500 
133 1302 0.59 5-ethyl-5-methyltridecane - 1507 1511 - 
134 1338 0.61 3-ethyl-3-methyltridecane - 1544 1549 - 
   
 
    
   Alkenes     
10 252 0.60 3-octene 592-98-3 803 800 - 
14 330 0.61 2,4-dimethyl-1-heptene 19549-87-2 836 842 - 
17 450 0.61 1-nonene 124-11-8 892 889 - 
27 546 0.57 alkene isomer (m/z 55, 41, 69) - 941 - - 
29 552 0.57 3-methyl-1-nonene 2980-41-4 944 944 - 
32 570 0.59 3,4-diethyl-2-hexene 19550-82-4 957 - - 
37 582 0.59 alkene isomer (m/z 69,41,56) - 960 - - 
44 606 0.59 alkene isomer (m/z 69,41,56) - 972 - - 
46 612 059 7-methyl-1-nonene 2980-71-4 975 960 - 
56 648 0.59 4-decene 19398-89-1 994 - 994 
65 762 0.55 alkene isomer (m/z 55, 69, 41) - 1066 - - 
67 768 0.56 alkene isomer (m/z 55, 69, 41) - 1070 - - 
70 780 0.56 (Z)-2-decene 20348-51-0 1077 1072 - 
75 798 0.56 alkene isomer (m/z 55, 69, 41) - 1089 - - 
79 810 0.55 alkene isomer (m/z 69, 55, 41) - 1097 - - 
83 828 0.57 alkene isomer (m/z 55, 69, 41) - 1109 - - 
85 870 0.59 2-methyl-1-undecene 18516-37-5 1140 1144 - 
92 918 0.60 (E)-5-methyl-4-undecene 41851-94-9 1174 - - 
93 924 0.60 (Z)-5-methyl-5-undecene 57024-93-8 1179 - - 
94 942 0.60 1-dodecene 112-41-4 1192 1192 - 
97 960 0.62 alkene isomer (m/z 55, 69, 41) - 1206 - - 
102 978 0.59 alkene isomer (m/z 55, 69, 43) - 1221 - - 
114 1062 0.61 1-tridecene 2437-56-1 1291 1292 - 
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Peak # 1tR a (s) 2tR a (s) Compounds CAS Number RIcalcb RIlit.c (GC) RIlit.
d  
(GC × GC) 
   Cyclic     
5 240 0.57 1,2,4-trimethylcyclopentane 930-57-4 780 779 - 
8 252 0.58 1,4-dimethylcyclohexane 589-90-2 800 - 806 
25 534 0.60 propylcyclohexane 2040-95-1 935 929 - 
34 576 0.59 1,1,2,3-tetramethylcyclohexane 6783-92-2 953 958 - 
47 618 0.60 2-ethyl-1,3-dimethylcyclohexane 7045-67-2 978 - - 
48 624 0.59 1-methyl-3-propylcyclohexane 4291-80-9 982 - - 
49 630 0.58 1-methyl-3-(2-methylpropyl)cyclopentane 29053-04-1 985 - - 
53 642 0.59 ethylpropylcyclopentane 54111-97-6 991 - - 
57 654 0.59 1-methyl-2-propylcyclohexane 4291-79-6 997 - - 
63 732 0.57 hexylcyclopentane 1003-19-6 1047 - - 
73 792 0.57 1,4-dimethylcycloctane 13151-98-9 1085 - - 
77 804 0.59 1-ethyl-2-propycylohexane 62238-33-9 1093 - - 
105 996 0.62 hexylcyclohexane 4292-75-5 1236 1237 - 
116 1068 0.65 1-hexyl-3-methylcyclohexane 591-48-0 1296 - - 
118 1080 0.60 1-butyl-2-propylcyclopentane 62199-50-2 1306 - - 
 
       
 
  Ketones     
2 138 0.79 2-butanone 78-93-3 601 602 - 
6 240 1.16 2-hexanone 591-78-6 781 790 - 
16 438 1.19 3-heptanone 106-35-4 887 885 884 
18 450 1.29 ketone isomer (m/z 43, 58, 71) - 892 - - 
19 450 2.07 ciclohexanone 108-94-1 893 895 - 
54 642 1.10 3-octanone 106-68-3 991 989 - 
55 642 1.33 6-methyl-5-hepten-2-one 110-93-0 991 989 - 
78 804 1.03 2-nonanone 821-55-6 1093 1093 - 
80 810 1.02 ketone isomer (m/z 43, 58, 71) - 1097 - - 
 
       
 
  Miscellaneous     
50 630 2.13 1-octen-3-ol 3391-86-4 985 986 - 
62 720 1.78 2-ethyl-1-hexanol 104-46-7 1040 1026 - 
69 774 0.99 2-nonen-1-ol 22104-79-6 1074 1105 - 
71 780 1.86 1-octanol 111-87-5 1078 1068 - 
91 912 0.97 2-decen-1-ol 22104-80-9 1170 - - 
51 630 3.78 aniline 62-53-3 986 971 - 
41 594 1.83 dimethyl trisulfide 58-80-8 967 972 - 
103 978 3.73 benzothiazole 95-16-9 1223 1227 - 
*–information not available 
a 
– Retention times in seconds (s) for first (1tR) and second (2tR ) dimensions. 
b 
– RI: retention index obtained through the modulated chromatogram. 
c
– RI: retention index reported in the literature for one dimensional GC with a 5%-Phenyl-methylpolysiloxane 
GC column or equivalent17-19,21-46,48-52. 
d 
– RI: retention index reported in the literature for a comprehensive GC×GC system with Equity-5 for the first 
dimension20,47. 
e
 – Set of 23 compounds previously reported in the GC-MS study related to allergic asthma that was used in 
Figure 2.9. 
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The most reliable way to confirm the identification of each compound is based on 
authentic standard co-injection, which in several cases is economically prohibitive, and often 
unachievable in the time available for analysis69, or are not commercially available. Thus, 
GC×GC is an ideal technique for the analysis of complex mixtures where compounds of 
similar chemical structure are grouped into distinct patterns in the 2D chromatographic plane 
providing useful information on both their boiling point and polarity (if  NP / P set of columns 
was used), and relationships of structured retentions have proved especially useful for 
compound identification70. Figure 2.6 demonstrates the structured chromatogram. 
 
Figure 2.6 - Peak apex plot of the alkanes (linear, ramified and cyclic), alkenes, aldehydes and ketones identified 
using allergic asthma exhaled breath sample 
 
A chromatographic space with higher peak density, ranging between 2tR 0.45 and 
1.45s, was chosen, and a peak apex plot was depicted regarding the alkanes, alkenes, 
aldehydes and ketones to better visualise the attained structured chromatogram (Figure 2.6). 
 The components of each chemical group were dispersed through the peak apex plot 
according to their volatility (1D) and polarity (2D) obtained by a combination of NP/P 
columns. For the selected chemical families, as expected, it was observed that the decrease in 
volatility (high 1tR) is mainly related to the increase in the number of carbons. The structured 
2D chromatographic profile was observed within each chemical family based on the 
properties and positions of their functional groups. Globally, based on the functional group of 
the chemical families under study, the 2tR values increase as follows: alkanes < alkenes ~ 
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cycloalkanes < ketones ~ aldehydes. This information can be also confirmed in Table 2.5. 
Alkanes have the lowest polarity (2tR≅ 0.48−0.64 s), followed by alkenes (2tR2tR≅ 0.57−0.62s) 
cycloalkanes (2tR≅  0.57−0.65 s ), ketones (2tR≅0.79−1.33 s), and 
aldehydes (2tR≅0.78−3.58 s). Τhis information is especially useful for classifying unidentified 
compounds.  
A further advantage of a comprehensive chromatographic system can be verified, as 
compounds with similar boiling points that could co-elute in a 1D system, as for example 4-
ethyloctane (33), 1,1,2,3-tetramethylcyclohexane (34) and 2-ethylhexanal (35), are able to be 
separated using the comprehensive chromatographic system (Figure 2.7). These compounds 
have similar volatility, the same 1tR of 576 s but present different polarities, and as a 
consequence they were separated by the second column (2tR of 0.56, 0.59 and 0.92 s, 
respectively). 
 
Figure 2.7 - Blow-up of a part of total ion GC×GC chromatogram contour plot obtained from an allergic asthma 
exhaled breath showing the corresponding ramified alkane, cycloalkane and ramified aldehyde: 4-ethyloctane 
(33), 1,1,2,3-tetramethylcyclohexane (34) and 2-ethylhexanal (35), respectively 
 
Different concentrations, ranging from nmolar to µmolar have been reported for volatile 
breath components71,72, so an important issue is the sensitivity of the used equipment. 
Consequently, the GC×GC–ToFMS sensitivity was verified, and for this purpose a standard 
solution comprising standards pertaining to the previously selected families (alkanes, alkenes, 
aldehydes and ketones) was used, whose concentration, for instance, varied between 20 pg/L 
to 200 ng/L. The standards from the tested compound families were detected at the level 
under study. For demonstration purposes, 1-dodecene (94) and dodecane (95), showed in 
Figure 2.8, were detected at pg/L and ng/L levels. The studied range was lower than the 
reported values to verify that this equipment is able to detect compounds at this concentration 
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level, which could be relevant to identify target compounds that could be important for 
asthma metabolomic studies. 
 
 
Figure 2.8 - Total ion GC×GC chromatogram and corresponding contour plots of 1-dodecene (94) and dodecane 
(95) varying the concentration from 20 (A) to 200×103 pg/L (B) 
 
Multivariate analysis in the establishment of asthma “breath-print”  
In the study performed with GC-MS, 28 compounds, from a total of 44, were selected 
and distinction was achieved with two relatively defined clusters between the healthy and the 
allergic asthma groups. As a first approach, using a different allergic asthma and healthy 
children population, from the 28 compounds identified by GC-MS, 23 were also identified by 
GC×GC–ToFMS and selected for multivariate analysis (indicated in Table 2.5) to verify the 
results obtained in the previous study. PLS-DA was applied to the GC×GC chromatographic 
unit variance scaled areas to establish a preliminary classification model and assess the 
relationships between the compounds and the samples under study (Figure 2.9).  
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Figure 2.9 - PLS-DA LV1×LV2 scores scatter plot (A) and LV1 loading weights plot (B) of exhaled breath for 
allergic asthma and healthy children using a sub-set of 23 compounds identified by GC×GC –ToFMS, and 
previously reported in a study related to allergic asthma3 (peak attribution shown in Table 2.5) 
 
Figure 2.9 A shows that there are two defined clusters with the healthy group being 
mainly associated to LV1 negative values and the allergic asthma group to LV1 positive 
values. From the previous study, the allergic asthma group was mainly characterized by 
decane, dodecane and tetradecane, which was confirmed with this new set of children (Figure 
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2.9 B). However a clear distinction was sought, thus PLS-DA was applied to the full dataset 
of 134 compounds identified by GC×GC–ToFMS. The results obtained are shown in Figure 
2.10.  
 
Figure 2.10 - PLS-DA LV1×LV2 scores scatter plot (A) and LV1 loading weights plot (B) showing the 
potentiality of exhaled breath using the full dataset of 134 compounds identified by GC×GC –ToFMS for 
allergic asthma and healthy children discrimination.. 
 
Figure 2.10 A that presents the scores scatter plot of LV1×LV2, while Figure 2.10 B 
(corresponding LV1 loading weights plot) establishes the contribution of each volatile 
compound that promotes the observed distinction.  
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Scores scatter plot (Figure 2.10 A) shows that the healthy group is associated to LV1 
negative values whereas the allergic asthma group is linked to positive LV1 values. As 
observed in Figure 2.10 B, nonane, 2,2,4,6,6-pentamethylheptane, decane, 2-methyldecane, 
dodecane, and tetradecane are related to the allergic asthma group. The healthy group is 
mainly characterized by 6-methyl-5-hepten-2-one, 1-dodecene, nonanal, decanal, and 
dodecanal. Comparing these results to the previous study, there was an increase in the number 
of compounds that characterize allergic asthma and healthy samples. Interestingly the healthy 
children are characterized mainly by aldehydes and the asthmatic children are characterized 
by alkanes, namely those that arise from the corresponding aldehydes. Hence a pattern seems 
to be noticeable that mainly involves these two chemical families. The behaviour shown in 
the healthy group has also been reported by Corradi et al.73 as nonanal had lower values in 
exhaled breath condensate of children with exacerbated asthma (before and after treatment) 
when compared to healthy. The behaviour of the remaining aldehydes compounds that have 
higher weight in the healthy group has not been previously described. 
According to MCCV statistics, the PLS-DA model had a classification rate of 98% 
and showed 96% sensitivity (≅4% allergic asthma children being misclassified as healthy 
children) and 95% specificity (≅5% of false positives). The most frequent Q2 value was 
around 0.9 (Figure 2.11), with a large prevalence of values in the range of 0.8-1. These results 
suggest that confounding factors, such as, ambient air, gender or age seems to have no 
significance in the distinction power. 
 
 
Figure 2.11 - Q2 values distribution of the original and permuted Monte-Carlo Cross Validation for PLS-DA of 
exhaled breath of full dataset (134 compounds) 
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A relevant aspect brought by the results is that from the 67 identified alkanes 19 are 
methylated, which corresponds to 28% of this chemical family and from these, two 
methylated compounds, as for example 2,2,4,6,6-pentamethylheptane and 2-methyldecane 
have a major contribution in the observed distinction. The methylated alkanes family have 
also been previously reported as these may well be important in asthma characterization13,74. 
These compounds also have an important role in diseases, in which oxidative stress 
apparently may be involved, but to other extents, and with different consequences than 
asthma, such as lung and breast cancer, as well as in lung cancer cell lines75,76,77. These 
compounds have been reported in literature in other exhaled breath studies associated to 
pathological states of the lungs, but as individual markers. For example, 2,2,4,6,6-
pentamethylheptane and decane were identified and compared by Poli et al.78 in exhaled 
breath of patients with non-small lung cancer (NSLC), chronic obstructive pulmonary disease 
(COPD), smokers and controls and their concentrations were higher for NSLC, COPD and 
smokers when compared to controls. Dodecane has been proposed as lung cancer markers79,80. 
These results evidence that overall, for the allergic asthma group, there is a greater 
weight of the alkanes confirming the GC-MS study whereas aldehydes have a major 
importance in the characterization of the healthy group. Alkanes, in the sequence of oxidation 
reactions, are end-compounds that have been associated to oxidative stress and inflammation 
processes81 and the hypothesis formed is that these compounds indicate that the oxidative 
state is at a higher extent in asthmatics when compared to healthy children leading to the 
obtained differences and consequently the alkanes can be associated to allergic asthma. These 
particular compounds can be formed in the inflammatory response induced by the immune 
system that leads to the production of activated leukocytes causing the cells to uptake oxygen 
releasing reactive oxygen species which can damage lung tissue contributing to elevated 
oxidative stress in asthma82 and there is evidence that alkanes can arise as products of LPO of 
unsaturated fats83. Lipid metabolism and oxidative metabolism in the mitochondria have been 
reported recently to be altered in urine of asthma patients84 and a conjecture could be made 
that this alteration shown in urine can also be noticed in exhaled breath, considering the 
alkanes as a measurement of lipid and oxidative metabolism that characterize the allergic 
asthma group.  
 
 “Breath-print” exploration as a potential aid to the clinical practice  
Therapy monitoring is one of the challenges of actual medicine as patients may or may 
not follow treatment as prescribed by the physician. To test the hypothesis that a change 
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would occur in the exhaled breath composition with the intake of the prescribed medication, a 
naive patient (patient that had never taken an asthma drug) was recruited. This naive patient 
was diagnosed by physician as having allergic asthma, and exhaled breath was collected 
previous medication intake and three other moments after intake. The medication that was 
prescribed was the combination of anti-histamine and a leukotriene receptor antagonist. Anti-
histamines are drugs that inhibit the action of histamine whereas leukotriene receptor 
antagonist inhibits leukotrienes that are compounds produced by the immune system that 
cause inflammation. This therapy combination directed to block the effects of histamine and 
leukotriene mediators was performed as it is shown that it is better than stand-alone therapy85. 
The behaviour of a naive child was monitored throughout 24 days (Figure 2.10 A, marked by 
the path trajectory). Initially and after 18 days after the intake of the prescribed drugs, the 
naive individual remains in LV1 positive values but far from the remaining controlled 
subjects. There is an evolution throughout LV1 axis with treatment administration explained 
by the area reduction of nonane, 2,2,4,6,6-pentamethylheptane, decane, 2-methyldecane, and 
tetradecane. Considering that asthma crisis is mainly characterized by inflammation, which is 
accompanied by oxidative stress and subsequently LPO, and that alkanes are evidence of 
these biochemical processes, the observed decrease may be due to a lesser inflammation state 
of this subject leading to lower areas of these compounds. Clinically, the child in the initial 
stages was in a crisis situation almost in a daily basis and throughout the 24 days there was a 
significant improvement of the asthma status control. 
As verified, the obtained “breath-print” allowed the distinction between allergic 
asthmatic and healthy children which could be helpful in understanding this pathology 
through a better insight into the metabolic pathways that may be associated to this condition. 
Nevertheless, for clinical purposes, and having in mind the future of molecular diagnosis, a 
smaller set of compounds is necessary to allow a rapid use of exhaled breath for 
complementary purposes in diagnosis, to follow the disease status and/or the medication 
effect. For this intent, and taking into consideration the previous assertion that a pattern of 
alkanes and aldehydes clearly defines both populations under study, just 9 compounds 
(nonane, 2,2,4,6,6-pentamethylheptane, decane, 2-methyldecane, dodecane, tetradecane, 
nonanal, decanal, and dodecanal) were selected for a new PLS-DA model. The results are 
shown in Figure 2.12 and the chosen pattern was able to discriminate both groups showing the 
exhaled breath testing is a tool that can be used as non-invasive diagnostic method for allergic 
asthma.  
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A remarkable result observed in Figure 2.12 is shown by the path of the naive child (a 
through d - four breath sampling), which suggest the mitigation of asthma symptoms 
following drug intake. This suggests the application of exhaled breath analysis, not only for 
metabolomic profiling of allergic asthma, but also in clinical practice as a possible surrogate 
to the invasive diagnosis tests performed actually. 
 
Figure 2.12 - PLS-DA LV1×LV2 scores scatter plot (A) showing the potentiality of using a sub-set of 9 
compounds of exhaled breath in discrminating allergic asthma and healthy children and the corresponding LV1 
loading weights plot (B): nonane (20), 2,2,4,6,6-pentamethylheptane (52), decane (58), 2-methyldecane (64), 
dodecane (95), tetradecane (128), nonanal (82), decanal (98), dodecanal (129). Path of the naive child - a 
through d - four breath sampling 
-5
-4
-3
-2
-1
0
1
2
3
-3 -2 -1 0 1 2 3
LV
2(2
1%
)
LV 1(35%) Healthy Asthma
a
b
c
d
(A)
-0.8
-0.6
-0.4
-0.2
0.0
0.2
0.4
0.6
20 52 58 64 95 128 82 98 129
Lo
a
di
n
gs
 
w
[1
]
Compound
Alkanes Aldehydes(B)
Chapter 2 - Exhaled breath analysis 
117 
 
To assess both the predictive power and classification model robustness, MCCV was 
also performed, using similar conditions to the previous test. According to MCCV statistics, 
the PLS-DA model had a classification rate of 96% and showed 98% sensitivity (≅ 2% 
allergic asthma children being misclassified as healthy) and 93% specificity (≅7% of false 
positives). The most frequent Q2 value was around 0.8 (Figure 2.13), with a large prevalence 
of values in the range of 0.7-0.9. Classification rate and specificity were slightly lower than 
those obtain for the full dataset, but, still, remained high. The sensitivity was improved. These 
results suggest that the model is robust, even using this set of 9 compounds, reducing the time 
of data processing, and thus, becoming more expedite method for the clinical purposes.  
 
.  
Figure 2.13 - Q2 values distribution of the original and permuted Monte-Carlo Cross Validation for PLS-DA of 
exhaled breath of sub-set of 9 compounds: nonane, 2,2,4,6,6-pentamethylheptane, decane, 2-methyldecane, 
dodecane, tetradecane, nonanal, decanal, and dodecanal 
 
2.3.5 Concluding remarks 
In this study, the development of the first HS–SPME/GC×GC–ToFMS methodology 
was reported for the analysis of exhaled breath of allergic asthma children and the advantages 
of comprehensive chromatography was explored in issues such as the structured 
chromatogram and sensitivity. The structured 2D chromatogram that arose from 1D volatility 
and 2D polarity was shown and sensitivity was assessed. A well-defined chromatographic 
space was obtained with the resulting structured chromatogram, which can aid posterior 
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exhaled breath analysis for example in the identification of otherwise unknown compounds. 
Subsequently, the potentiality of the GC×GC–ToFMS was verified in exhaled breath samples 
from allergic asthma and healthy children. 
The methodology allowed the identification of several hundred compounds belonging 
to different chemical families (linear and ramified alkanes, cycloalkanes, alkenes, aldehydes, 
ketones, aromatic compounds, terpenoids and esters). Multivariate analysis was performed by 
PLS-DA to a group of selected compounds pertaining to alkanes, alkenes, aldehydes, and 
ketones and the GC×GC–ToFMS showed to be advantageous as distinction between both 
groups was attained and a high classification rate was achieved. The obtained “breath-print” 
allowed the discrimination between allergic asthmatic and healthy children, providing insights 
into the metabolic pathways that may be associated to allergic asthma. In general, a pattern of 
six compounds pertaining to the alkanes characterized the asthmatic population: 2-
methyldecane, nonane, 2,2,4,6,6-pentamethylheptane, decane, dodecane, and tetradecane. 
Otherwise, a set of aldehydes (nonanal, decanal, and dodecanal) characterizes the healthy 
population. Thus, a smaller set of 9 compounds comprising alkanes and aldehydes was chosen 
to verify the potential clinical usefulness of exhaled breath for allergic asthma evaluation and 
the obtained results are very satisfactory as, with this set, distinction was obtained. It was also 
confirmed that it is also possible to follow through the effects of medication.  
Exhaled breath metabolome presents itself as a challenge, and in our opinion, 
GC×GC–ToFMS offers advantages that were verified in the present study that corresponded 
to the challenge. This new methodological approach to characterize allergic asthma as a 
function of its metabolomic patterns will enhance the possibility of further allergic asthma 
pathways knowledge. It also provides with an easier methodology combined with a non-
invasive sampling for allergic respiratory disease assessment, regarding diagnostic, prognostic 
and treatment follow-up. Further studies with a larger population are necessary to confirm 
these findings. 
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2.5  The unexplored potential of exhaled breath analysis in the 
aid of asthma clinical management 
 
 
2.5.1 Abstract 
Molecular diagnosis is the epitome of personalized medicine where physicians and 
biochemists play a crucial role in the development of tools for a more rational and objective 
disease monitoring and screening. The main goal of this research study was to use of 
previously developed breath based metabolomic models in asthma disease control, diagnosis 
and monitoring using a new cohort of children with asthma, attending on the secondary health 
care consultations. The ability of using these exhaled breath models in a clinical scenario was 
tentatively performed to monitor the clinical outcome of three children in an exacerbation 
condition, and in addition, to follow the Omalizumab therapy effect on a patient with severe 
asthma. SPME combined with GC×GC-ToFMS was used to recover the breath volatile 
metabolomic signature. A supervised multivariate analysis technique was used to extract 
signal features, to tentatively characterize the disease evolution and to predict the outcome. 
MCCV was applied to the PLS-DA models to evaluate the sensitivity and specificity levels 
and to assess classification model robustness. The prediction tool using the reported models 
was successful based on classification rate, sensitivity and specificity values (≥ 93%). 
Aldehydes and alkanes, end-products of lipid peroxidation, known to be involved in asthma 
oxidative stress, seems to be increased in exacerbation state compared to stable state. 
Furthermore, Omalizumab therapy promoted changes in the patient exhaled breath profile 
over time, namely with the decrease of nonane, 2,2,4,6,6-pentamethylheptane, decane, 2-
methyldecane, dodecane, and tetradecane. Exhaled breath sampling combined with 
comprehensive two-dimensional gas chromatography and multivariate feature extraction, 
represents a non-invasive and rapid tool allowing the molecular data recovering, useful to 
monitor the disease status as a part of the medical treatment or even its interruption, i.e., the 
adherence to medication. 
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2.5.2 Framework 
Exhaled breath is a realistic matrix to be studied in asthma as it contains metabolites 
whose relative concentrations may be altered by the disease81 echoing the metabolic activity 
within the airways. The study of exhaled breath, known as breathomics, is an emerging 
research field focused in health. Usually, method development is crucial and it finds a pattern 
of metabolites related to the abnormal metabolic processes that occurs with the studied 
disease86. The volatile analysis of exhaled breath analysis has captured interest in clinical 
practice87, since it comprises thousands of volatile organic metabolites that are expelled with 
each breath one exhale, making it a high potential non-invasive source for medical purposes 
in lung related diseases, such as asthma, among others74. The exhaled breath volatile 
composition has been relevant in this field shown by many studies that have been reported on 
exhaled breath of asthmatic patients13.  
The aim was to explore the potential of exhaled breath analysis in the aid of asthma 
clinical management (diagnosis and monitoring) using non-invasive sampling methodologies 
developed in our laboratory that combines the SPME with a high throughput technology such 
as GC×GC-ToFMS in tandem with PLS-DA. Firstly, the applicability of the previous 
developed breath metabolomics based models was done using a new cohort of asthmatic 
children (n=49) attending on the secondary health care consultations. Also, the ability of 
using these models of exhaled breath in a medical scenario was tentatively done to gauge the 
clinical improvement of three children in an exacerbation condition, and to follow the 
Omalizumab therapy effect on one patient with severe asthma. MCCV was applied to the 
PLS-DA models to evaluate the sensitivity and specificity levels and to assess classification 
model robustness. 
 
2.5.3 Material and methods 
 
Patients clinical history and samples collection schedule 
A group of 49 children (4-18 years) with allergic asthma, from which 25 had allergic 
asthma and allergic rhinitis, volunteered for this study. The 49 individuals correspond to a 
total of 74 exhaled breath samples. The general traits of the patients are presented in Table 
2.6. 
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Table 2.6 - Traits of the allergic asthma population. 
 Allergic asthma (n=49) 
Age and Gender  
Age in years (range/median)  4-18/8 
Gender (male/female) 28/21 
Pathology 
Allergic Asthma 24 (49%) 
Allergic Asthma + Allergic Rhinitis 25 (51%) 
Allergensa 
Dust mite 26 (53%) 
Dust mite + gramineae 11 (23%) 
Gramineae 3 (6%) 
Dust mite + cat fur + gramineae 2 (4%) 
Dust mite + dog fur 1 (2%) 
Dust mite + eucalyptus 1 (2%) 
Dust mite + platan leaves 1 (2%) 
Dust mite + olive tree pollen 1 (2%) 
Gramineae + cat fur + dog fur 1 (2%) 
Birch pollen 1 (2%) 
Gramineae + weeds 1 (2%) 
Therapy 
CCS LTRA BRC ATH NCCS 
 
x x x x x 1 (2%) 
x x x - - 2 (4%) 
x - x - - 5 (10%) 
x x - - x 1 (2%) 
x - x - x 1 (2%) 
- x - - - 1 (2%) 
x - - - - 4 (8%) 
x x - - - 7 (15%) 
x - - x - 1 (2%) 
- - - x - 1 (2%) 
- x - x x 4 (8%) 
- - x - x 1 (2%) 
- - - x x 8 (17%) 
- x - x - 3 (6%) 
- x - - x 3 (6%) 
No therapy 6 (12%) 
a
 Results obtained by prick-tests 
Chapter 2 - Exhaled breath analysis 
 
122 
 
Usually, each individual corresponds to one breath sample; nevertheless, some 
volunteers had some pertinent asthma conditions that were further studied, and hence, for that 
reason were sampled in different moments: i) all patient were analysed in asthma stable state, 
ii) three patients were analysed in stable state and in asthma exacerbation condition, and iii) 
Omalizumab therapy adherence was follow-up just for one patient. 
The group of three patients studied under stable and exacerbation condition included a 
5 years old male Caucasian child that had never taken an asthma drug and was diagnosed by 
physicians with allergic asthma and rhinitis based on symptoms history and skin prick tests 
were performed being positive for dust mites and gramineae. After the first consult, this child 
was prescribed a combination of corticosteroids anti-histamine, a nasal corticosteroid and a 
bronchodilator (when in exacerbation). A 7 years old female Caucasian child diagnosed with 
allergic asthma with skin prick tests positive for dust mites, cat and dog fur and using a 
combination of corticosteroids and bronchodilator (when in exacerbation) was recruited to 
follow the disease status throughout 3 months, from a exacerbation situation to a controlled 
asthma status. For this patient the effect of nebulisation (salbutamol) was also verified with 
two exhaled breath samples being collected before and after the nebulisation procedure. Also, 
a child whose exhaled breath was collected over a three year period was a 12 years old female 
Caucasian diagnosed with allergic asthma and rhinitis. The allergen, determined by skin prick 
tests and confirmed by allergen-specific Immunoglobulin E blood test, that this child is 
sensitized to are dust mites and the prescribed medication is a combination of leukotriene 
receptor antagonist, corticosteroids and bronchodilator (when in exarcebation). 
For the Omalizumab study, a recruited patient was an 18 years old female white 
Caucasian diagnosed by physicians with severe persistent asthma and rhinitis. Skin prick tests 
were performed and showed sensitization to dust mites (Dermatophagoides farinae), storage 
mites (Lepidoglyphus destructor) and grass pollens (Dactylis glomerata, Festuca elatior, 
Loliumperenne, Phleum pratense, Poa pratensis). Appropriate therapy was prescribed 
associating inhaled fluticasone/salmeterol (500/100 µg/daily), and as rescue therapy 
salbutamol (400 to 1200 µg/daily). To control rhinitis symptoms 5 mg desloratadine/daily 
budesonide nasal spray and 64 µg/daily was prescribed. As the severe asthma symptoms 
persisted, although subcutaneous specific immunotherapy and corticosteroids in higher doses 
were performed, 600 mg of Omalizumab was initiated and administered fortnightly via 
subcutaneous in the deltoid region of both arms and both anterior thighs. In this case, exhaled 
breath collection (two samples each time) started 4 months after the Omalizumab therapy 
initiation. Omalizumab therapy was performed in accordance to physician prescription, i.e., 
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twice a month, until the first six months and half. After that period until the last collection 
(20th month), the therapy was performed intermittently due to the fact that the patient was not 
compliant, and only performed 13 out of 26 treatments. Each child was doing their specific 
therapy and was in different clinical conditions. Also, the time of day at which samples were 
collected was variable (depending on the moment of the medical consultation) and there were 
no dietary or pharmacologic restrictions, as these conditions are more representative of the 
reality demonstrating the applicability of the developed methodologies in the clinical context. 
 
Breath sampling and analysis 
Exhaled breath was collected in 1 L Tedlar® bags. The breath sampling parameters 
are reported in Chapter 2.1. At each sampling moment, the patient was asked to cleanse her 
mouth with water before sampling. Subsequently, the patient was instructed to inhale and 
exhaled normally and then exhale deeply using a disposable mouthpiece into the Tedlar® bag 
previously holding her breath for ca. 5s. As breath samples were not CO2-controlled, each 
breath represents a single mixed expiratory sample, and was analysed once. The SPME fibre 
(DVB/CAR/PDMS) was introduced in the Tedlar® sampling bag for 60 min, at 22 ºC to 
extract breath metabolites. Following the extraction procedure, the SPME fibre was retracted 
from the bag and inserted into the GC×GC-ToFMS injection port. The instrumental details were 
described in Chapter 2.2. Briefly, GC×GC–ToFMS LECO Pegasus 4D (LECO, St. Joseph, MI, 
USA) consists of an Agilent GC 7890A gas chromatograph (Agilent Technologies, Inc., 
Wilmington, DE), with a dual stage jet cryogenic modulator (licensed from Zoex) and a 
secondary oven, and mass spectrometer equipped with a high resolution ToF analyzer. An HP-5 
column (30 m × 0.32 mm I.D., 0.25 µm film thickness, 5% Phenyl-methylpolysiloxane, J&W 
Scientific Inc., Folsom, CA, USA) was used as 1D column (first dimension) and a DB-FFAP 
(0.79 m × 0.25 mm I.D., 0.25 µm film thickness, nitroterephthalic acid modified polyethylene 
glycol, J&W Scientific Inc., Folsom, CA, USA) was used as 2D column (second dimension). 
The carrier gas was helium at a constant flow rate of 2.50 mL/min. The GC×GC–ToFMS 
injection port was at 250 °C. The primary oven temperature program was: initial temperature 35 
ºC (hold 1 min), raised to 40 ºC (1 ºC/min), and finally rose to 220 ºC (7 ºC/min) and hold for 1 
min. The secondary oven temperature program was 15 ºC offset above the primary oven. The 
MS transfer line temperature was 250 ºC and the MS source temperature was 250 ºC. A 6 s 
modulation time with a 30 ºC secondary oven temperature offset (above secondary oven) was 
chosen. The ToFMS was operated at a spectrum storage rate of 125 spectra/s. The mass 
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spectrometer was operated in the EI mode at 70 eV using a range of m/z 35-350 and the detector 
voltage was -1695 V. The GC×GC area data was used as an approach to estimate the relative 
content of each volatile component of exhaled breath.  
 
Multivariate Analysis 
PLS-DA8 is a widely used procedure for classification purposes, where the MCCV 
framework was used to assess the predictive power and classification models robustness. The 
PLS-DA models previously developed (Chapter 2.2) for distinction between asthmatic and 
healthy children were used as starting-point for prediction purposes in this study. The MCCV 
had a classification rate of 96%, and showed 98% of sensitivity (∼ 2% allergic asthma 
children being misclassified as controls) and 93% of specificity ∼7% of false positives). For 
the projection purposes, a dataset comprising 130 metabolites (Table S1 in Appendix) and a 
data set of 9 metabolites (nonane, 2,2,4,6,6-pentamethylheptane, decane, 2-methyldecane, 
dodecane, tetradecane, nonanal, decanal, and dodecanal), previously established in Chapter 
2.2 as relevant for asthma diagnosis were used. The projections were performed for both 
datasets 130 and 9 metabolites tentatively identified by HS-SPME/GC×GC-ToFMS, using the 
previously developed and validated PLS-DA models (Chapter 2.4), by applying the regression 
models to new dataset of 62 asthmatic children breath samples (corresponding to 49 
individuals) to obtain the response variable. Each sample was mean normalized and UV (unit 
variance) scaled. 
Model robustness was assessed using MCCV with 500 iterations. 60 % of the data 
comprised the calibration set whilst the remaining 40% were the validation set. Then, each 
iteration, with randomly changed composition of the calibration and validation sets, 
performed internal cross validation of the calibration set using seven blocks and prediction of 
class membership for samples in the validation set. For each of the 500 randomly generated 
classification models, the number of LVs, the Q2 (expressing the cross-validated explained 
variability), and the confusion matrix was computed. The selection of model complexity was 
based on the most frequent list of model properties that maximizes the predictive power (i.e., 
lower LV and higher Q2). The sensitivity and the specificity of the model were then depicted 
from the confusion matrix resulting into a ROC space to further assess the results 
significance. Then, the same procedure was applied using permuted class membership. 
Sensitivity is calculated from the ratio between true positives (asthma samples correctly 
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predicted) and the total number of modelled breath samples, whereas specificity is determined 
from the ratio between true negatives (control samples correctly predicted) and the total 
number of modelled control GC×GC data. 
 
2.5.4 Results and Discussion 
PLS-DA model prediction: applicability of developed breath metabolomics based model 
Taking into consideration the previous developed breath metabolomics based model in 
chapter 2.4, a new group of children with asthma (coded as Asthma Projection) was studied 
and the robustness of the developed classification model was confirmed (Figure 2.14 A). 
 
Figure 2.14 – (A) Projection of new exhaled breath dataset using the breath metabolomics based model of 
chapter 2.4 for asthmatic and healthy children and (B) validation of the obtained results Q2 values distribution of 
the original and permuted MCCV (1000 permutations).  
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Using a full dataset, scores scatter plot (Figure 2.14 A) shows that the healthy group is 
associated to LV1 negative values whereas the asthma group is mainly linked to positive LV1 
values. The new set of 49 asthmatic children were projected mainly along the LV1 positive 
values, close to model asthma children population.  
The validation of PLS-DA models has been thoroughly studied to verify the quality of 
the obtained discrimination models88. Due to the large number of variables, the chance of 
false correlations and the risk of overfit are high89. Several diagnostic tools have been 
developed, among them cross validation, such as MCCV, first reported by Cook90 and tested 
for chemometric purposes by Xu and Liang91. MCCV can avoid an unnecessary large model 
and therefore decreases the risk of over-fitting for the calibration model. MCCV splits the 
data into a learning set or a test set and the model developed on the learning set and the error 
evaluated in the test set. The test set estimates are averaged over the learning-testing random 
splits and each case only appears in the learning set or the test set, but not in both92. MCCV is 
used in assessing the robustness and accuracy of PLS-DA models being used in different 
fields93,94,95. It has been reported that MCCV is a valuable and effective tool in estimating 
model complexity91. According to MCCV statistics for projection analysis (figure 1b), the 
PLS-DA model had a classification rate of 98%, showed 100% sensitivity (no asthmatic 
children being misclassified as controls) 93% specificity (∼7% of false positives) The 
prediction error measure Q2 is based on the evaluation of the error between the predicted 
categorical variable ŷ and the known y. It focuses on how well the class label can be predicted 
from new data depending on class separation but also on within class variability88. The most 
frequent Q2 value in MCCV statistics was around 0.9 whilst the model Q2 was 0.8. In spite the 
addition of new asthmatic exhaled breath samples, the classification rate and most frequent Q2 
values were the same and the sensitivity increased by 4%. However, the specificity decreased 
by 2% when compared with the previously developed model. Despite these asthmatic children 
presented a stable asthma status, this group is relatively heterogeneous since it contains 
patients with severe and non-severe asthma, also different therapies were considered, which 
may explain the dispersion of the data along LV1. 
Using the sub-set of 9 compounds reported in chapter 2.4 as relevant for asthma 
diagnosis, it was observed that the asthmatic children were projected mainly in LV1 positive 
(Figure 2.15 A), close to model asthma children population. According to MCCV statistics for 
projection analysis (Figure 2.15 B), the PLS-DA model had a classification rate of 96% and 
showed 96% sensitivity (∼ 4% allergic asthma children being misclassified as controls) and 
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96% specificity (∼4% of false positives). The most frequent Q2 value was around 0.7 with a 
large prevalence of values in the range of 0.6-0.8 whilst the model Q2 was 0.7. Comparing 
these results with the previously reported method we observed that the classification rate was 
identical, a decrease in sensitivity by 2% and an increase of 3% in specificity. The most 
frequent Q2 value decreased as the previously reported value was 0.8. The high predictive 
power and robustness of these results and those obtained for the previous data projection 
(Figure 2.15 B) suggest that confounding factors, such as, ambient air, gender or age seems to 
have a low or even no influence in the discrimination power.  
 
Figure 2.15 – (A) Projection of new exhaled breath dataset using the breath metabolomics based model of 
chapter 2.4 using a sub-set of 9 compounds (nonane, 2,2,4,6,6-pentamethylheptane, decane, 2-methyldecane, 
dodecane, tetradecane, nonanal, decanal, and dodecanal) and (B) validation of the obtained results Q2 values 
distribution of the original and permuted MCCV (1000 permutations).  
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Also, Figures 2.16 A and 2.16 B show that the main factor that explains the classes 
discrimination is the disease versus healthy condition, and within each class, individuals with 
different age or breath collected at different location are represented, indicating that these 
possible confounding factors seem not be relevant. 
 
Figure 2.16- PLS-DA LV1×LV2 scores scatter plot of exhaled breath for asthmatic and healthy children using a 
data set with 130 compounds coloured according to (A) age range (3 to 5 years old, 6 to 9 years old and 10 to 16 
years old) and (B) according to exhaled breath collection site demonstrating no influence on the discrimination. 
Figures based on metabolomic PLS-DA based models previously developed. 
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Asthma clinical management through breath analysis: exacerbation condition 
 
The ability of the developed models was tested regarding a relevant condition for the 
asthma clinical management, i.e., the disease state evaluation (stable state versus exacerbation 
condition). Exacerbation condition may promote several lung damages, and the evaluation 
and understanding of the alterations associated represent a significant improvement in the 
asthma management. Breath from an asthmatic child (IND) was collected throughout three 
years, corresponding to 10 breath samples, and Figure 2.17 A represents the volatile 
composition of six alkanes, that characterize asthma population, on those 10 sampling 
moments. These data were normalized against the median of the corresponding data of the 
healthy group. Figure 2.17 B depicts the plot of the predict Y-value (data from model plus 10 
breath samples projection) obtained from built PLS-DA model, against the reference Y-value 
(group classification, 0 for healthy and 1 for asthmatic population). 
According to Figure 2.17 A, slight variations were observed throughout this period of 
time. Relevant changes may be noticed when the child was in exacerbation, highlighting 
mainly the alterations on the relative content of nonane, decane and 2-methyldecane. 
Nevertheless when observing the predicted Y values from figure 2.17 B we can verify that 
these breath samples are still included in the asthma group, suggesting that despite the intra-
individual variability observed, the asthma pathology superimposes the intra-individual 
variability that might occur due to all external factors that cannot be controlled. These results 
also showed that alkane levels increased in exacerbation condition compared to control state, 
indicating the inflammation and lipid peroxidation are associated to this condition, as 
previously reported by Loureiro et al. 96.  
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Figure 2.17 – (A) Alkane variations for 10 breath samples collected for three years in the same asthmatic child 
based on the built PLS-DA model with two LVs and (B) predicted Y value against reference Y value behavior. 
a.u. arbitrary units. 
 
To verify the usefulness of the methodology under study, two other case-studies were 
evaluated. Breath samples of two children in exacerbation (E1 and E2) were sampled in 
different sampling moments. Stable state (S1 and S2) exhaled breaths were also collected. As 
verified in Figure 2.18, both patients showed an evolution along LV1 axis from an asthmatic 
volatile profile toward the healthy group.  
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Figure 2.18 -  PLS-DA LV1×LV2 scores scatter plot of exhaled breath for asthmatic and healthy children using 
the 9 compounds subset and projection of new exhaled breath dataset (state sate and exacerbation conditions for 
two patients). The path of two children in exacerbation condition (E) and stable state (S) is shown, through 
different sampling times. E1 and E2 are the initial exhaled breath samples: S1 exhaled breath was collected 
twice: 1 month and half and 3 months and nine days after the initial samples. S2 was collected 3 months and half 
later after the initial sampling  
 
The volatile composition behaviour was accompanied by the clinical improvement of 
both patients with treatment administration. Considering the breath profile, it was observed a 
relative area reduction of the alkanes. E1 exhaled breath was collected twice (separated by an 
hour from each other) in the first consult as a nebulisation procedure (only using salbutamol) 
was performed. It was found that, although from a clinical stand-point there was a slight 
improvement, the breath samples had similar composition leading to the conclusion that 
although the improvement of the patient clinical status, the biochemical processes inherent to 
asthma change slowly and herein there are no differences in the exhaled breath composition 
that was collected. 
 
Omalizumab therapy adherence: Evaluation of breath sampling relation and patient’s clinical 
status 
Patients with severe persistent asthma are at high risk of serious exacerbations and 
asthma-related mortality and treatment with Omalizumab has shown a significant reduction of 
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asthma exacerbations and emergency visits97. The recruited patient was an 18 years old white 
Caucasian female diagnosed by physicians with severe persistent asthma and rhinitis. 
Omalizumab therapy was proposed, as the patient severe asthma status was persistent and 
respiratory function deterioration was observed. The response to this therapy was assessed by 
symptoms severity and frequency, such as exacerbations, emergency room visit/unscheduled 
consultations, medication increase and school absenteeism. Figure 2.19 A shows the 
Omalizumab therapy monthly frequency monitoring and Figure 2.19 B represents the PLS-
DA LV1×LV2 scores scatter plot of exhaled breath for asthmatic and healthy children 
highlighting the path of the severe asthma patient throughout the therapy.  
 
Figure 2.19 - (A) Omalizumab therapy monthly frequency monitoring and (B) PLS-DA LV1×LV2 scores 
scatter plot of exhaled breath for asthmatic and healthy children using a sub-set of 9 compounds. Path of the 
severe asthma patient is highlighted - A through F sampling moments: 4 months (a), 4 months and half (b), 6 
months (c), 6 months and half (d), 17 months (e), and 20 months (f) after Omalizumab initial treatment 
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There was a significant improvement in the clinical status of the patient by the second 
month of Omalizumab therapy and there was no need to use the prescribed corticosteroid 
medication, β−2-agonist, and the patient did not attend the emergency room. However, there 
was an irregular adherence to Omalizumab therapy from the sixth month and half, and for the 
subsequent two months whilst between the tenth and twelfth month no therapy was performed 
(Figure 2.19 A). During this period, there was a progressive deterioration of health status with 
daily episodes of breathlessness, and the prescribed medication had to be used in higher 
dosages (preventive β−2-agonist and an inhaled corticosteroid). Also, during this period the 
patient had to go to the emergency room for treatment. The same behaviour was observed in 
the nineteenth month, with the patient not adhering to treatment and this reflected in a 
deterioration of the health status and an emergency room visit on the twentieth month (Figure 
2.19 A. 
The patient was in the twentieth month of Omalizumab therapy, and the irregularity in 
which therapy is performed, affects the outcome with progressive deterioration of the patient 
health status with subsequent aggravation in symptoms severity and frequency. In the periods 
that the patient adhered to medication there was clinical improvement without nocturnal 
exacerbation or effort dyspnea, an improvement of rhinitis symptoms and from the respiratory 
point of view there is a slight functional improvement.  
The hypothesis was to verify if the effect of the therapy on the clinical status could be 
followed through exhaled breath analysis. Using the developed model reported in Chapter 2.4  
that included the screening of 9 compounds associated to oxidative stress, a prediction was 
made and a interesting result is observed by the path of the patient (Figure 2.19 B, a through f 
– six breath sampling), in which Omalizumab intake can be followed throughout LV1 axis. 
For the first four and half months, this patient had an asthmatic volatile profile and then after 
six months of therapy her volatile profile converged towards a control volatile signature. This 
behaviour was also accompanied by a clinical improvement throughout this period. The 
tendency along LV1 axis with treatment administration can be explained by the relative area 
reduction of all alkanes, with a higher prevalence for nonane, decane and 2-methyldecane. 
These alkanes are an indication of oxidative stress and subsequently lipid peroxidation and 
the decrease may be due to a reduced inflammation state of this subject leading to lower 
relative amount of these compounds. After seventeen and twenty months of treatment (Figure 
2.19 B, e and f), a pathway relapse was observed in the patient behaviour (irregular adherence 
to Omalizumab therapy). The patient missed several treatments; however it was possible to 
confirm this behaviour based on the exhaled breath composition. The alkanes signal 
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increased, mostly by dodecane. According to LV1, the patient distanced herself from the 
healthy group (Figure 2.19 B) and from a clinical point-of-view the patient health status 
deteriorated. These results show the potential applicability of exhaled breath in the clinical 
practice for drug follow-up and health status monitoring showing inflammatory changes that 
current physiologic or functional tests might not always reflect. 
 
2.5.5 Concluding remarks 
Multivariate analysis of exhaled breath sampling combined with two-dimensional gas 
chromatography based methodology represents a non-invasive and rapid (ca. 2 hours) tool 
allowing the recovery of molecular data, useful for diagnosis and monitoring asthma. The 
results obtained using the breath metabolomics based models reported in Chapter 2.4 
confirmed the usefulness of this methodology. Breath metabolic composition was highly 
altered in asthmatic population compared to healthy ones used as control. Also, relevant 
changes may be noticed in the exacerbation condition compared to the stable state, and the 
Omalizumab therapy also promoted modifications on breath metabolomics. Indeed, the 
alkanes and aldehydes profile indicate an oxidative state and have been found consistently 
altered in asthmatic population. Within this population, in the exacerbated state compared to 
the stable condition the behaviour is similar. The prospect to follow-up the individual 
response was very interesting, as it unlocks potentialities as the therapy evaluation and 
adjusting. For instance, it was observed for the child with severe asthma that only the 
fortnightly Omalizumab therapy intake promoted the decrease of inflammation and oxidative 
stress level. The clinical observations are in accordance to the breath alkane pattern. 
Although requiring validation using a much larger sample cohort, these results clearly 
show the potential of this methodology for future clinical assessments, allowing timely 
therapeutic approaches and/or future antioxidant therapies to prevent the broad damaging 
effects associated to asthma. The obtained results support the up-rising issue of personalized 
medicine and the implementation of this methodology in a hospital laboratory, as well as, the 
use of exhaled breath in clinical settings could be easily achieved. 
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3.1 Overview 
Urine is an easily obtained matrix in large volumes when compared to other biofluids 
and in the last years this matrix has been increasingly studied. The identified compounds may 
be end products of normal and pathological cellular processes or compounds of environmental 
exposure. Urinary metabolomics is still in a developmental phase moving from discovey 
towards a method validation phase that will lead this matrix to be a considerable part of 
diagnosis, treatment evaluation and prognosis. The goal of our study was to ascertain the 
volatile and non-volatile urinary metabolomic changes caused by the asthma pathology. 
With this in mind, in-lab developed and reported method GC×GC-ToFMS was used to 
ascertain the overall urine volatile metabolome. The volatile urinary of 26 asthma patients and 
10 healthy children was obtained with c.a. 200 compounds being identified. From these 
compounds, 78 belonging to the alcohols, aldehydes, alkanes, alkenes and ketones were 
selected as these metabolites have been linked to lipid peroxidation, consequently connected 
to oxidative stress that has been related to asthma. A heat map, a quick and simple 
visualization tool, of the selected compounds was built and it was possible to verify that the 
levels of the 78 compounds in the urine of the asthmatic children were higher in the majority 
of the selected compounds. MVA analysis was then performed, namely the supervised 
method PLS-DA, and discrimination was attained. The developed models were also validated 
using MCCV. It was possible to verify that, with the exception of 9 metabolites, most of 
metabolited characterized the asthma population. 
The use of 1H NMR in analysing urine of asthmatics has been already proven and 
reported in literature1. Nevertheless, and to complement the volatile metabolome results, urine 
analysis of 92 asthmatic children and 50 healthy children by 1H NMR was performed. The 
goal was to ascertain the urinary metabolomic changes thus revealing the compounds 
involved in central metabolic pathways affected by the asthma pathology and in addition 
develop a method that could be used in the clinical practice. Before performing the analysis 
three normalization procedures and metabolite selections were tested. It was possible to 
sucessfully differentiate asthma patients from heatlhy children with compounds that are 
involved in fulcral metabolic pathways such as tricarboxylic acid (TCA) cycle, histidine 
metabolism, lactic acidosis, modification of free tyrosine residues after eosinophil stimulation 
and DNA damage. 
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3.2 Asthma volatile urinary metabolome uncovered by 
comprehensive two-dimensional gas chromatography-time of 
flight mass spectrometry  
 
3.2.1 Abstract  
The use of a powerful and high throughput analytical technique, such as GC×GC–ToFMS, in 
the evaluation of a biological system provides an array of bicohemical information otherwise 
unobtainable. This tool combined with SPME was considered to explore the urinary volatile 
metabolomic profile of asthma yielding c.a. 200 compounds that belonged to different 
chemical families. A targeted analysis was then performed to assess the impact provoked, 
comparing asthma individuals with healthy ones, on lipid peroxidation due to the oxidative 
stress levels. Five biochemically relevant families used as a lipid peroxidation index 
(alcohols, aldehydes, alkanes, alkenes and ketones), in a total of 78 compounds, were 
carefully selected. A heat map was built to quickly compare the urine volatile metabolome of 
the asthmatics versus the healthy and it was possible to verify that the levels of urine volatile 
compounds of the asthmatics was higher in the majority (88%) of the selected compounds. 
MVA tools were applied and it was found out that from the 78 compounds only 9 compounds 
(octane, tridecane, 3-methylhexane, 2,2,4,6,6-pentamethylheptane, 6-methyldodecane, 3-
ethyl-3-methylundecane, 3-methy-1-heptene and 2,4-dimethyl-1-heptene) characterized the 
healthy population whilst the remaining characterized the asthmatic population. MCCV was 
performed to assess the predictive power. The results suggest that the model is robust, 
considering the high classification rate (97.3%), sensitivity (98.7%), and specificity (93.9%). 
Beside the development of statistical models that were able to discriminate asthmatic children 
from healthy ones, urine analysis by GC×GC–ToFMS allowed to use compounds that are 
reportedly linked to lipid peroxidation, thus revealing the impact of oxidative stress on 
asthma. These results showed the possibility to obtain this knowledge as the compound levels 
related to lipid peroxidation were predominantly increased for the asthma population. 
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3.2.2 Framework 
Metabolomics is the global unbiased analysis of all the small-molecule metabolites 
within a biological system under a given set of conditions. These methods offer the potential 
for a holistic approach to clinical medicine, as well as improving disease diagnosis and 
understanding of pathological mechanisms2. It is an emerging field useful in the detection of 
metabolic profiles of the pathologies under study and pathology exploration by metabolomics 
has evolved throughout the years driven by the technological advances in instrumentation, 
data analysis software and in the development of metabolite databases. Asthma diagnosis 
metabolomic studies have been carried out to provide new tools for diagnosis purposes, 
disease management and knowledge on molecular alterations.  
When compared with other biofluids, urine has several advantages as it can be 
obtained in large quantities non-invasively and usually less pre-treatment is required. Urine 
metabolome is potentially vast including all endogenous and exogenous metabolites that 
might be established in a wide dynamic concentration range. Asthma is a lung condition, that 
could alter the metabolism of cells outside the lung leading to a different metabolome that 
could be potentially measured in urine. Several cellular pathways can be studied through this 
matrix, assuming that there is no significant renal disease, making urine as an accurate 
reflection of a person’s metabolic health and disease3.  
The metabolomic urinary profile of 26 children with allergic asthma (from which 12 
with allergic rhinitis) and 10 healthy children was explored using the SPME/GC×GC–ToFMS 
methodology developed by Rocha et al.4. Urine volatile metabolome in asthma, to the best of 
our knowledge, has not been previously described. Relevant biochemical families (alcohols, 
aldehydes, alkanes, alkenes and ketones) were selected as these metabolites are generated 
though the interaction of ROS with fatty acids (in a known series of reactions known as lipid 
peroxidation) measuring the increased oxidative stress in asthma5,6.  PLS-DA was performed 
in order to obtain the metabolites responsible for class discrimination. MCCV was applied to 
the PLS-DA models to evaluate the sensitivity and specificity levels and to assess 
classification model robustness.  
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3.2.3 Material and Methods 
Subjects  
Twenty-six patients with allergic asthma (from which 12 with allergic rhinitis) and 10 healthy 
control subjects were enrolled in this study following informed consent and approval of the 
study protocol by the Hospital Infante D. Pedro E.P.E (Aveiro, Portugal) and the healthy 
population consisted of children of the faculty staff. The characteristics of the patients and 
controls are presented in Table 3.1.  
Table 3.1 - Characteristics of the studied population: allergic asthma patients and healthy controls. 
 
Allergic asthma 
(n=26) 
Control 
(n=10) 
Age (mean±SD) 8.8±3.4 9.7±3.3 
Gender (male/female) 16/10 5/5 
Pathology 
Allergic Asthma 14 (54%) - 
Allergic Asthma + Allergic Rhinitis  12 (46%) - 
Allergensa 
Dust mite  10 (38%) - 
Dust mite + gramineae 7 (27%) - 
Gramineae 4 (15%) - 
Dust mite + cat fur  2 (8%) - 
Dust mite + cat fur + dog fur  2 (8%) - 
Dust mite + olive tree 1(4%) - 
Therapy 
Corticosteroid + bronchodilator 6 (22%) - 
Corticosteroid + leukotriene receptor antagonist + bronchodilator 4 (15%) - 
Leukotriene receptor antagonist + bronchodilator + nasal 
corticosteroid 4 (15%) - 
Nasal corticosteroid and antihistamine 3 (12%) - 
Leukotriene receptor antagonist + bronchodilator 3 (12%) - 
Corticosteroid + leukotriene receptor antagonist 2 (8%) - 
Nasal corticosteroid and bronchodilator 1 (4%) - 
Corticosteroid 1 (4%) - 
                                                                  No therapy 2 (8%) - 
a
 Results obtained by prick-tests 
 
All parents signed an informed consent for participation in the study. The children 
with allergic asthma were recruited from the outpatient clinic of the Immunoalergology 
Department of the Hospital Infante D. Pedro E.P.E (Aveiro, Portugal). Asthma diagnosis was 
made based on clinical symptoms and exams (skin prick tests and IgE values, among other 
specific tests). Appropriate therapy was prescribed by the patient’s own physician. The 
allergic asthma population represented a controlled asthma status. No restrictions were 
applied regarding drugs or diet. Each individual (either patient or healthy volunteer) provided 
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a urine sample in a sterile cup. Then, aliquots of approximately 1 mL were transferred into 
vials, frozen and stored at -80 °C, until analysis. 
 
Urine analysis using SPME/GC×GC–ToFMS 
The SPME experimental parameters and the GC×GC–ToFMS conditions have been 
previously reported by Rocha et al.4. Briefly, 500 µL of urine (pH adjusted to 2.0), 0.1g NaCl 
and a stirring bar (0.5×0.1 mm) were placed into a 5 mL glass vial and the vial was capped 
with a PTFE septum and a screw cap (Chromacol, Hertfordshire, UK). The DVB/CAR/PDMS 
fibre was used with an extraction temperature and time of 40.0±0.1 ºC and 30 min, 
respectively, with constant stirring of 500 rpm. Three independent replicates of each sample 
were performed. After the extraction/concentration step, the SPME coating fibre was 
manually introduced into the GC×GC–ToFMS LECO Pegasus 4D (LECO, St. Joseph, MI, 
USA), consisted of an Agilent GC 7890A gas chromatograph equipped with a dual stage jet 
cryogenic modulator (licensed from Zoex) a secondary oven and an high-speed time-of-flight 
mass spectrometer detector. Most (> 90%) of the identified compounds presented similarity 
matches > 850. The DTIC (Deconvoluted Total Ion Current) GC×GC area data was used as 
an approach to estimate the relative content of each volatile metabolite of urine. 
 
Data Processing 
The dataset comprised 78 metabolites belonging to selected chemical families: 
alcohols, aldehydes, alkanes, alkenes and ketones. Scaling procedures divide each variable by 
a factor removing the dependence on concentration and magnitude of the metabolites7. Each 
sample was range-scaled between 0 and 1, as this scaling procedure proved to be the most 
adequate in urine analysis as Weber et  al.8 and  Van den Berg7 demonstrated. Mean 
normalization procedure was then applied to the 78 selected metabolites, by dividing each 
row of data matrix by its average. A heat map was then built to visualise the quantitative data 
on two axes using R statistical software9. On the x-axis the samples are represented whereas 
in the y-axis the normalized areas of the 78 metabolites of the selected chemical families. The 
colours are coded to reflect quantitation with higher levels corresponding to red whilst lower 
levels are blue.  
Partial Least Squares (PLS) is a widely used procedure for both regression and 
classification purposes. PLS-DA10, commonly uses a Y matrix containing dummy variables 
which defines sample memberships to pre-defined groups and this allows to extract relevant 
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information/variability that could describe the reasons for the observed patterns (clusters) 
allowing to verify which metabolites contribute for the observed separation.  
Then, PLS-DA was applied to the selected 78 volatile scaled and normalized 
metabolites tentatively identified by GC×GC-ToFMS in all urine samples. 
For classification purposes two groups were used, healthy subjects and asthma 
patients. A random internal cross validation method has been computed with 20 segments and 
6 samples per segment. The data is divided into the calibration set containing all samples used 
to compute the model components, using X- and Y-values. The test set that contains the 
remaining samples for which X-values are fed into the model once a new component has been 
computed. Their predicted Y-values are then compared to the observed Y-values, yielding a 
prediction residual. MCCV was first reported by Picard and Cook11 and has proven to be 
assymptotically consistent and is characterized by leaving out a major part of samples at a 
time for validation instead of leaving out one sample at a time12. Model robustness was 
assessed using MCCV with 500 iterations. The classification model complexity (number of 
LVs) of the dataset (78 metabolites) was computed, as well as classification rate and Q2 were 
estimated by cross-validation (7 blocks splits). For each of the 500 randomly generated 
classification models, the number of LV, the Q2 and the confusion matrix were computed. 
The selection of model complexity was based on the most frequent list of model properties 
that maximizes the predictive power (i.e., lower LV and higher Q2). The sensitivity and the 
specificity of the model were then depicted from the confusion matrix resulting into a ROC 
map to further assess the results significance. Then, the same procedure was applied using 
permuted class membership. Sensitivity is calculated from the ratio between true positives 
(allergic asthma samples correctly predicted) and the total number of modelled breath 
samples, whereas specificity is determined from the ratio between true negatives (control 
samples correctly predicted) and the total number of modelled control GC×GC data. 
 
3.2.4 Results and discussion  
Urine volatile composition provided by HS-SPME/GC×GC–ToFMS 
The urinary volatile metabolome was attained using a high throughput and powerful 
technique, GC×GC-ToFMS that is an established technique in the analysis of complex 
samples due to its enhanced separation capacity, sensitivity, peak resolution and 
reproducibility13,14,15. A non-polar/polar (NP/P) column combination was used and the HS-
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SPME/GC×GC–ToFMS data was automatically processed using in the identification of all 
peaks in the GC×GC chromatogram contour plots with signal-to-noise threshold > 50. The 
peak finding routine based on deconvolution method allowed to identify several hundred 
compounds. A manual inspection of the mass spectra was performed combined with the use 
of retention index and compared with literature values for similar chromatographic columns. 
Table 3.2 shows a list of ca. 200 volatile  compounds belonging to different chemical families 
including acids, alcohols, aldehydes, alkanes, alkenes, esters, furan compounds, ketones, 
lactones, norisoprenoids, sulphur compounds and terpenic compounds.  
 
Table 3.2 - Urinary compounds dataset tentatively identified by GC×GC–ToFMS from allergic asthma and 
healthy children  
Peak # 1tR a (s) 2tR a (s) Compounds CAS Number RIcalcb RIlit.c (GC) RIlit.
d  
(GC × GC) 
 
  Acids     
1 678 5.81 hexanoic acid 142-62-1 1000 990 - 
2 876 5.91 ethylhexanoic acid 149-57-5 1132 1128 - 
3 1062 5.46 nonanoic acid 112-05-0 1276 1280 - 
4 1176 4.56 decanoic acid 334-48-5 1372 1380 - 
5 1380 3.52 dodecanoic acid 143-07-7 1568 1571 - 
6 1566 2.90 tetradecanoic acid 544-63-8 1763 1780 - 
7 1656 2.62 pentadecanoic acid 1002-84-2 1867 1866 - 
8 1740 2.43 hexadecanoic acid 57-10-3 1967 1964 - 
        
   Alcohols     
15 186 2.34 3-methyl-3-buten-1-ol 763-32-6 655 667 - 
12 192 1.85 2-methyl-1-butanol 137-32-6 677 677 - 
9 234 2.33 1-pentanol 71-41-0 741 741 760 
13 402 1.27 2-methyl-2-propanol 78-93-1 853 853 - 
14 744 1.47 2-ethyl-1-hexanol 104-46-7 1040 1026 - 
16 792 0.76 2-octen-1-ol 22104-79-6 1074 1060 - 
10 798 1.56 1-octanol 111-87-5 1078 1068 1069 
17 936 0.79 2-nonen-1-ol 22104-80-9 1170 1171 - 
11 942 1.37 1-nonanol 143-08-8 1170 1175 1171 
   Aldehydes     
12 126 0.55 pentanal 110-62-3 685 697 690 
13 192 1.06 2-methyl-2-butenal 497-03-0 697 753 - 
14 276 0.96 hexanal 66-25-1 801 802 800 
15 396 1.60 (E)-2-hexenal 6728-26-3 872 857 851 
16 504 0.98 heptanal 111-71-7 904 904 - 
17 600 0.92 2-ethylhexanal 123-05-7 957 955 954 
18 690 0.86 octanal 124-13-0 1005 1003 1003 
19 774 1.10 (E)-2-octenal 2548-87-0 1074 1056 1058 
20 846 0.81 nonanal 124-19-6 1105 1106 1103 
21 918 1.04 (E)-2-nonenal 18829-56-6 1162 1164 1168 
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Peak # 1tR a (s) 2tR a (s) Compounds CAS Number RIcalcb RIlit.c (GC) RIlit.
d (GC × 
GC) 
23 1104 0.85 undecanal 112-44-7 1311 1310 1309 
24 1218 0.81 dodecanal 112-54-9 1412 1410 - 
25 1326 0.85 tridecanal 10486-19-8 1513 1511 - 
26 1428 0.82 tetradecanal 124-25-4 1613 1611 - 
27 1524 0.80 pentadecanal 09/11/2765 1714 1711 - 
28 1614 0.85 hexadecanal 629-80-1 1815 1819 - 
        
   Hydrocarbons     
   Alkanes     
29 90 0.37 3-methylpentane 107-83-5  560 558 
30 150 0.40 3-methylhexane 589-34-4 640 671 672 
31 222 0.43 C7 isomer (m/z 57, 43, 71) - 759 - - 
32 276 0.40 octane 111-65-9 800 800 800 
33 318 0.46 4-ethyl-2-methylhexane 3074-75-7 831 833 - 
34 498 0.42 nonane  111-84-2 900 900 900 
35 624 0.45 3-methylnonane 06/04/5911 975 976 971 
36 666 0.44 2,2,4,6,6-pentamethylheptane 13475-82-6 988 997 997 
37 684 0.42 decane  124-18-5 1000 1000 1000 
38 720 0.45 3,9-dimethylnonane  17302-32-8 1039 1038 - 
39 840 0.42 undecane  1120-21-4 1100 1100 1100 
40 876 0.45 C11 isomer (m/z 57, 43, 71) - 1144 - - 
41 930 0.46 2-methylundecane 7045-71-8 1193 1164 1165 
42 972 0.43 dodecane  112-40-3 1200 1200 1200 
43 1020 0.45 6-methyldodecane 6044-71-9 1256 1253 - 
44 1098 0.44 tridecane  629-50-5 1300 1300 1300 
45 1128 0.46 3-ethyl-3-methylundecane  - 1348 1347 - 
46 1212 0.45 tetradecane  629-59-4 1400 1400 1400 
47 1314 0.45 pentadecane  629-62-9 1500 1500 - 
48 1416 0.46 hexadecane 544-76-3 1600 1600 - 
49 1512 0.47 heptadecane 629-78-7 1700 1700 - 
50 1608 0.46 octadecane 593-45-3 1800 1800 - 
        
   Alkenes      
94 210 0.44 3-methyl-1-heptene 3769-23-1 727 743 748 
89 258 0.47 1-octene 592-98-3 803 800 790 
90 366 0.50 2,4-dimethyl-1-heptene 19549-87-2 853 855 - 
92 672 0.49 4-decene 19398-89-1 1008 991 993 
93 756 0.48 4-methyl-2-decene 74630-30-1 1062 - - 
94 810 0.47 C11 isomer (m/z 69, 55, 41) - 1097 - - 
95 966 0.49 1-dodecene 112-41-4 1211 1192 - 
96 1116 0.48 7-methyl-1-undecene 74630-42-5 1337 - - 
97 1200 0.53 1-tetradecene 1120-36-1 1412 1392 - 
98 1308 0.56 1-pentadecene 13360-61-7 1511 1481 - 
        
   Cyclic     
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Peak # 1tR a (s) 2tR a (s) Compounds CAS Number RIcalcb RIlit.c (GC) RIlit.
d (GC × 
GC) 
51 594 0.48 1,1,2,3-tetramethylcyclohexane 6783-92-2 966 958 - 
52 828 0.48 1-hexyl-3-methylcyclopentane 61142-68-5 1109 - - 
        
   Aromatics     
53 126 0.59 benzene 71-43-2 628 648 660 
54 222 0.82 toluene 108-88-3 768 762 770 
55 402 1.03 ethylbenzene 100-41-4 857 858 868 
56 420 1.04 p-xylene 106-42-3 865 864 - 
57 474 1.07 o-xylene 95-47-6 890 893 - 
58 540 0.86 isopropylbenzene 98-82-8 923 922 - 
59 594 0.86 propylbenzene 103-65-1 952 952 959 
60 642 0.91 o-ethyltoluene 611-14-3 978 973 - 
62 666 0.92 1,2,4-trimethylbenzene 9563-6 991 988 - 
63 702 0.87 1-allyl-4-methylbenzene 3333-13-9 1012 1033 - 
64 714 0.98 1,2,3-trimethylbenzene 526-73-8 1020 1020 - 
65 762 0.78 m-propyltoluene 1074-17-5 1051 1058 - 
66 786 0.82 (1-methylpropyl)-benzene 135-98-8 1066 1014 - 
67 612 0.87 m-ethyltoluene 620-14-4 962 959 - 
68 624 0.90 p-ethyltoluene 622-96-8 968 960 - 
69 774 0.82  1-ethyl-2,3-dimethylbenzene 933-98-2 1058 1094 - 
70 798 0.84 1-ethyl-2,4-dimethylbenzene 847-41-9 1078 1087 - 
71 948 1.83 naphthalene 91-20-3 1183 1183 - 
72 1356 0.65 (1-butylhexyl)-benzene 4537-11-5 1542 - - 
73 1416 0.70 (1-methylnonyl)-benzene 4537-13-7 1601 - - 
74 1482 0.67 (1-ethyloctyl)-benzene 4621-36-7 1669 - - 
75 1512 0.70  (1-methyldecyl)-benzene 4536-88-3 1701 - - 
76 1542 0.65 (1-butyloctyl)-benzene 2719-63-3 1734 - - 
77 1554 0.66 (1-propylnonyl)-benzene 2719-64-4 1747 - - 
78 1572 0.67  (1-ethyldecyl)-benzene 2400-00-2 1767 - - 
79 1608 0.70 (1-methylundecyl)-benzene 2719-61-1 1808 - - 
80 1632 0.66 (1-butylnonyl)-benzene 4534-50-3 1837 - - 
81 1644 0.66 (1-propyldecyl)-benzene 4534-51-4 1851 - - 
82 1698 0.70 (1-methyldecyl)-benzene 4536-88-3 1915 - - 
        
   Chlorinated compounds     
100 588 1.23 o-chlorotoluene 95-49-8 949 955 - 
101 600 1.26 p-chlorotoluene 106-43-4 956 956 - 
102 780 0.65 1-chlorooctane 111-85-3 1062 1064 - 
103 924 0.64 1-chlorononane 2473-01-0 1164 1167 - 
104 1056 0.64 1-chlorodecane 1002-69-3 1267 1256 - 
        
   Esters     
105 108 0.52 ethyl acetate 141-78-6 607 608 609 
107 450 1.39 1-methoxy-2-propyl acetate - 879 - - 
108 876 0.76 methyl octanoate 111-11-5 1128 1126 - 
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Peak # 1tR a (s) 2tR a (s) Compounds CAS Number RIcalcb RIlit.c (GC) RIlit.
d (GC × 
GC) 
109 972 0.70 ethyl octanoate 106-32-1 1201 1202 - 
110 1122 0.74 methyl decanoate 110-42-9 1322 1326 - 
111 1206 0.69 ethyl decanoate 110-38-3 1395 1397 - 
112 1338 0.73 methyl dodecanoate 111-82-0 1524 1526 - 
113 1344 1.66 ethyl-4-ethoxybenzoate 23676-09-7 1531 1522 - 
114 1422 0.59 2-ethylhexyl 2-ethylhexanoate 7245-14-1 1607 - - 
115 1536 0.73 methyl tetradecanoate 124-10-7 1728 1727 - 
116 1710 0.73 methyl hexadecanoate 112-39-0 1929 1928 - 
        
   Furan compounds     
117 102 0.50 2-methylfuran 534-22-5 601 603 - 
118 120 0.48 tetrahydrofuran 109-99-9 621 620 634 
119 156 0.62 2,5-dimethylfuran 625-86-5 663 701 - 
120 276 0.79 2-ethyl-5-methylfuran 1703-52-2 800 800 - 
121 306 0.85 2,3,5-trimethylfuran 10504-04-8 814 817 - 
122 432 2.28 2-(methylthio)-furan 13768-59-6 871 - - 
123 480 0.77 2,5-diethylfuran 10504-06-0 892 888 - 
124 564 1.07 2-methyl-5-isopropenylfuran - 936 - - 
125 672 0.76  2-pentylfuran  994 992 995 
126 924 0.90 menthofuran 3777-69-3 1164 1164 - 
127 990 1.42 4,7-dimethyl-1-benzofuran 28715-26-6 1215 1220 - 
        
   Ketones     
128 150 0.92 2-pentanone 107-87-9 595 636 681 
129 192 0.74 2-methyl-pentan-2-one 108-10-1 - 733 748 
130 204 0.74 3-methylpentan-2-one 565-61-7 746 - 750 
131 246 1.42 4-methyl-3-penten-2-one 123-54-6 790 798 - 
132 252 0.86 2-hexanone 591-78-6 800 790 788 
133 258 0.97 C6 isomer (m/z 43, 58, 71) - 808 - - 
134 258 1.46 1-hexen-3-one 1629-58-9 808 775 - 
135 264 0.68 2,3-dimethyl-3-pentanone 565-80-0 810 806 - 
136 354 0.89 4-methylhexan-2-one 17042-16-9 837 846 850 
137 438 0.95 4-heptanone 123-19-3 873 895 884 
138 636 0.80 3-octanone 106-68-3 991 989 989 
139 660 1.10 6-methyl-5-hepten-2-one 110-93-0 991 989 985 
140 828 0.84 2-nonanone 821-55-6 1093 1093 1089 
141 894 1.02 1-nonen-3-one 24415-26-7 1142 1077 - 
142 1086 0.82 2-undecanone 112-12-9 1296 1296 1293 
143 1206 0.82 2-dodecanone 6175-49-1 1396 1396 - 
144 1314 0.86 2-tridecanone 593-08-8 1501 1500 - 
        
   Lactones      
146 828 3.53 δ-hexanolactone 823-22-3 1095 1084 1060 
148 1632 0.97 Muskolactone 106-02-5 1837 1839 1841 
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Peak # 1tR a (s) 2tR a (s) Compounds CAS Number RIcalcb RIlit.c (GC) RIlit.
d (GC × 
GC) 
   Norisoprenoids     
149 1068 0.75 γ-ionone 79-76-5 1277 1340 - 
150 1092 0.70 dihydroedulan I 74006-61-4 1296 1298 - 
151 1098 0.67 theaspirane A 66537-39-1 1301 1301 - 
152 1110 0.80 edulan I 41678-29-9 1311 1313 - 
153 1116 0.70 theaspirane B 36341-72-8 1316 1319 - 
154 1158 1.00 1,2-dihydro-1,1,6-trimethylnaphthalene (TDN) 30364-38-6 1354 1354 - 
155 1230 1.11 dihydro-β-ionone 20489-53-6 1419 1424 1450 
156 1302 1.24  3,4-dihydro-β-ionone 17283-81-7 1490 1485 - 
157 1470 1.47 methyl dihydrojasmonate 24851-98-7 1658 1649 - 
        
   Sulphur Compounds     
158 192 0.96 dimethyl disulfide 624-92-0 753 730 747 
159 228 1.03 2 methylthiophene 554-14-3 759 771 - 
160 618 1.53 dimethyl trisulfide 3658-80-8 965 964 - 
        
   Monotepenic compounds     
   Hydrocarbon type     
161 558 0.54 α-pinene 7785-70-8 933 933 940 
162 582 0.58 camphene 79-92-5 945 947 959 
163 594 0.66 verbenone 80-57-9 952 951 - 
164 636 0.59 β-pinene 7785-70-8 975 975 987 
166 684 0.63 α-phellandrene 99-83-2 1000 1000 1035 
168 708 0.63 α-terpinene 99-86-5 1016 1016 1023 
169 720 0.77 o-cymene 502-99-8 1024 1027 1042 
170 726 0.64 limonene 5989-27-5 1027 1027 1037 
171 732 0.65 1,8-cineole 470-82-6 1031 1031 1032 
172 744 0.81 β-cimene 99-87-6 1039 1030 1038 
173 774 0.66 γ-terpinene 99-85-4 1058 1059 1062 
174 822 1.00 p-cymene 99-87-6 1089 1088 1039 
175 852 0.83 p-mentha-1,5,8-triene 21195-59-5 1110 1110 - 
176 888 0.84 E,E-2,6-dimethyl-1,3,5,7-octatetraene 460-01-5 1137 1134 - 
        
   Ketone type     
177 828 1.11 6-camphenone 53803-33-1 1093 1093 1103 
178 1026 1.38 carvone 2244-16-8 1244 1242 1242 
        
   Alcohol type     
179 798 1.13 dihydromyrcenol 18479-58-8 1074 1076 1079 
181 840 1.31 linalool 78-70-6 1101 1101 1098 
182 900 1.70 verbenol 18881-04-4 1147 1147 - 
186 942 1.17 4-terpineol 562-74-3 1178 1178 1181 
187 948 2.64 p-cimeno-8-ol 1197-01-9 1184 1184 - 
        
   Aldehyde type     
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Peak # 1tR a (s) 2tR a (s) Compounds CAS Number RIcalcb RIlit.c (GC) RIlit.
d (GC × 
GC) 
188 870 1.04  α-canfolenal - 1124 1127 - 
189 966 1.22 myrtenal 18486-69-6 1196 1195 - 
        
   Ester type     
190 1080 0.82 bornyl acetate 76-49-3 1286 1285 - 
        
   Sesquiterpenic compounds     
   Hydrocarbon type     
191 1224 0.63  α-cedrene 469-61-4 1412 1409 - 
192 1296 0.66 aromadendrene 489-39-4 1483 1447 1496 
193 1344 0.70 δ-cadinene 483-76-1 1530 1530 - 
194 1362 0.91 α-calacorene 21391-99-1 1548 1546 - 
        
   Alcohol type     
195 1344 0.79 spathulenol  6750-60-3 1530 1548 - 
196 1380 1.06 nerolidol 7212-44-4 1566 1565 - 
197 1440 1.16 γ-eudesmol 1209-71-8 1626 1629 - 
198 1638 0.94 farnesol 4602-84-0 1844 1749 - 
        
   Miscellaneous     
147 960 2.19 3-methyl-4-propyl-2,5-furandione 16493-20-2 1193 - - 
165 666 0.70 monoterpene m/z (91, 77, 119, 39, 134) - 991 - - 
167 690 0.71 monoterpene m/z (91, 77, 119, 39, 134) - 1004 - - 
183 906 1.58 monoterpene m/z (91, 77, 119, 39, 134) - 1151 - - 
184 918 1.85 monoterpene m/z (91, 77, 119, 39, 134) - 1161 - - 
185 930 1.85 monoterpene m/z (91, 77, 119, 39, 134) - 1170 - - 
*- information not available 
a
- Retention times in seconds (s) for first (1tR) and second (2tR ) dimensions. 
b
- RI: retention index obtained through the modulated chromatogram. 
c
- RI: retention index reported in the literature for one dimensional GC with a 5%-Phenyl-methylpolysiloxane GC column or equivalent. 
d
- RI: retention index reported in the literature for a comprehensive GC×GC system with Equity-5 for the first dimension. 
 
The most reliable way to confirm the identification of each compound is based on 
authentic standard co-injection, which in several cases is economically prohibitive and often 
unachievable in the time available for analysis, or commercially unavailable standard16. With 
the use of NP/P columns chemically related compounds are grouped forming ordered patterns 
facilitating group-type analysis and conditional classification of unknown compounds17.With 
this column combination, the chemical families are grouped based on the boiling point (1D) 
and polarity (2D) offering a clear visual separation between compound classes as shown in 
several reports4,18. The identification was also supported by experimentally determining the 
retention index (RI) values that were compared, when available, with values reported in 
literature for chromatographic columns similar to that used as the 1D column and whenever 
available compared to RI values obtained by GC×GC. 
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Figure 3.1 - Peak apex plot of the compounds identified in urine depicting all the chemical families present in 
Table 3.2.  
 
In Figure 3.1, a peak apex plot can be visualized depicting all chemical families 
identified in urine. The increase in the number of carbons leads to an increase in the first 
retention time (1tR) due to the decrease in volatility. In the second retention time (2tR) the 
compounds are dispersed by polarity. The alkanes are the least polar compounds (2tR 0.370s) 
and the acids the most polar compounds (2tR 5.910s). It is also possible to clearly verify, for 
the acids family, that the increase of the carbon chain leads to a decrease in the 2tR. 
The alkanes and alkenes behave in quasi linear fashion and the separation is based on 
volatility. The ramified alkanes and alkenes presented a slight higher 2tR when compared to 
the linear alkanes and alkenes (Table 3.2). The aromatics are depicted in Figure 3.1 in the 
rounded rectangle varying in 1tR between 126s to 948s and 1356s to 1698s and 2tR between 
0.590s and 0.890s and. The exceptions were 2-phenylpropene and naphthalene that have a 2tR 
of 1.140s and 1.830s, respectively. This behavior is explained by the presence of the double 
bond in the substituted benzene for the former and the presence of another benzene ring for 
the latter. The introduction of a methyl group led to a significant increase in 2tR as it can be 
exemplified for benzene (0.590s) and p-xylene (1.040). However, when additional groups are 
present 2tR decrease is observed (0.820s for 1-ethyl-2,3-dimethylbenzene). It was also possible 
to identify clusters with monoterpenes (C10H16) found between 1tR 558 and 774s, monoterpene 
alcohols between 1tR 798 and 1026s and the sesquiterpenes from 1tR 1224 to 1638s (Table 
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3.2). As for the furan compounds, the presence of additional methyl groups led to a slight 
increase effect on 2tR (1.420s for 4,7-dimethyl-1-benzofuran) and a bigger increase is 
observed when the compound had sulphur in its composition (2.280s for 2-(methylthio)-
furan). The norisoprenoids varied between 1068 and 1470s for 1tR and 0.670 and 1.470s for 
2tR, as depicted in Figure 3.1. The sulphur compounds have increased polarity with the 
addition of a sulphur atom in its structure, 0.960s for dimethyl sulfide and 1.530s for dimethyl 
trisulfide. As for the chlorinated compounds, it can be observed from Table 3.2 that there is 
an increase in 2tR in the presence of a chlorinated toluene when compared with the substituted 
chloroalcane due to the increase in polarity of the former.  
The general behavior of compounds with a carbonyl group can be observed in Figure 
3.1 depicted by dashed line. Initially, for the ketones and aldehydes, there was an increase in 
polarity (consequently increase in 2tR) with the increase of carbons until C8. After, there is a 
decrease and stabilization of 2tR due to the increase of hydrophobicity, and 2tR remains 
constant throughout the chromatogram. It was possible to verify the increase on 2tR when the 
compound has a double bond, as for example 4-methyl-3-penten-2-one and 1-hexen-3-one, 
with 1.460s and 1.020s respectively (Table 3.2). The presence of a benzene ring (ethyl-4-
ethoxybenzoate) and even the presence of a metoxy group (1-methoxy-2-propyl acetate) 
promoted the increase on 2tR in these chemical families. In the linear alcohols, it was possible 
to confirm that the increase of the carbon chain led to a decrease in the 2tR. However, the 
ramified alcohols have a lower 2tR when compared to the correspondent linear alcohols. The 
same behavior is noted for the unsaturated alcohols, with the exception of 3-methyl-3-buten-
1-ol mainly due to the presence of the double bond. The 2tR generally follows: alkanes < 
alkenes ≈ cyclic hydrocarbons <aromatic hydrocarbons ≈ esters ≈ terpenoids ≈ norisoprenoids 
< ketones ≈ aldehydes < sulphur compounds < alcohols < lactones < acids.  
However, not all identified compounds are endogenous, i.e. there are compounds that 
are contaminants, not an internal metabolic product. For example, organochlorides or 
aromatic hydrocarbons from environmental cumulative exposure19 or can have its origin from 
ingested foods as for example esters, furan compounds, lactones, norisoprenoids and 
terpenoids20,21. The metabolic pathways yielding sulphur compounds are regarded as 
detoxification routes22. Seventy eight compounds belonging to aldehydes, ketones, alkanes, 
alkenes and alcohols were selected. These metabolites are linked to the oxidative degradation 
of lipids (lipid peroxidation) due to increased oxidative stress that has been reported in 
asthma30 and this study assessed the impact at the oxidative stress level on the fatty acids in 
individuals with asthma when compared to healthy individuals23. 
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Targeting urinary asthma  metabolomics toward oxidative stress impact 
Figure 3.2 depicts the differences between the asthmatic and healthy individuals scaled 
chromatographic peak areas of the five selected families. It clearly shows differences in the 
selected dataset, with a highly altered chromatographic pattern for the asthmatic group as a 
whole.  
 
Figure 3.2 - Peak apex plots depicting five biochemically relevant selected families: alcohols, aldehydes, 
alkanes, alkenes and ketones. Comparison between the asthma and healthy groups scaled peak areas 
 
However, the visualization of complex data through heat maps is a more suitable tool 
for a rapid inspection of the obtained data24. Mieth and co-authors25 reported it in the analysis 
of exhaled breath and Rocha et al.4 in urine. This approach was adapted to the scaled 78 
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compounds to quickly visualize the differences among asthma and healthy groups (Figure 
3.3).  
 
Figure 3.3 – Heat map representation of biochemically relevant selected families, aldehydes, ketones, alkanes, 
alkenes and alcohols. Each line represent a range- scaled and  mean normalized volatile compound (organized by 
chemical families) and each column represents a subject (organized by healthy and asthma children). For peak 
assignment see Table 3.1. 
 
At a first glance, it is confirmed that the urinary metabolomic composition is that the 
levels of urine volatile compounds of the asthmatics was higher in the majority (88%) of the 
selected compounds. 
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Methods of correction, i.e. normalization, are a crucial pre-processing step normally 
applied to urine samples to account for the different sample dilutions before applying 
multivariate tools to the dataset. Post sample analysis normalization allows investigating urine 
samples without full volume 24-h collection simplifying the overall process26. For this 
purpose, the mean normalization procedure was performed to the scaled chromatographic 
areas. After, PLS-DA was apllied to the selected dataset. Scores plot for the first two LV of 
PLS-DA model for volatile compounds are shown in Figure 3.4 A, while Figure 3.4 B 
(corresponding LV1 and LV2 loading weights plot) establishes the contribution of each 
volatile compound that promotes the observed distinction.  
Figure 3.4 A shows that the healthy group is associated with LV1 and LV2 negative 
values whilst the asthma group is more dispersed by the remaining three quadrants. The 
healthy group is mainly characterized by octane, tridecane, 3-methylhexane, 2,2,4,6,6-
pentamethylheptane, 6-methyldodecane, 3-ethyl-3-methylundecane, 3-methy-1-heptene and 
2,4-dimethyl-1-heptene (Figure 3.4 B). The remaining compounds described the asthma 
group, however among these, the aldehydes, the heavier alkanes (from tetradecane to 
octadecane) and alcohols, have a bigger weight in discriminating the asthma group taking into 
account LV1 positive values. Comparing these results to the result in the heat map, 
differences are observed in the compounds that characterize the populations under study.  
From Figure 3.3, 4-methyl-3-penten-2-one had higher chromatographic areas in the healthy 
population (in the PLS-DA this compound characterized the asthma population) and from 
loading analysis (Figure 3.4 B) there were other compounds that characterized the healthy 
population such as 2,4,6,6-pentamethylheptane, 3-ethyl-3-methylundecane and 3-methy-1-
heptene. These differences could be attributed to the normalization procedure adopted before 
applying MVA analysis due to the accounting for dilution factors in urine samples bringing 
all the compounds into proportion with one another.  
 Chapter 3 – Urine analysis 
161 
 
 
Figure 3.4 – (A) PLS-DA scores scatter plot showing a clear discrimination between allergic asthma and healthy 
children, (B) LV1 loading weights plot of the selected 78 metabolites with the identification of main compounds 
related to the healthy group.  
 
As for validation purposes, an internal cross validation and MCCV described in the 
multivariate analysis section, were applied. In the performed internal cross validation, the R2 
was 0.907 whilst the validation results had a R2 of 0.814. Therefore, to assess the predictive 
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ability of the classification model and evaluate the robustness of the developed models, 
MCCV was applied to add confidence to the obtained results.  
 
Figure 3.5 - ROC space (A) where each point represents a prediction result (sensitivity and 1-specificity) of the 
confusion matrices obtained from MCCV (500 iterations) of the PLS-DA model for the different data 
normalization techniques employed and Q2 values distribution (B) of the original and permuted Monte-Carlo 
Cross Validation for PLS-DA of exhaled breath of full dataset. 
 
The average Q2 for the 500 runs was 0.9, with a large prevalence of values within the 
range 0.8-1.0. According to the resulting confusion matrix, the PLS-DA model showed 98.7% 
sensitivity, with approximately 1.3% of asthma patients being misclassified as controls, and 
93.9% specificity, with 6.1% false positives. The classification rate (total number of samples 
correctly classified) was 97.3% . 
0
0.2
0.4
0.6
0.8
1
0 0.2 0.4 0.6 0.8 1
T
PR
 
(se
n
sit
iv
ity
)
FPR (1-specificity)
True classes Permuted classes(A)
0%
10%
20%
30%
40%
50%
60%
-1 -0.9-0.8-0.7-0.6-0.5-0.4-0.3-0.2-0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Fr
eq
u
en
cy
Q2 values
True Classes Permuted Classes
(B)
 Chapter 3 – Urine analysis 
163 
 
The metabolic activity of children with asthma is different from those without asthma 
revealed by their urine volatile composition. Several metabolic pathways may be associated to 
asthma, nevertheless this study focused on the fatty acid oxidation that is summarized in 
Figure 3.6. Airway inflammation is closely linked to asthma27,28 and studies have shown that 
ROS are mediators in the inflammatory process becoming clear that oxidative stress increases 
this process29. ROS alters key enzymatic and non-enzymatic antioxidants that lead to an 
oxidant-antioxidant imbalance in airways and this imbalance leads to known 
pathophysiological effects associated with asthma30. ROS are common initiators in living 
cells of the fatty acid oxidation process30 and alcohols, aldehydes, alkanes, alkenes and 
ketones are commonly associated to lipid peroxidation that is linked to fatty acid oxidation5,6. 
Alcohols, aldehydes, alkanes and alkenes are linked to oxidative stress and inflammation23. 
The main mechanism that affects the release of these chemical families in the body is 
oxidative stress and is essentially formed via lipid peroxidation by ROS of polyunsaturated 
fatty acids (PUFA)23. PUFA, found in cellular and subcellular membranes in the body, 
undergo lipid peroxidation due to the existence of multiple double bonds, in particular the 
methylene groups that have especially reactive hydrogen, forming aldehydes, alkanes and 
alkenes. Heavier ketones, under metabolic conditions, can also be associated with the β-
oxidation of branched fatty acids, a high oxidation rate of fatty acids20,31. Branched ketones 
may arise from branched aldehydes and can partially arise from bacterial action in the gut, 
probably by decarboxylation from the corresponding oxo-acids20 Therefore, this study was 
focused on identification of these metabolites in urine of an asthmatic population and 
compared them to the healthy population. Taking into account the results where the majority 
of the selected compounds pertaining to the aldehydes, alkanes, and alkenes are increased 
(Figure 3.3) and characterized the asthma group (Figure 3.4 B) The alcohol levels are no 
exception to this behavior and are generally increased in the urine of the asthmatic patients 
characterizing the asthmatic population (Figure 3.3 B). Accordingly to Figure 3.4 B, ketones 
levels in urine are increased in the asthmatic population, . These results suggest the possibility 
of assessing lipid peroxidation through the measurement of these urinary volatile compounds 
linked to lipid peroxidation and consequently fatty acid oxidation. 
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3.2.5 Concluding remarks 
 In this study, GC×GC–ToFMS combined with SPME was applied, for the first time to 
the best of our knowledge, in the uncovering the urinary metabolome of a paediatric asthmatic 
population. The use of a powerful technique such as GC×GC–ToFMS allowed the 
identification of c.a. 200 compounds, common in all samples, belonging to 10 different 
chemical families. A targeted analysis was performed to assess the impact that asthma has in 
oxidative stress on fatty acids and for that purpose five biochemically relevant families linked 
to these processes were selected. A set of 78 compounds belonging to aldehydes, ketones, 
alkanes, alkenes and alcohols was used. A heat map, a quick visualization tool, was built and 
it was possible to verifyt that the urine of asthmatics was highly altered when compared to the 
urine of the healthy population. MVA tools were then applied  and discrimination between the 
asthmatic and healthy populations was attained. Loading analysis enabled gathering 
metabolomic information through the identified compounds, therefore demonstrating that the 
levels of oxidative stress related to lipid peroxidation processes on asthma individuals was 
higher than in healthy individuals. Although the initial set of children is small (n=36), the 
achieved results led to the successful unravelling the asthma urinary volatile metabolome and 
led to the successful development of validated statistical models.  The use of high throughput 
technology (GC×GC–ToFMS) in the analysis of urine from a pediatric asthmatic population 
yielded an easy and novel strategy for asthma assessment, which may be a valuable tool in 
assessing lipid peroxidation levels in a population affected by asthma. 
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3.3 Exploring the urinary metabolomic profile of children with 
asthma by 1H Nuclear Magnetic Resonance 
 
3.3.1 Abstract 
Recently non-invasive sampling strategies have emerged as an attractive and useful 
approach combined to high throughput techniques such as 1H NMR. Therefore, this study 
focused on the establishment of the urinary metabolomic pattern of asthmatic and healthy 
children using 1H NMR in tandem with partial least squares discriminant analysis. Data pre-
treatment is an important step in metabolomics previous to multivariate analysis. Thus, three 
methods were applied: normalization to creatinine signal, to total spectral area and 
probabilistic quotient normalization (PQN). PQN yielded the most positive impact when 
compared to the remaining studied methods. To further improve the obtain results variable 
selection was studied taking into account the compounds with variable importance in 
projection (VIP) higher than 1 and specific 1H NMR spectral areas. The results showed that 
selecting VIP higher than 1 and for the spectral region between  0.5-3.0 and 6.0-9.5ppm was 
the best alternative. MCCV was also performed to assess both, the predictive power and 
classification models robustness of the developed models. The previously mentioned 
conditions yielded a classification rate of 83.9%, sensitivity of 90.3% and specificity of 
72.1%.  
Upon loading analysis, the compounds that characterized the healthy children were 
trimethylamine-N-oxide and trigonelline whilst a broader set of compounds characterized the 
asthma children β-aminoisobutyrate, lactate + threonine, histidine, phenylacetylglutamine, 
acetate, p-cresol, succinate, citrate, tyrosine and indoxyl sulphate. This metabolomic pattern 
allowed to obtain hypothesize on possible affected metabolic pathways by asthma such as 
TCA cycle, histidine metabolism, lactic acidosis, modification of free tyrosine residues after 
eosinophil stimulation, and DNA damage. The study led to a methodology able to monitor 
asthma patients allowing to ascertain urinary metabolomic changes providing the compounds 
involved in central metabolic pathways. The 1H NMR urine analysis yielded a metabolomic 
pattern for asthma, and the identified compounds allowed a comprehensive study of asthma 
metabolic related pathways. 
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3.2.2 Framework 
NMR is non-destructive technique enabling, highly reproducible, both qualitative and 
quantitative measurements while studying a number of metabolites in a biological fluid32,33. 
There has been a recent surge in the application of 1H NMR in biofluids research, with 
metabolic profiles being used to characterize, diagnose, and predict pathological states34,35.  
The application of 1H NMR spectroscopy to urine and plasma samples has been 
extensively used36,37,38. Saude et al.1, developed statistical models with 70 metabolites using 
urine of asthmatics analyzed by 1H NMR proving the potential of this tecnique in asthma 
research. The study allowed the identification of biochemical pathways that are possibly 
influenced by asthma such as the TCA, stress on energy metabolism, the protein and amino 
acid metabolism and inflammation. These authors proposed other possible pathways that are 
related to the modification of free tyrosine residues by eosinophil activity and lactic acidosis.  
Recently, Loureiro et al.39 analyzed urine by 1H NMR to evaluate the changes in 
urinary metabolites associated to asthma exarcebation and verified that lipid peroxidation 
associated to oxidative stress and TCA are the main altered metabolic pathways. Jung and co-
authors40 analyzed serum from patients with asthma using 1H NMR and compared to healthy 
children. The metabolites responsible for the attained discrimination are reportedly involved 
in hypermethylation, response to hypoxia, immune reaction and lipid metabolism. 
In this research study, the metabolomic urinary profile of an asthmatic childhood and 
healthy populations was explored using a 1H NMR methodology in order to extract relevant 
information that can be used further on asthma management. Firstly, three normalization 
statistical techniques were tested to normalize the urine 1H NMR spectra namely, total area 
normalization, normalization to creatinine reported in literature in studies related to asthma 
and PQN41. PLS-DA and Orthogonal Projections to Latent Structures (OPLS-DA) models 
were developed. MCCV was applied and loading analysis was performed to reveal the 
modifications on 1H NMR urinary metabolome of childhood promoted by asthma condition.  
 
3.2.3 Experimental 
Subjects  
Ninety-two patients with allergic asthma (from which 34 with also present allergic 
rhinitis) and 50 healthy subjects were enrolled in this study following informed consent and 
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approval of the study protocol by Hospital Infante D. Pedro E.P.E (Aveiro, Portugal) and the 
healthy population consisted of children of the faculty staff. The characteristics of the 
asthmatics and healthy population are presented in Table 3.3.  
Table 3.3 - Characteristics of the studied population: allergic asthma patients and healthy children.  
 Allergic asthma 
(n=92) 
Healthy 
Children 
Age (mean±SD) 9.5±3.2 8.8±3.5 
Gender (male/female) 44/48 22/28 
Pathology 
Allergic Asthma 58 (63%) - 
Allergic Asthma + Allergic Rhinitis 34 (37%) - 
Allergensa 
Dust mite 47 (51%) - 
Dust mite + gramineae 22 (23%) - 
Gramineae 10 (10%) - 
Dust mite + cat fur 5 (5%) - 
Dust mite + cat fur + dog fur 4 (4%) - 
Dust mite + gramineae + gat fur 2 (2%) - 
Gramineae + cat fur 2 (2%) - 
Gramineae + cat fur + dog fur 1 (1%) - 
Dust mite + dog fur 1 (1%) - 
Dust mite + olive tree 1 (1%) - 
Therapy 
Corticosteroid + bronchodilator 14 (15%) - 
Corticosteroid + leukotriene receptor antagonist + bronchodilator 12 (13%) - 
Corticosteroid + leukotriene receptor antagonist 9 (10%) - 
Nasal corticosteroid and bronchodilator 8 (9%) - 
Leukotriene receptor antagonist + bronchodilator 8 (9%) - 
Nasal corticosteroid and antihistamine 7 (8%) - 
Leukotriene receptor antagonist + bronchodilator + nasal 7 (8%) - 
Bronchodilator 5 (5%) - 
Antihistamine 5 (5%) - 
Leukotriene receptor antagonist  + nasal corticosteroid 4 (4%) - 
Corticosteroid 4 (4%) - 
Corticosteroid + bronchodilator + antihistamine 2 (2%) - 
Corticosteroid + antihistamine 1 (1%) - 
No therapy 6 (7%) - 
a
 Results obtained by prick-tests 
 
Asthma diagnosis was made based on characteristic clinical symptoms and exams 
(skin prick tests, lung function evaluation based on spirometry tests and IgE values). 
Appropriate therapy was prescribed by the patient’s own physician and the allergic asthma 
population represented a controlled asthma status. No restrictions were applied regarding 
drugs or diet. The study was approved by the Hospital Ethics Committee. Each individual 
(either patient or healthy volunteer) provided a urine sample in a sterile cup. Then, aliquots of 
approximately 1 mL were transferred into vials, and stored at -80 °C (in average one month) 
until analysis being each sample thawed once only for analysis. 
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Sample Preparation and 1H NMR analysis 
For 1H NMR analysis, urine samples were thawed and prepared as described by 
Carrola et. al.42 Briefly, fine pH adjustment to 7.00 was performed by adding a few drops of 4 
M solutions of KOD (98% atom D, Sigma-Aldrich, Madrid, Spain) or DCl (99% atom D, 
Sigma-Aldrich, Madrid, Spain). After, the samples were centrifuged (8000 rpm for 5 min) and 
transferred to a 5 mm NMR tube.  
1H NMR spectra were acquired on a Bruker Avance DRX-500 spectrometer operating 
at 500.13 MHz for 1H observation, at 300 K based on the developed method by Carrola et 
al.42 for urine analysis. For each sample, a standard 1D 1H NMR spectrum was acquired, 
using a water suppression pulse sequence.   
 
Data processing 
All spectra were processed with a line broadening of 0.3 and a zero filling factor of 2 
manually phased and baseline corrected. The chemical shifts were referenced internally to the 
sodium trimethlysilyl propionate-d4 (TSP) (98% atom D, Sigma-Aldrich, Madrid, Spain) 
signal at δ 0.00. The obtained data was matched to reference spectra in the BBIOREFCODE-
2-0-0 database (Bruker Biospin, Rheinstetten, Germany), as well as other existing 
databases43,44. 
A total of 142 spectra corresponding to 92 allergic asthma patients and 50 healthy 
children have been considered for multivariate analysis. To build the data matrix, variable 
sized bucketing was performed in the δ 10.00-0.40 region of the standard 1D spectra, 
excluding the sub-region δ 4.55-6.05 to remove variability arising from water suppression and 
from possible cross-relaxation effect on the urea signal via solvent exchanging protons. The 
bucketing procedure, carried out in Amix version 3.9 (Bruker BioSpin, Rheinstetten, 
Germany), consisted of dividing the spectra into small regions (buckets) of 0.005 ppm42. 
These buckets were then integrated and normalized by: i) adjusting the total area to unity, ii) 
by creatinine signal and iii) through PQN. In the total area normalization, each observation is 
set to have total unit intensity, dividing each data point by the total spectral area45. 
Normalization by creatinine signal consists in the ratio of each data point to urinary creatinine 
signal at 4.06ppm46 whilst PQN scales spectra, is estimated by analyzing the distribution of 
quotients of the amplitudes of the spectrum to be normalized with those of a reference 
spectrum47. PQN assumes that a majority of metabolites keep their concentrations unchanged 
across the samples. Therefore, normalization is carried out based on the maximum probability 
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of dilutions, which is estimated by the calculation of the most probable quotient between a 
target spectrum and a reference spectrum. The PQN method takes the median of many 
estimates rather than a single sum as the standard of normalization, and this makes it less 
susceptible to outliers48. Data normalization takes into account the inevitable variation in 
sample concentration and the efficiency of sample preparation procedure making data from all 
samples directly comparable with each other49. This step is necessary, especially with urine 
samples due to the variable nature of urinary concentration50.  
Then, after data normalizing, PLS-DA, and OPLS-DA were performed in SIMCA-
P11.5 (Umetrics, Umeå, Sweden), employing a default 7-fold internal cross validation, from 
which Q2 and R2 values, representing, respectively, the predictive capability and the explained 
variance, were extracted. VIP is a summary of the importance of an X variable for both Y and 
X. It is weighted sum of squares of the PLS-weights calculated from the amount of Y-
variance of each PLS component51. 
Model robustness was assessed by MCCV with 500 iterations. For each of the 500 
randomly generated classification models, the number of LV, the Q2 (expressing the cross 
validated explained variability), and the classification rate (percentage of samples correctly 
classified) were recovered. The selection of model complexity was based on the most frequent 
list of model properties that maximizes the classification rate (i.e., lower LV and higher Q2). 
The sensitivity and the specificity of the model were then depicted from the confusion matrix 
resulting into a ROC map to further assess the results significance. Further validation was 
performed by permutation analysis, consisting of randomly permuting class membership and 
running 500 MCCV iterations. Sensitivity is calculated from the ratio between true positives 
(asthma samples correctly predicted) and the total number of modelled urine samples, 
whereas specificity is determined from the ratio between true negatives (control samples 
correctly predicted) and the total number of modelled control RMN data. 
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3.2.4 Results and discussion  
 
Normalization of urinary compounds 
Appropriate pre-treatment of metabolomic data is an essential step before the 
application of multivariate statistical methods as it takes into account the inevitable variation 
in sample concentration and the efficiency of sample preparation procedure52. In asthma 
related NMR studies, different normalization methods were applied. For example, Saude et 
al.1 referenced the identified metabolites in urine to creatinine levels whilst Jung et al.53 
normalized the identified serum metabolites to the total spectral area. However, PQN has 
been increasingly used in metabolomics as shown by Dieterle47 and Kohl52, among others. In 
this study, a comparison of the performance of the data pre-treatment, previously reported in 
asthma NMR studies, (creatinine signal and to total spectral area) and the increasingly used 
PQN was performed and the reliability of data pre-treatment was evaluated using PLS-DA 
models. 
Scores plot for the first two latent variables of PLS-DA models for 1H NMR data are 
shown in Figure 3 comparing different normalization procedures, total area normalization 
(Figure 3.6 A), creatinine normalization (Figure 3.6 B) and PQN (Figure 3.6 C). As observed, 
PQN transformation has a positive impact in the discrimination power and the models, 
consisting of two components, had R2, which is the cumulative sum of squares of all the X’s 
explained by all extracted components, for total area normalization of 0.03, creatinine 
normalization of 0.11 and using PQN 0.22. The application of PQN resulted in an improved 
R2 when compared with the remaining two normalization procedures. Normalizing samples 
through creatinine has shown some disadvantages as this compound is not constant and may 
be related to muscle mass particularly in children46. PQN has shown that performs adequately 
in compensating for different urine dilutions and is more accurate even with low metabolic 
variations47. For further studies, the model that used PQN was chosen as it was demonstrated 
that the PQN normalization provided the best results in terms of group discrimination.  
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Figure 3.6 - Partial Least Squares Discriminant Analysis (PLS-DA) applied to 1H NMR urine spectra (δ0.50 to 
10.0, excluding 4.55-6.05) using different data normalization techniques: (A) normalized to total area, (B) 
normalized to creatinine signal and (C) by probabilistic quotient normalization (PQN). The R2 for the total area, 
creatinine normalizations and PQN was 0.03, 0.11 and 0.22, respectively. The healthy subjects are in full 
symbols whilst the asthma patients are represented by open symbols.  
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PLS-DA is often used in the metabolomics field and this tool is known to overfit the 
data specially when a smaller number of samples is used whe compared to the number of 
varibales. Therefore, validating the obtained models is necessary and cross validation is often 
performed with the analysis of several parameters such as Q2 value, true positives, true 
negatives, false positives, misclassifications and receiver operating characteristic curves54. 
MCCV statistics was applied to the PQN-PLS-DA model (Figure 3.6 C) to assess the 
predictive ability of the classification model.  
 
Figure 3.7 – ROC space, where each point represents a prediction result (sensitivity and 1-specificity) of the 
confusion matrices obtained from MCCV of the PLS-DA model with PQN; full symbols, prediction results in 
the original model (class membership, healthy or asthma, correctly assigned); open symbols, prediction results in 
the permuted model (class membership randomly permuted) 
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The average Q2 for the 500 runs was 0.5, with a large prevalence of values in the range 
0.4-0.6. According to the resulting confusion matrix, the PQN-PLS-DA model (Figure 3.7) 
showed approximately 85% sensitivity, with 15% of asthma patients being misclassified as 
healthy, and 72% specificity, with 18% false positives. The classification rate (total number of 
samples correctly classified) was 80%. 
 
Improving metabolomic data through variable selection 
The PLS-DA LV1 loadings were colored according to VIP and carefully inspected 
(Figure 3.8). The identification of compounds with VIP>1 was performed and 12 compounds 
were responsible for the attained discrimination.   
 
 
Figure 3.8 – PLS-DA LV1 loadings plot of all compounds colored as a function of VIP. Blue represents VIP 
starting from 0 and red represents the highest obtained VIP value 
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succinate, citrate, tyrosine and indoxyl sulphate meaning that these compounds were 
consistently elevated in the urine of asthma patients relatively to healthy children (Table 3.4).  
 
Table 3.4 – Compounds (variables) contributing for the discrimination between healthy subjects and asthma 
patients (VIP>1; highest VIP and corresponding chemical shift highlighted) and comparison between the data 
available in the literature for each compound and the obtained results in this study.  
Compounds δ 
1H(ppm) 
VIP  Possible biochemical 
origin(s) ↑ 
Comparison to 
literature results 
Phenylacetylglutamine 
1.93 2.70 Increased in  
syndromes of 
phospholipidosis 
impaired 
amino acid absorption; 
gut microflora 
Asthma - 
2.11 2.00 
2.27 2.30 
7.36 2.50 
7.43 2.97 
Succinate 2.41 2.89 TCA cycle Asthma Saude et al.
1
 
Asthma↑ 
Acetate 1.93 2.70 TCA cycle Asthma 
Jung  et al.53 
Control↑ 
 
Tyrosine 6.91 2.65 
Modification of 
free tyrosine residues 
by eosinophil activity 
in the airways of 
humans with asthma; 
Amino acid oxidation 
Asthma Saude  et al.
1
 
Asthma↑ 
Indoxyl sulphate 
7.51 2.42 
Oxidative stress Asthma - 
7.70 2.19 
p-Cresol 
2.35 1.60 End-product of protein 
breakdown; compound 
of the amino acid 
tyrosine (gut 
microflora) 
Asthma - 7.21 2.16 
7.28 2.18 
Histidine 
3.74 2.07 
Histamine metabolism Asthma Saude  et al.
1
 
Control↑ 3.75 2.08 7.97 2.12 
Lactate + threonine 1.33 1.95 Lactic acidosis Asthma 
Saude  et al.1 
Asthma vs. 
Emergency 
Department 
Asthma↑ 
Citrate 2.54 1.91 TCA cycle Asthma - 2.68 1.77 
β-Aminoisobutyrate 1.20 1.70 Thymine 
catabolism/metabolism Asthma - 
Trigonelline 
4.44 3.28 Diet; Impairment of 
nicotinate and 
nicotinamide 
metabolism 
Healthy Saude  et al.
1
 
Asthma↑ 
8.83 3.11 
8.85 3.12 
9.12 3.25 
Trimethylamine-N-
oxide 3.27 1.89 Diet Healthy 
Saude  et al.1 
Control ↑ 
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Metabolomic studies benefit from variable selection methods, based on VIP or even 
from selecting specific chemical shifts creating new datasets improving the developed 
models55. The VIP assesses the significance of each variable in the projection, summarizing 
the contribution that a variable makes to the model and usually an appropriate threshold is 
1.056,57. The yielded R2 values of PQN-PLS-DA model were low for studies in metabolomic 
field for complex sample analysis. With this in mind, VIP and spectrum region selection 
variable selection were performed. A new model was constructed using only the variables 
with VIP>1 and the results are shown in Figure 3.9 A. An improvement of Q2 was observed 
from 0.221 to 0.558.  
 
Figure 3.9 – Scores plot for the first two latent variables of PLS-DA models from 1H NMR spectra of urine 
using PQN using two possible variable selection: (A) Variable Importance in Projection (VIP) higher than 1 and 
(B) by selecting regions  between 0.5-3 ppm and 6-9.5ppm combined with VIP>1 
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Another variable selection tested was to select regions between 0.5-3 ppm and 6-9.5 
ppm and choosing the signals with VIP>1 (Figure 3.9 B). With this selection,  Q2 improved 
but to a lesser extent of 0.539 and MCCV was also performed for the regions models and the 
results are shown in Table 3.5. Table 3.5 summarizes the results obtained in MCCV. These 
results show that variable selection (VIP>1 and δ 0.5-3+6-9.5 combined with VIP>1), in 
which subsets are created from the original dataset, improved predictive power and MCCV 
performance, which allowed to filter the information and focus on the significant compounds. 
 
Table 3.5 – Prediction Results Obtained by MCCV (500 Iterations) of PLS-DA Models Built for the Classes: 
Healthy vs Asthma (n=142).Comparison between the PLS-DA using PQN, and a selection of variables with VIP 
higher than 1 (VIP>1) and by selecting regions between 0.5-3ppm and 6-9.5ppm combined with VIP>1 (regions) 
Model Q2 Classification 
Rate (%) 
Sensitivity (%) Specificity (%) 
PLS-DA PQN 0.221 80.3 85.2 71.8 
PLS-DA PQN VIP>1 0.558 83.3 89.3 72.3 
PLS-DA PQN regions 0.539 83.9 90.3 72.1 
 
MCCV was performed to the two variable selections performed and as seen on Table 
3.5 all parameters improved: classification rate of 83.3%, and method sensitivity of 89.3%, 
whilst the specificity remained at 72.3% (Figure 3.10). Another possibility to improve the 
developed statistical models and to reduce the number of variables is to choose specific 1H 
NMR spectral regions. This was performed by choosing regions PQN δ0.5-3 and 6-9.5ppm 
selecting the compounds with VIP>1.  
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Figure 3.10 - ROC space, where each point represents a prediction result (sensitivity and 1-specificity) of the 
confusion matrices obtained from MCCV (500 iterations) of the (A) PLS-DA model with PQN and selecting 
variables VIP >1 and (B) model with PQN and selecting regions between 0.5-3ppm and 6-9.5ppm combined 
with VIP>1. Full symbols, prediction results in the original model (class membership, healthy or asthma, 
correctly assigned); open symbols, prediction results in the permuted model (class membership randomly 
permuted) 
 
Asthma urinary asthma metabolomics based on 1H NMR  
From Table 3.4, it was possible to identify the compounds that discriminate asthma 
and healthy groups, where trimethylamine-N-oxide and trigonelline characterizes the healthy 
population and β-aminoisobutyrate, lactate + threonine, histidine, phenylacetylglutamine, 
acetate, p-cresol, succinate, citrate, tyrosine and indoxyl sulphate the asthmatics. The possible 
biochemical origins of the compounds are shown in Table 3.3 and a closer look into the 
metabolic pathways that might be affected by asthma will be made.  
Succinate and citrate58 are known compounds related to the TCA cycle, which have 
been reported to be increased in the asthma patients1 show similar behavior in the results 
obtained in urina of the asthma population (Table 3.4), confirming  that this biochemical 
pathway is affected by the asthma pathology. Citrate has been reported by Loureiro et al.59 to 
be increased in asthmatic patients with a stable condition, relating this compound with the 
disturbance of the TCA cycle. Acetate, which is oxidized in TCA cycle, was found to be 
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elevated in urine of the asthma population (Table 3.4). Jung et al.53 detected it in the sera of 
asthma patients, nevertheless exihibiting an opposite behavior from the one observed in our 
study. As urine is an excretion fluid, we may conjecture that the higher levels obtained in 
urine are due to kidneys activity. The decreased levels of these compounds may lead to 
conclude that the energy metabolism may be affected in asthmatics because hypoxia is known 
to affect all processes from the TCA cycle and it is a well known fact that asthmatics have 
decreased lung capacities and thus affecting the TCA cycle. Wang et al.60 have found this 
compound to be elevated in COPD patients  and associated it to an accelerated lipid 
catabolism to satisfy energy requirements. TCA cycle anomalies have been known to cause 
several diseases61, as it is a crucial process for the cell basal metabolism.  
Another biochemical pathway that might be affected by asthma pathology is lactic 
acidosis, which is a physiological condition characterized by low pH in body tissues 
accompanied by lactate build-up and which is indicative of hypoxia. This leads to metabolize 
glucose anaerobically and by this way lactate is formed58. Our results show that lactate + 
threonine are elevated in the asthma population under study (Table 3.4). Saude et al.1, 
reported that the level of this compound was elevated when comparing stable asthma patients, 
emergency department asthma patients and healthy children. According to Loureiro et al59., 
its content seems to be higher in exarbeated condition when compared to patients with an 
asthma stable condition. 
Histidine is a precursor for histamine biosynthesis and the compound histidine is 
increased in the asthmatic urine profile (Table 3.4). This behavior allowed to infer  that the 
metabolic pathway that involves histidine may be affected by the asthma pathology as Jung et 
al.53 demonstrated in their study. The hypothesis that can be formed by the elevated levels of 
histidine in asthmatics is that the higher bioavailability of this compound can lead to a higher 
rate in histidine decarboxylation to yield histamine. Histamine is a inflammatory mediator 
always present and associated to the asthma pathology as potent constrictor of airway smooth 
muscle62.  
Eosinophils promote tissue injury contributing to asthma pathogenesis and it has been 
verified that tyrosine is a part of the modification of free tyrosine residues after eosinophil 
stimulation and degranulation that occurs in the airways of humans with asthma63. This 
compound is also formed by amino acids oxidation induced directly by reactive oxygen 
species or indirectly by secondary by-products of oxidative stress reactions64. According to 
the results obtained (Table 3.4), this compound is also responsible for the discrimination 
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attained between the asthmatic and healthy population, being elevated in the former, which 
leads to confirm that this biochemical pathways may be affected by the asthma pathology. 
The levels of phenylacetylglutamine are elevated in the asthma population, and 
observing the VIP of this compound in Table 3.4, we can verify that from all compounds it 
has the highest VIP (2.97) correspondent to the peak at 7.43ppm. This compound has shown 
to be increased in syndromes of phospholipidosis impaired amino acid absorption, states of 
increased gut absorption of phenylacetate65, and the development of atopy and asthma may be 
influenced by gut permeability and gut microflora66. Asthma and gut permeability has been 
previously linked67, as asthma is a T lymphocyte mediated inflammatory disease. It has been 
suggested that the whole mucosal system might be involved, with activated T lymphocytes 
migrating from one mucosal site to another68. The link between gut microflora and asthma is 
related to the “hygiene hypothesis”.  The “hygiene hypothesis” for allergies and asthma states 
that a lack of microbial stimulation results in aberrant immune responses to innocuous 
antigens later in life69. Evidence that sustains this hypothesis directs to the “microbiota 
hypothesis” where changes in the gastrointestional microbiota composition (specially in the 
Western geographical areas) change the mechanisms of mucosal immunologic tolerance 
owing to antibiotic use, dietary changes and other lifestyle variations. Epidemiologic and 
clinical data supporting this information includes, for example, a positive association between 
increasing risk for asthma/allergies and the increase use of antibiotics and the intake of oral 
probiotics and/or dietary changes in some individuals prevented/reduced allergies70. p-Cresol 
is also a compound generated from tyrosine by gut microflora71. As previously shown, the 
asthmatic gut microflora might be affected by asthma and elevated levels of p-cresol might 
show this effect. 
 β-Aminoisobutyrate is the product of the catabolism of the pyrimidine bases uracil 
and thymine in what constitutes the first step of pyrimidine degradation pathway62. This 
compound was found to be increased in urine of asthmatics (Table 3.4) and to the best of our 
knowledge this pathway has not been associated to asthma . Oxidative stress related to asthma  
is a studied phenomena72. This phenomenon damages several biomolecules as lipids, proteins 
and DNA. ROS react with DNA adding to the DNA double bond. By abstraction of an 
hydrogen atom from methyl group of thymine several pyrimidine radicals are formed73. 
Hasbal and co-authors74 documented an increase in DNA strand breaks in children with 
asthma that can be formed by direct interaction with ROS and as β-aminoisobutyrate is 
related to the catabolism of pyrimidine bases this compound identified in our study may 
indicate the DNA damage that asthma causes. 
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Indoxyl sulphate is increased in urine of asthma patients (Table 3.4). Indoxyl sulphate, 
beside being a compound of the common amino acid tryptophan75, induces oxidative stress in 
vascular endothelial cells76 and strongly decreases the levels of glutathione, one of the most 
active antioxidant systems of the cells77.  
 
3.2.5 Concluding remarks 
 In this study, metabolomic urinary profile of  an asthma pediatric population was 
explored by 1H NMR. 1H NMR technology in the analysis of urine combined with 
multivariate tools can be used to differentiate allergic asthma children from a healthy 
population.  
The pre-treatment of metabolomic data is a ubitiquous step before the application of 
multivariate statistical tools. In this study three normalization methods were tested and PQN 
yielded the best results when compared to normalization to total area and creatinine signal. 
Variable (VIP >1) and spectrum region (0.5-3ppm and 6-9.5ppm) selection was also tested. 
The results showed that a combination between these selection gave the same results. MCCV 
was performed for all developed models. The improvement by the aforementioned selections 
was also observed by the validation results where all parameters from Q2, classification rate, 
sensitivity and specificity improved. Analysing the obtained loadings, the compounds 
responsible for the discrimination of the asthma and healthy groups were identified. These 
were trimethylamine-N-oxide and trigonelline for the healthy population and β-
aminoisobutyrate, lactate + threonine, histidine, phenylacetylglutamine, acetate, p-cresol, 
succinate, citrate, tyrosine and indoxyl sulphate for the asthmatics. 
A metabolic signature comprising an array of biochemical pathways altered in asthma 
patients was obtained. Overall, TCA cycle, lactic acidosis, histidine metabolism, modification 
of free tyrosine residues after eosinophil stimulation, alterations in intestinal microflora, DNA 
damage and oxidative stress were the possible identified biochemical pathways. It was also 
possible to obtain information on DNA damage produced by ROS probably derived from 
hypoxia state. 
Urine  analysis by 1H NMR can be used as a diagnostic tool as it is easily applied in a 
clinical setting and can be incorporated into a laboratory, as other technology has been in the 
past. Moreover, urinary metabolomic profiles related to asthma can be made using 1H NMR, 
bringing information on asthma-related changes in several biochemical pathways. 
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4.1 Conclusions 
The challenges proposed for this PhD thesis were addressed and methodologies 
using high throughput techniques in the analysis of biological examples obtained in a 
non-invasive manner were developed. Nowadays, certain gold standards, such as 
spirometry, are routinely used to assess the asthma disease status, but do not provide 
sufficient information. The feasibility of sampling exhaled breath and urine in an 
effortlessly manner, namely in children, must also be a purpose to take into account. 
The use of exhaled breath and/or urine yields additional information that could change 
the current hallmark on diagnosis, prognosis, in following a prescribed therapy for a 
single patient or even verify the disease status.  
The initial step in the analysis of exhaled breath volatile composition was the 
development of a HS-SPME method and then combine it with GC-MS. It was possible 
to verify the richness of the volatile composition of this matrix with the identification of 
several compounds belonging to different chemical families. The use of MVA tools was 
fundamental to verify that a pattern of compounds, belonging to the alkanes and 
aldehydes, was formed. It was observed that the asthmatic population was characterized 
by ramified alkanes and these compounds are connected to lipid peroxidation from the 
degradation of fatty acids that occurs due to the oxidant and antioxidant imbalance 
characteristic in asthma. Due to the advantages presented by the GC×GC-ToFMS, this 
analytical technique was used to obtain more information on exhaled breath. A more 
complete metabolomic profile was obtained and from the hundreds of identified 
compounds,  an alkane/aldehyde pattern was obtained and this pattern characterized the 
asthmatic and healthy populations, respectively. This outcome, combined with the 
previous GC-MS results, links oxidative stress (measured in the lipid peroxidation 
products) to asthma. Complementarily, urine volatile analysis by HS-SPME/ GC×GC-
ToFMS also revealed this information and it allowed to assess lipid peroxidation 
measuring compounds belonging to the alcohols, aldehydes, alkanes, alkenes and 
ketones. These compounds are associated to lipid peroxidation, and consequently to 
oxidative stress on fatty acids. Additionaly, the urine non-volatile metabolomic pattern 
was also obtained using 1H NMR to supplement the information attained from the urine 
volatile analysis. It was possible to identify several other biochemical pathways affected 
by asthma namely TCA cycle, histidine metabolism, lactic acidosis, changes in gut 
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microflora, modification of free tyrosine residues by eosinophil activity in the airways 
of humans with asthma and oxidation of amino acids.  
The use of the developed methodologies for clinical purposes was also tested, 
namely in exhaled breath. The first step was to reduce the GC×GC-ToFMS dataset (134 
compounds) and still have a method with a high classification rate, specificity and 
sensitivity. This was obtained with 9 compounds within the alkane/aldehyde pattern. 
The applicability of using the exhaled breath metabolomic pattern was then tested 
through the follow-up: of a naive patient over 24 days, of a patient with severe asthma 
treated with Omalizumab® over 20 months, of a patient thoughout 3 years and of 
patients in exarcebation and stable conditions.  A new cohort of asthmatic children was 
also tested in the verification of the  developed metabolomic based models in diagnosis 
and monitoring the disease status through exhaled breath. The metabolite pattern 
obtained by GC×GC-ToFMS and the developed models were successful as there was a 
clinical positive evolution accompanied by exhaled breath change in composition 
towards the healthy group. A noteworthy result was obtained in the severe asthma case 
as this patient failed several treatments in the 20 month period and this reflected 
clinicaly as well as it could be observed in the exhaled breath volatile composition.  
In conclusion, the analysis of two matrices obtained non-invasively using two 
high throughput techniques yielded a myriad of information, beside the successful 
development of statistical models with excellent results in terms of classification rate, 
sensitivity and sensibility. The information obtained from studying exhaled breath and 
urine, from a volatile point of view, was complementary and allowed to measure 
oxidation products that reflect lipid peroxidation in asthma. The non-volatile 
characterization of urine added information to that obtained in the volatile counterpart 
with several biochemical pathways being connected to asthma. The use of both matrices 
and both techniques was a paramount aspect in the work developed for this PhD thesis 
that allowed obtaining a more complete and complementary information on the 
metabolic changes in asthma.  
The results presented demonstrate the potential of volatile and/or non-volatile 
exhaled breath and urine metabolomic profiling in asthma. This PhD thesis lays the 
foundations for future studies in asthma through the use of this matrices combined with 
the high throughput techniques. 
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4.2 Future Work 
 Exhaled breath and urine analysis are promising biofluids in monitoring asthma, 
being easily implemented in asthma management. These matrices produce an unique 
print and this can result in a new healthcare paradigm that intends more efficient drug 
uses, earlier/more accurate diagnosis resulting in a better medical outcome. 
Nevertheless there are still issues that can be studied from the results presented in this 
PhD thesis and that could be considered for the future endeavors: 
• Enlarge the sample numbers to strengten the results and applying the 
developed methodologies to other locations in the country or even abroad; 
• Use of other high throughput methodologies such as liquid 
chromatography coupled to mass spectrometry to attain more information 
of the studied matrices; 
• Study the possiblity of characterizing different asthma phenotypes;  
• Complementing the metabolomic information by performing proteomic 
and genomic studies; 
• Deepening the biochemical origin of the found compounds analysing 
human bronchial cells; 
• Clinical orientied studies for diagnosis, therapy follow-up and disease 
monitoring performing longitudinal studies and randomized controlled 
trials. 
• Development of point-of-care platform to be implemented in medical 
practice as an aid to diagnosis, follow-up therapy and disease monitoring.  
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QUESTIONÁRIO 
Código do Voluntário: Idade:  Idade de início da doença: 
Peso (Kg):  Altura (cm):  Crises (estimativa): 
Motivo da consulta: Asma Rinite Alérgenos:  
Medicação:  
A criança teve algum episódio de pieira ou chieira nos últimos doze meses? Sim 
 Não 
Nos últimos doze meses a criança fez tratamento imunoterapêutico ,ou seja, vacina 
para alergia?  Sim  Não 
Nos últimos doze meses a criança teve crise asmática? Sim     Não 
Nos últimos doze meses a criança espirrou ou teve rinorreia sem que estivesse 
constipada? Sim  Não 
Nos últimos doze meses a criança quando fez exercício teve episódios de pieira ou 
chieira?       Sim  Não 
HABITAÇÃO (Assinale as opções adequadas 
 
Cidade Apartamento Nova Ar condicionado Aquecimento: 
Campo Vivenda Velha Desumidificador Nenhum 
 Outro: Arejada Óleo 
  Poeirenta Eléctrico 
  Húmida Lareira 
  Zona Poluída Braseira 
   Central 
   Outro: 
QUARTO (Assinale as opções adequadas 
[FICHA DO VOLUNTÁRIO] 
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Tipo de Pavimento: Alcatifa Tapete de lã   Outro: 
Colchão:  Molas Espuma   Palha Outro: 
Almofada:  Não Usa Espuma   Fibra Sintética 
Outros: Peluches Livros Expostos  Material dos cortinados: 
Cuidados Especiais com o colchão: Aspira de semana a semana  Lava os lençóis a 60ºC 
AMBIENTE (Assinale as opções adequadas 
 
Tem animais domésticos: Canário Cão Gato Coelho Cavalo 
   Periquito Hamster Outros: 
Há Fumadores em casa: Não  Pai Mãe Outros: 
PROBLEMAS (Assinale as opções adequadas 
 
Época do ano em que passa pior: Primavera Outono Qualquer altura Verão Inverno 
 Meses Piores: 
 
A criança tem problemas: Tosse   Urticária 
    Expectoração   Inchaço 
    Farfalheira   Dorme de boca aberta 
    Pieira   Faz barulho a dormir 
    Falta de ar   Mau hálito de manhã 
    Comichão nos Olhos Otites 
    Olhos a chorar  Amigdalites 
    Comichão no nariz Adenodites 
    Perda do cheiro  Diarreia 
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    Espirros frequentes Vómitos 
    Borbulhas na cara Outros: 
    Comichão na cara 
 
Aparecimento dos sintomas: Dia Noite Madrugada Indiferente 
Os sintomas são:  Leves Moderados  Graves Sempre Muitas Vezes Poucas 
vezes  Raramente 
Os sintomas interferem no dia-a-dia da criança? Não Pouco Moderamente  Muito 
Alguns factores podem ser a causa dos sintomas ou podem agravar: 
Dentro de casa  Zonas húmidas  Cosméticos Leite e derivados 
Fora de casa   Poluição do ar  Insecticidas Ovos 
Tempo seco   Poeiras   Celeiros  Frutas 
Tempo húmido  Ar condicionado  Feno  Chocolate 
Dias quentes   Fumo do cigarro  Trigo  Nozes, amêndoas 
Dias Frios  Papéis  Cheiro de comida   Amendoins 
Dias ventosos  Perfumes  Peixe      Legumes  
Mudanças de tempo  Medicamentos  Carne    Vegetais verdes: 
Mais informações (familiares com doenças alérgicas e/ou outras doenças da criança): 
 
 
Quem respondeu a este questionário: 
Pai 
Mãe 
Outra pessoa  
Data do Inquérito:        /        / 201__     
Contactos (telemóvel/email): 
[FICHA DO VOLUNTÁRIO] 
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Obrigado pela sua participação! Qualquer dúvida não hesite em contactar-nos! 
 
Dados clínicos: 
IgE: 
Prick tests: 
Espirometria (Fev1; Fev25-75; Peak Flow): 
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Table S1 -Dataset of volatile compounds identified by GC×GC–ToFMS in exhaled breath used for projection purposes in Chapter 2.5 
1tR a (s) 2tR a (s) Compounds 
                            
                            
                            
  Hydrocarbons S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 S23 S24 S25 S26 S27 S28 
  Alkanes                             
138 0.48 hexane 0.3 0.4 0.1 0.4 1.7 2.0 1.3 0.2 1.4 0.2 0.4 0.5 1.1 0.3 0.2 0.6 0.6 0.2 0.7 0.6 0.5 0.4 0.8 0.6 4.3 1.0 0.5 0.5 
210 0.52 2,4-dimethylhexane 0.2 0.2 0.7 0.3 0.5 0.1 4.3 0.1 1.0 0.1 0.3 0.1 1.1 0.4 0.1 1.1 4.5 0.4 1.1 0.6 0.2 0.0 2.1 0.8 0.9 1.7 0.4 0.6 
252 0.54 octane 1.4 0.7 4.0 1.0 0.9 1.2 2.1 0.5 1.7 0.3 0.6 0.6 1.9 0.8 0.4 0.5 1.9 0.7 2.0 1.1 0.6 0.3 0.4 1.5 2.0 2.8 1.1 1.4 
276 0.55 2,2,4-trimethylhexane 0.1 0.1 0.2 0.6 2.3 1.7 3.7 1.7 2.9 0.5 0.9 1.0 3.6 1.1 0.0 4.2 3.9 1.3 1.5 1.6 0.1 0.1 2.7 3.1 2.4 3.6 0.2 0.3 
288 0.55 2,4-dimethylheptane  1.0 1.0 0.7 0.6 0.3 0.8 0.2 0.3 1.5 0.0 0.2 0.4 0.5 0.0 1.0 0.2 0.8 0.2 0.6 0.6 0.9 0.7 0.1 0.4 1.2 1.6 3.1 2.6 
318 0.56 4-ethyl-2-methylhexane 0.2 0.2 1.0 0.2 1.2 0.8 0.9 0.3 1.2 0.2 0.3 0.2 1.0 0.4 0.2 1.1 2.6 0.4 1.4 0.5 0.1 0.1 1.3 1.0 0.7 1.4 0.3 0.5 
366 0.58 alkane isomer (m/z 43, 57, 85) 0.0 0.0 2.6 0.3 0.7 1.1 0.4 0.1 1.2 0.3 0.2 0.2 0.9 1.8 0.0 0.0 0.0 2.1 3.0 1.6 0.3 0.2 0.9 1.5 0.5 0.8 1.0 1.2 
468 0.56 nonane  3.1 3.0 4.9 3.5 3.4 3.3 3.3 2.1 3.6 2.1 1.3 1.3 4.2 0.7 2.5 3.3 2.6 2.8 2.8 3.0 2.1 2.3 3.4 3.0 3.8 3.4 4.5 5.5 
504 0.55 alkane isomer (m/z 43, 57, 85) 0.3 0.2 2.0 0.2 0.8 0.5 0.9 0.3 0.8 0.6 1.2 1.0 0.5 1.7 0.1 1.8 1.1 0.5 1.1 0.6 0.2 0.2 1.0 0.7 0.7 0.9 0.5 0.7 
516 0.55 2,4-dimethyloctane  0.2 0.1 0.0 0.1 0.1 0.2 0.2 0.0 0.2 0.0 0.1 0.1 0.2 0.0 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.2 0.3 0.5 
528 0.56 3-ethyl-3-methylheptane  0.2 0.1 2.2 0.2 0.3 0.3 0.2 0.1 0.3 0.1 0.2 0.1 0.2 0.1 0.2 0.2 0.5 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.3 0.7 0.3 0.5 
540 0.55 2,6-dimethyloctane 0.0 0.9 7.1 1.0 0.7 0.7 1.0 0.4 1.6 0.5 0.3 0.2 1.4 0.7 0.5 0.7 0.8 0.6 0.7 0.6 0.4 0.6 0.7 0.6 0.8 0.9 1.4 1.7 
552 0.55 3-ethyl-2-methylheptane 0.4 0.4 0.8 0.6 0.2 0.4 0.4 0.2 0.5 0.3 0.1 0.0 0.2 0.2 0.7 0.4 0.4 0.2 0.3 0.3 0.3 0.2 0.4 0.3 0.5 0.7 1.0 1.3 
558 0.55 alkane isomer (m/z 57, 43, 71) 0.1 0.2 0.6 0.1 0.3 0.4 2.1 0.2 0.2 0.2 0.6 0.4 0.2 0.1 0.0 0.4 0.4 0.2 0.2 0.1 0.1 0.1 0.3 0.2 0.2 0.4 0.2 0.2 
564 0.55 alkane isomer (m/z 43, 57, 71) 0.4 0.3 3.0 0.3 0.3 0.3 0.2 0.1 0.4 0.1 0.1 0.1 0.3 0.1 0.0 0.2 0.3 0.1 0.2 0.2 0.3 0.1 0.3 0.2 0.4 0.3 0.5 0.9 
576 0.56 4-ethyloctane  0.1 0.1 1.5 0.2 0.2 0.2 0.2 0.1 0.8 0.2 0.2 0.2 0.2 0.3 0.0 0.4 0.3 0.2 0.2 0.2 0.1 0.1 0.3 0.2 0.3 0.2 0.2 0.3 
582 0.55 4-methylnonane  0.2 0.2 1.1 0.4 0.4 0.4 0.5 0.2 0.6 0.4 0.2 0.2 0.3 0.2 0.1 0.3 0.6 0.2 0.2 0.5 0.1 0.2 0.4 0.4 0.5 1.2 0.2 0.4 
588 0.54 alkane isomer (m/z 57, 43, 85) 0.6 0.2 3.5 0.4 0.2 0.3 0.4 0.3 0.5 0.1 0.1 0.1 0.2 0.0 0.4 0.1 0.1 0.3 0.1 0.2 0.3 0.2 0.4 0.2 0.5 0.4 0.6 1.1 
594 0.55 alkane isomer (m/z 57, 43, 71) 1.1 0.7 3.7 1.3 0.8 0.8 0.6 1.7 1.1 0.5 0.4 0.4 0.8 0.6 5.8 0.9 1.1 0.5 1.2 0.6 0.8 0.5 0.7 0.5 1.0 1.0 1.4 2.5 
600 0.55 2-methylnonane 0.5 0.4 3.4 1.0 0.8 0.7 0.6 0.4 0.8 0.4 0.1 0.1 0.6 0.5 0.8 0.6 0.7 0.5 0.6 0.6 0.5 0.4 0.7 0.6 0.8 0.9 0.9 1.3 
606 0.55 alkane isomer (m/z 57, 43, 41) 0.7 0.2 4.3 0.6 0.3 0.4 0.2 0.2 0.5 0.1 0.5 0.4 0.4 0.5 2.4 0.2 0.3 0.5 0.2 0.6 0.4 0.2 0.3 0.6 0.5 0.4 0.7 1.5 
612 0.55 3-methylnonane 0.5 0.4 2.9 0.8 0.7 0.5 0.7 0.4 0.7 0.4 0.1 0.1 0.4 0.6 0.5 0.7 0.6 0.7 0.6 0.0 0.4 0.4 0.7 1.0 0.7 1.1 0.7 1.0 
636 0.54 2,2,4,6,6-pentamethylheptane 12.9 6.0 1.7 2.2 5.4 7.6 1.4 1.3 1.5 2.4 2.2 3.5 2.1 1.0 4.5 1.7 2.9 1.9 2.8 2.0 3.2 0.0 1.5 2.3 1.5 1.8 5.3 3.3 
660 0.56 decane 6.3 4.0 6.2 11.0 3.9 3.8 3.8 3.4 5.9 4.3 3.0 3.1 4.9 1.1 4.6 4.2 3.4 3.4 4.2 5.2 3.7 4.1 4.3 3.5 3.9 3.5 4.8 5.2 
672 0.54 alkane isomer (m/z 57, 41, 71) 1.1 1.2 1.1 0.0 0.4 0.6 0.1 0.1 0.2 0.2 1.2 2.7 0.3 0.3 4.6 0.1 0.1 0.2 0.0 0.1 0.2 0.1 0.5 0.1 0.4 2.4 0.2 0.8 
720 0.54 3,9-dimethylnonane  0.8 0.2 2.3 0.4 1.5 1.3 0.1 0.4 0.8 0.4 6.8 5.1 1.2 2.7 0.9 0.5 5.5 0.2 4.6 0.8 0.6 0.8 0.6 0.2 1.0 0.1 0.5 0.6 
756 0.54 2-methyldecane 6.5 4.0 2.7 3.2 2.5 5.4 1.4 3.3 3.1 3.8 0.7 2.6 2.3 1.5 10.1 3.2 1.4 1.7 1.5 1.5 10.0 3.1 1.9 2.3 2.7 3.6 12.3 10.7 
768 0.54 alkane isomer (m/z 57, 43, 85) 0.7 0.3 1.6 0.3 0.7 0.8 0.5 0.3 1.0 0.4 0.4 0.3 1.1 0.5 6.4 0.4 0.5 0.4 0.7 0.5 0.6 0.4 0.5 0.5 0.5 0.9 0.6 0.6 
774 0.55 3-methyldecane 1.2 0.0 3.3 1.2 0.5 0.5 0.4 0.3 0.5 0.3 0.3 0.3 0.5 0.6 1.2 0.2 0.6 1.0 0.7 0.8 1.0 0.3 0.4 0.9 0.5 0.5 1.1 1.2 
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1tR a (s) 2tR a (s) Compounds 
                            
                            
                            
S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 S23 S24 S25 S26 S27 S28 
864 0.56 2,3-dimethyldecane 0.5 0.5 0.8 0.0 0.5 0.6 0.1 0.0 0.2 0.1 0.9 0.3 0.2 0.9 0.7 0.9 0.1 1.1 0.7 0.1 0.4 0.5 0.3 0.4 1.1 0.2 0.9 0.5 
876 0.56 alkane isomer (m/z 57, 43, 71) 0.3 0.3 0.3 0.3 1.9 1.8 1.1 1.3 1.4 1.2 1.7 1.3 1.7 1.1 0.2 1.5 1.3 1.7 1.2 1.2 0.2 2.0 2.3 1.6 2.0 1.2 0.3 0.1 
894 0.55 5-methylundecane 0.0 0.6 1.3 0.8 0.7 0.9 0.3 0.1 0.3 0.1 0.3 0.4 0.6 0.5 1.1 0.2 0.3 1.0 0.3 0.0 0.7 0.8 0.9 0.7 0.6 0.9 0.7 0.8 
906 0.57 alkane isomer (m/z 57, 43, 71) 0.7 0.8 1.3 1.0 0.5 1.0 0.4 1.0 2.6 0.4 0.6 0.3 0.4 0.7 0.5 0.4 0.5 0.5 0.5 0.5 0.7 0.7 0.6 0.6 0.5 1.2 0.7 0.6 
912 0.57 3,9-dimethylundecane 0.6 0.6 1.1 0.9 3.8 0.7 0.7 1.9 0.8 1.0 2.2 1.4 0.8 1.0 0.4 0.1 1.1 0.9 0.4 0.9 0.5 0.5 1.0 0.9 1.0 0.5 0.5 0.5 
948 0.57 dodecane 10.3 7.9 3.8 6.6 2.9 2.9 2.7 2.8 2.7 2.8 2.9 2.9 2.8 3.8 6.9 2.2 1.9 3.7 2.8 4.0 8.3 3.4 3.7 3.0 2.7 2.1 8.5 6.4 
960 0.58 alkane isomer (m/z 57, 71, 43)  0.3 0.3 0.5 0.4 0.1 0.1 0.3 0.1 0.1 0.1 1.9 1.5 0.2 2.6 0.1 0.3 0.3 3.2 0.2 2.3 0.3 0.5 0.2 2.6 0.1 0.1 0.2 0.2 
966 0.57 alkane isomer (m/z 57, 43, 71) 0.4 0.6 0.5 0.8 2.1 2.5 2.0 2.6 1.9 2.6 0.3 0.0 2.5 1.9 0.4 2.4 1.4 3.2 1.5 2.3 0.6 2.8 2.4 2.6 1.2 2.2 0.4 0.4 
972 0.56 2,5,6-trimethyldecane 0.6 0.6 0.5 1.0 0.2 0.2 4.3 1.1 0.7 0.5 1.6 2.1 0.2 0.1 0.4 1.1 4.1 0.3 0.2 0.3 0.9 0.2 0.3 0.3 0.2 0.2 0.6 0.6 
978 0.57 alkane isomer (m/z 57, 43, 71) 0.2 0.3 0.4 0.4 0.9 0.8 0.7 1.2 0.7 1.0 2.2 0.3 0.8 1.2 0.2 0.9 4.1 1.5 6.2 1.3 0.4 0.4 1.0 2.2 0.3 0.4 0.2 0.2 
996 0.56 alkane isomer (m/z 57, 43, 71) 0.1 0.2 0.1 0.1 0.5 0.6 0.4 0.2 0.6 0.2 0.1 0.2 0.6 0.2 0.1 1.0 0.5 0.4 0.5 0.2 0.2 0.7 0.8 0.2 0.7 0.5 0.1 0.2 
1002 0.57 alkane isomer (m/z 57, 43, 71) 0.2 0.3 0.1 0.2 0.8 1.3 0.8 0.9 0.6 0.7 1.4 1.2 0.6 0.9 0.1 0.4 0.7 0.5 0.5 0.6 0.2 1.4 1.6 0.5 0.7 0.5 0.1 0.1 
1008 0.57 6-methyldodecane 0.3 0.4 0.1 0.3 2.0 2.0 1.5 1.8 2.2 1.8 1.9 1.5 1.7 1.9 0.2 1.7 1.4 2.2 1.4 0.7 0.4 2.0 2.3 1.8 2.0 2.1 0.2 0.2 
1020 0.57 alkane isomer (m/z 43, 57, 71) 0.2 0.7 0.1 0.6 0.4 0.4 0.2 0.2 0.4 0.3 0.2 0.1 0.4 0.3 0.2 0.1 0.3 0.1 0.4 0.2 0.3 0.2 0.4 0.2 0.2 0.3 0.2 0.5 
1044 0.55 alkane isomer (m/z 57, 43, 71) 0.7 1.3 0.3 0.9 1.8 1.7 1.4 2.1 0.7 2.1 0.8 0.3 0.7 0.6 0.7 1.8 0.6 0.7 0.6 0.7 1.7 0.7 2.1 0.6 1.7 0.5 1.0 1.0 
1050 0.55 4-ethylundecane  3.3 3.9 1.4 2.7 3.0 2.3 2.3 3.7 2.0 3.3 1.3 1.7 2.5 1.9 3.6 2.0 1.5 2.1 1.9 2.1 6.0 2.3 0.5 3.8 2.6 1.4 3.8 3.8 
1056 0.57 alkane isomer (m/z 57, 43, 71) 0.2 0.6 0.1 0.3 0.4 0.2 0.2 0.0 0.3 0.9 0.1 0.1 0.5 0.3 0.1 0.3 0.7 1.5 0.7 1.7 0.3 0.0 0.5 1.2 0.6 0.2 0.2 0.2 
1062 0.55 alkane isomer (m/z 57, 71, 43) 0.9 1.2 0.3 1.1 0.3 0.3 1.1 1.1 0.3 0.4 1.3 0.6 0.4 1.0 1.4 0.3 0.4 0.3 0.5 0.5 1.2 0.6 0.8 0.5 0.3 0.4 0.9 1.0 
1068 0.56 alkane isomer (m/z 43, 57, 71) 0.8 2.3 0.3 1.0 0.4 0.5 1.1 0.4 0.7 0.4 0.8 0.7 0.8 0.6 0.7 0.3 0.4 0.3 0.5 0.2 1.2 0.7 0.5 0.4 0.3 1.7 0.9 0.8 
1074 0.57 tridecane 1.6 2.5 0.7 1.9 1.9 2.0 3.2 1.7 2.9 0.8 2.9 2.3 3.5 1.6 1.9 0.9 2.3 1.9 3.4 2.4 3.3 3.3 2.2 1.3 1.7 1.2 1.8 1.9 
1092 0.57 2,2-dimethyldodecane 0.7 3.1 0.2 0.6 0.4 0.6 0.5 0.5 0.5 1.2 0.7 0.6 0.6 0.5 0.3 0.7 0.4 0.4 0.6 0.7 0.6 1.1 0.7 1.1 0.6 0.4 0.4 0.4 
1104 0.57 alkane isomer (m/z 57, 43, 71) 3.9 4.8 1.5 3.4 3.3 3.3 3.4 4.5 4.3 6.5 1.5 2.8 4.8 2.8 6.6 3.5 3.2 3.8 2.5 3.9 6.5 4.1 2.6 3.9 3.0 2.9 4.3 4.0 
1110 0.57 alkane isomer (m/z 57, 43, 71) 0.4 0.5 0.2 0.5 0.6 0.6 0.4 0.5 0.5 0.5 1.1 1.0 0.4 0.2 0.3 0.2 0.3 0.3 0.5 0.6 0.4 0.2 0.6 1.3 0.5 0.3 0.3 0.3 
1116 0.57 alkane isomer (m/z 57, 71, 43) 1.8 2.5 0.8 1.7 1.6 1.3 2.1 2.4 2.0 1.4 1.1 1.1 2.4 2.1 1.5 1.1 1.9 2.3 2.0 2.5 3.2 2.6 1.5 2.3 1.6 0.8 3.2 3.7 
1128 0.57 3-ethyl-3-methylundecane 1.0 1.5 0.4 1.2 2.1 1.9 3.2 3.0 2.3 4.2 2.0 1.9 3.7 2.0 1.6 2.6 2.3 2.5 6.4 0.5 1.6 3.7 2.1 0.8 1.6 2.7 1.1 1.2 
1152 0.60 2-methyltridecane 0.4 0.0 0.2 0.6 1.3 1.3 1.0 1.5 1.4 1.8 1.7 1.6 1.0 1.1 0.3 1.8 0.7 2.3 1.1 2.5 0.6 1.2 1.6 1.5 1.0 1.5 0.3 0.4 
1158 0.59 alkane isomer (m/z 57, 43, 71)  0.4 3.5 0.4 0.6 0.8 0.7 1.2 0.8 1.1 0.9 1.7 1.1 1.3 0.7 0.6 0.7 0.5 1.1 1.6 1.3 0.6 0.8 0.8 0.8 0.9 0.5 0.4 0.4 
1170 0.61 alkane isomer (m/z 57, 43, 71) 0.2 0.4 0.1 1.2 2.0 1.0 0.4 1.6 0.4 1.2 2.7 1.1 0.5 1.1 0.1 0.7 0.2 1.5 0.5 1.7 0.3 0.4 1.4 1.1 1.4 1.4 0.2 0.2 
1188 0.61 tetradecane 2.7 4.2 0.8 3.2 2.3 2.6 3.7 3.7 2.9 3.9 4.1 3.9 3.5 3.9 2.1 2.5 2.1 3.3 2.9 4.4 3.3 1.7 2.7 3.7 1.9 2.3 2.3 1.9 
1284 0.58 alkane isomer (m/z 57, 43, 85) 0.2 0.4 0.1 0.3 0.2 0.3 0.4 0.3 0.3 0.4 0.3 0.5 0.3 0.5 0.3 0.4 0.2 0.5 0.3 0.6 0.5 0.5 0.5 0.4 0.4 0.2 0.4 0.3 
1290 0.58 6,6-diethyldodecane 1.0 1.5 0.5 1.6 1.9 1.9 2.1 2.1 1.1 1.7 0.7 0.6 1.1 2.5 1.5 1.4 1.0 2.5 1.6 1.7 2.6 1.9 1.4 2.5 1.1 0.8 1.8 1.7 
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1tR a (s) 2tR a (s) Compounds 
                            
                            
                            
S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 S23 S24 S25 S26 S27 S28 
  Cyclic                             
240 0.57 1,2,4-trimethylcyclopentane 0.3 0.4 0.2 0.3 0.1 0.3 0.2 0.0 0.3 0.1 0.1 0.1 0.2 0.1 0.0 0.2 0.6 0.1 0.5 0.2 0.3 0.1 0.3 0.1 0.7 0.5 0.2 0.2 
534 0.60 propylcyclohexane 0.2 0.3 0.7 0.3 0.9 0.7 1.6 0.5 2.4 1.0 0.4 0.3 1.3 0.9 0.3 1.1 1.4 0.9 0.8 1.0 0.1 0.8 1.0 1.4 1.7 2.8 0.2 0.3 
576 0.59 1,1,2,3-tetramethylcyclohexane 0.1 0.3 0.2 0.8 0.5 0.4 0.9 0.5 0.8 0.5 0.6 0.3 0.4 0.5 0.1 1.3 0.9 0.5 0.6 0.6 0.1 0.5 0.0 0.7 0.7 0.7 0.2 0.3 
618 0.60 2-ethyl-1,3-dimethylcyclohexane 0.1 0.1 0.1 0.2 0.4 0.3 0.7 0.1 0.5 0.2 0.2 0.2 0.2 0.2 0.3 0.4 0.4 0.3 0.2 0.3 0.0 0.1 0.4 0.4 0.5 0.4 0.1 0.1 
624 0.59 1-methyl-3-propylcyclohexane 0.5 0.3 3.0 0.9 0.5 0.5 0.3 0.2 0.7 0.2 0.4 0.4 0.4 0.2 0.5 0.3 0.5 0.2 0.3 0.2 0.2 0.3 0.4 0.2 0.7 0.6 0.5 1.1 
630 0.58 1-methyl-3-(2-methylpropyl)cyclopentane 0.5 0.8 3.8 1.2 0.6 0.5 0.5 0.3 1.2 0.6 0.2 0.2 0.5 0.4 0.8 0.5 0.6 0.5 0.5 0.8 0.4 0.6 0.6 0.4 0.7 1.2 0.7 1.2 
642 0.59 ethylpropylcyclopentane 0.2 0.1 1.4 0.3 0.2 0.3 0.2 0.1 0.2 0.1 0.1 0.0 0.3 0.2 0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.3 
654 0.59 1-methyl-2-propylcyclohexane 0.4 0.3 0.5 0.5 0.4 0.4 0.3 0.2 0.5 0.2 0.1 0.1 0.3 0.2 0.1 0.3 0.4 0.1 0.3 0.2 0.3 1.1 0.3 0.1 0.5 0.4 0.4 0.5 
732 0.57 hexylcyclopentane 0.3 0.3 0.8 0.4 0.6 1.0 0.6 0.4 0.9 0.4 0.8 0.7 0.9 0.4 0.4 0.4 1.5 0.6 0.9 0.6 0.3 0.5 0.7 0.7 1.1 2.6 0.3 0.4 
792 0.57 1,4-dimethylcycloctane 0.5 0.7 1.8 0.5 0.9 0.8 0.8 0.6 0.9 0.6 0.8 0.9 1.0 0.7 0.7 0.7 3.7 0.7 1.4 0.5 0.7 0.7 0.9 0.7 0.9 0.9 0.8 1.0 
804 0.59 1-ethyl-2-propycylohexane 0.3 1.1 0.4 0.3 1.0 1.4 0.9 0.8 1.6 0.8 0.3 0.3 2.6 1.4 0.2 1.1 1.1 1.0 1.4 0.9 0.3 2.2 1.5 1.9 1.1 1.0 0.4 0.3 
996 0.62 hexylcyclohexane 0.1 0.1 0.1 0.2 0.6 0.5 0.2 0.9 0.4 0.9 0.3 0.8 0.4 0.3 0.1 0.2 0.6 0.9 0.4 1.2 0.2 0.5 1.0 0.9 0.6 0.3 0.1 0.2 
1068 0.65 1-hexyl-3-methylcyclohexane 0.2 0.5 0.1 0.4 1.8 1.5 0.9 1.9 0.2 2.2 0.8 0.9 1.3 1.7 0.2 1.7 1.1 2.2 1.3 2.5 0.5 0.3 2.4 1.3 1.5 1.0 0.3 0.3 
1080 0.60 1-butyl-2-propylcyclopentane 0.3 0.5 0.1 0.4 2.1 1.8 2.3 0.6 1.9 1.0 2.9 1.5 2.1 0.6 0.2 1.8 1.1 0.4 2.6 3.2 0.6 1.8 2.5 1.0 2.2 1.1 0.3 0.4 
  
 
                            
  
Alkenes                             
252 0.60 3-octene 0.1 0.1 0.0 0.2 0.3 0.3 0.1 0.0 0.4 0.0 1.0 1.4 0.5 0.1 0.0 0.1 0.3 0.2 0.2 0.1 0.0 0.0 0.2 0.1 0.4 0.1 0.1 0.2 
330 0.61 2,4-dimethyl-1-heptene 0.3 0.2 0.2 0.3 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.4 0.1 0.4 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.4 0.3 
450 0.61 1-nonene 0.2 0.2 0.2 0.1 0.4 0.4 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.1 0.2 0.1 0.6 0.2 0.9 0.2 0.2 0.3 
546 0.57 alkene isomer (m/z 55, 41, 69) 0.2 0.2 0.8 0.2 0.4 0.4 0.4 0.2 0.5 0.2 0.3 0.2 0.7 0.2 0.3 0.4 0.4 0.2 0.2 0.3 0.1 0.1 0.4 0.4 0.7 0.6 0.3 0.8 
552 0.57 3-methyl-1-nonene 0.4 0.3 2.0 0.5 0.5 0.7 0.4 0.5 0.7 0.5 1.2 0.9 0.6 0.3 0.3 0.6 1.1 0.3 0.5 0.4 0.2 0.3 0.5 0.6 1.0 1.0 0.2 0.8 
570 0.59  3,4-diethyl-2-hexene  0.1 0.1 0.4 0.1 0.5 0.4 0.7 0.3 0.6 0.4 0.6 0.5 0.6 0.6 0.5 0.8 0.5 0.6 0.4 0.6 0.1 0.2 0.7 0.6 0.5 0.7 0.1 0.1 
582 0.59 alkene isomer (m/z 69,41,56) 0.2 0.1 0.8 0.4 0.2 0.2 0.3 0.1 0.2 0.1 0.0 0.0 0.4 0.1 0.0 0.2 0.1 0.1 0.1 0.1 0.1 0.3 0.2 0.1 0.2 0.4 0.1 0.3 
606 0.59 alkene isomer (m/z 69,41,56) 0.5 0.6 1.7 0.6 0.5 0.5 0.4 0.3 0.3 0.3 0.3 0.2 0.4 0.1 0.4 0.4 0.5 0.1 0.4 0.2 0.2 0.2 0.5 0.3 0.7 0.6 0.5 0.3 
612 0.59 7-methyl-1-nonene 0.1 0.2 0.4 0.3 0.4 0.3 0.3 0.2 0.4 0.3 0.2 0.1 0.3 0.2 0.1 0.3 0.4 0.3 0.2 0.6 0.1 0.1 0.3 0.3 0.4 0.5 0.1 0.1 
648 0.59 4-decene 0.3 0.4 0.9 0.4 0.4 0.4 0.3 0.2 1.5 0.3 0.3 0.3 0.3 0.2 0.6 0.3 0.3 0.3 0.3 0.3 0.3 0.2 0.4 0.3 0.5 0.3 0.3 0.4 
762 0.55 alkene isomer (m/z 55, 69, 41) 0.1 0.0 0.2 0.2 1.5 1.4 0.8 2.0 1.5 2.2 0.6 0.9 1.8 1.0 3.7 2.4 0.8 0.9 1.0 0.9 0.2 1.2 1.1 2.5 1.5 2.9 0.2 0.2 
768 0.56 alkene isomer (m/z 55, 69, 41) 0.5 0.3 0.4 0.3 0.6 0.3 0.4 1.3 0.5 0.4 0.3 0.4 1.0 0.3 0.5 0.4 0.5 0.9 0.3 0.5 0.4 0.4 0.5 0.8 0.1 0.4 0.4 0.3 
780 0.56 (Z)-2-decene 0.4 0.3 0.4 0.2 0.8 0.8 0.8 0.5 2.8 1.0 0.7 1.0 0.8 0.5 0.3 0.6 0.7 0.6 0.5 0.6 0.4 0.5 0.8 0.7 2.3 0.9 0.4 0.4 
798 0.56 alkene isomer (m/z 55, 69, 41) 0.7 0.8 1.6 0.9 1.6 1.6 1.5 1.2 1.6 1.2 2.2 4.0 2.6 1.0 0.7 1.3 3.7 1.3 1.4 1.4 0.6 3.1 1.7 0.4 1.6 1.7 0.7 0.7 
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1tR a (s) 2tR a (s) Compounds 
                            
                            
                            
S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 S23 S24 S25 S26 S27 S28 
924 0.60 (Z)-5-methyl-5-undecene 0.2 0.3 0.2 0.4 0.2 0.2 0.8 0.8 0.8 0.6 0.7 0.5 0.9 0.7 0.2 0.7 0.8 0.8 0.7 0.8 0.4 0.8 0.2 0.7 1.0 0.9 0.2 0.2 
942 0.60 1-dodecene 0.3 0.5 0.4 0.9 2.0 1.7 1.1 1.4 1.3 0.9 1.3 1.3 2.3 2.2 0.8 0.7 1.3 1.6 0.9 2.6 1.2 3.4 2.4 1.6 1.7 0.8 1.1 1.1 
960 0.62 alkene isomer (m/z 55, 69, 41) 0.3 0.5 0.2 0.4 2.7 2.6 1.8 2.0 3.4 1.6 1.2 0.7 2.1 6.6 0.3 1.1 1.0 1.0 1.3 1.8 0.4 1.7 2.3 1.6 2.0 2.4 0.3 0.4 
978 0.59 alkene isomer (m/z 55, 69, 43) 0.2 0.4 0.1 0.2 0.5 0.4 0.7 0.8 1.2 0.9 5.3 1.5 0.4 1.2 0.1 1.0 1.1 1.5 3.2 1.5 0.3 1.1 0.5 2.3 0.5 1.0 0.2 0.2 
1062 0.61 1-tridecene 0.3 0.9 0.1 0.8 2.3 2.9 2.9 2.6 4.4 2.7 3.2 2.4 2.5 2.9 0.3 2.1 2.4 3.6 2.9 3.8 1.1 4.9 2.9 2.6 2.5 2.7 0.4 0.8 
                               
  Aldehydes                             
144 0.78 butanal 0.1 0.2 0.0 0.2 0.2 0.2 0.5 0.2 0.4 0.7 0.3 0.3 0.2 0.5 0.2 0.3 0.1 0.2 0.2 0.2 0.0 0.5 0.1 0.2 0.1 0.2 0.0 0.0 
252 1.17 hexanal 1.2 0.3 0.3 2.2 0.7 0.6 0.8 1.6 0.4 1.2 0.1 0.0 0.4 3.6 0.9 1.3 0.6 1.4 0.3 1.1 0.9 1.7 1.2 1.3 0.8 0.3 0.6 2.5 
474 1.22 heptanal 0.6 1.1 0.2 1.3 0.4 0.5 0.5 0.5 0.4 1.0 0.4 0.8 0.4 0.3 0.4 0.6 0.3 0.5 0.3 0.3 0.4 0.7 0.5 0.4 0.5 0.3 0.3 1.2 
576 0.92 2-ethylhexanal 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.2 
588 3.58 benzaldehyde  1.0 1.3 0.3 1.1 1.1 1.3 0.9 1.0 0.9 1.5 1.0 1.4 1.0 1.4 0.8 1.1 0.7 1.3 1.1 1.1 1.3 0.8 1.4 0.9 1.1 0.6 1.1 0.9 
666 1.06 octanal 1.6 2.4 0.4 2.1 1.0 1.0 1.5 1.5 0.8 1.7 1.1 1.4 0.8 2.0 0.9 1.9 0.6 1.5 0.8 0.8 0.7 1.6 1.1 1.0 1.0 0.7 0.6 1.5 
822 1.00 nonanal  12.5 7.8 1.7 8.7 2.3 2.6 3.7 6.5 2.7 5.5 4.9 6.3 2.0 8.7 3.4 5.9 1.8 4.8 1.6 3.3 2.8 4.8 2.7 3.9 2.4 1.7 2.2 5.3 
900 1.28 (E)-2-nonenal 0.2 0.5 0.1 0.5 0.1 0.1 0.2 0.3 0.1 0.2 0.2 0.3 0.1 0.7 0.2 0.2 0.1 0.3 0.1 0.2 0.0 0.4 0.2 0.2 0.2 0.1 0.1 0.2 
960 0.97 decanal 5.9 6.6 1.4 7.4 1.8 1.7 4.7 6.4 1.4 5.1 3.6 4.9 1.6 5.8 2.4 6.3 1.2 5.2 1.4 3.7 3.2 5.1 2.3 4.2 1.9 1.5 2.0 3.1 
1038 1.03 aldehyde isomer (m/z 41, 55, 71) 0.2 0.3 0.1 0.2 0.5 0.4 0.5 1.1 0.4 1.1 0.6 1.0 0.4 0.8 0.2 0.8 0.3 0.9 0.4 0.9 0.0 0.9 0.3 0.9 0.4 0.3 0.0 0.0 
1086 1.02 undecanal 0.2 0.2 0.0 0.3 0.1 0.1 0.3 0.5 0.1 0.3 0.3 0.4 0.1 0.3 0.1 0.5 0.0 0.3 0.0 0.3 0.3 2.2 0.1 0.3 0.1 0.3 0.1 0.1 
1200 1.09 dodecanal 0.2 0.3 0.1 0.5 0.1 0.1 0.4 0.5 0.1 0.5 0.6 0.5 0.1 0.3 0.2 0.5 0.1 0.6 0.1 0.5 0.3 0.3 0.1 0.4 0.1 0.1 0.2 0.2 
                               
  Ketones                             
138 0.79 2-butanone 2.7 1.8 0.1 0.4 0.4 0.6 0.1 0.1 0.2 0.4 0.5 0.5 0.3 0.2 0.2 0.2 0.1 0.3 0.2 0.2 0.2 0.3 0.1 0.3 0.4 0.2 0.2 0.4 
240 1.16 2-hexanone 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 1.0 0.0 0.1 0.0 0.0 0.1 
438 1.19 3-heptanone 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 1.4 0.1 0.2 0.1 0.8 0.1 0.1 0.1 0.2 0.1 0.6 0.1 0.2 0.0 0.2 0.1 0.1 0.1 0.3 
450 1.29 ketone isomer (m/z 43, 58, 71) 0.4 0.6 0.1 0.3 0.0 0.0 0.1 0.2 0.1 0.2 0.2 0.3 0.1 0.1 0.3 0.1 0.2 0.2 0.1 0.1 0.2 0.1 0.1 0.2 0.0 0.1 0.3 0.2 
642 1.10 3-octanone 0.0 0.1 0.0 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.7 0.1 0.1 0.1 0.1 0.0 0.0 0.0 
642 1.33 6-methyl-5-hepten-2-one  3.4 5.9 0.9 5.5 2.4 2.5 1.9 5.1 0.3 5.5 1.2 3.2 0.2 3.0 1.8 5.4 0.1 3.0 0.2 2.4 1.3 3.8 3.6 2.3 3.8 1.3 1.0 1.5 
804 1.03 2-nonanone 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.1 
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1tR a (s) 2tR a (s) Compounds 
                            
                            
S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 S23 S24 S25 S26 S27 S28 
  Miscellaneous                             
630 2.13 1-octen-3-ol 0.2 0.4 0.1 0.4 0.1 0.2 0.2 0.3 0.1 0.1 0.0 0.0 0.1 0.3 0.2 0.2 0.1 0.3 0.1 0.3 0.9 0.3 0.1 0.4 0.2 0.0 0.2 0.1 
720 1.78 2-ethyl-1-hexanol 0.4 0.5 1.5 0.5 5.2 5.1 0.3 7.4 0.3 5.6 4.0 6.8 0.4 1.0 0.4 5.3 5.3 0.4 4.9 0.3 0.4 0.4 4.4 0.3 4.8 3.6 0.4 0.3 
774 0.99 2-nonen-1-ol 0.1 0.2 0.0 0.2 0.1 0.1 0.2 0.2 0.1 0.2 1.9 2.0 0.1 0.2 0.2 0.3 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 
780 1.86 1-octanol 0.2 0.2 0.0 0.2 0.1 0.1 0.1 0.2 0.1 0.2 0.0 0.1 0.1 0.2 0.2 0.2 0.1 1.0 0.1 0.2 0.6 0.2 0.1 0.2 0.1 0.1 0.1 0.1 
912 0.97 2-decen-1-ol 0.3 0.3 0.1 0.3 0.3 0.1 0.4 0.5 0.3 0.5 0.5 0.6 0.3 0.4 0.1 0.6 0.3 0.5 0.2 0.1 0.2 0.5 0.4 0.1 0.1 0.3 0.1 0.2 
 
Table S1 continued 
1tR a (s) 2tR a (s) Compounds 
                           
                           
S29 S30 S31 S32 S33 S34 S35 S36 S37 S38 S39 S40 S41 S42 S43 S44 S45 S46 S47 S48 S49 S50 S51 S52 S53 S54 S55 
  Hydrocarbons                            
  Alkanes                            
138 0.48 hexane 0.8 2.1 0.5 0.7 0.8 0.5 0.5 0.5 0.5 0.2 0.3 0.8 0.8 0.6 0.9 1.9 1.1 1.0 0.4 0.7 0.6 0.8 0.9 1.0 0.6 0.6 0.7 
210 0.52 2,4-dimethylhexane 0.6 1.1 0.2 0.4 0.3 0.5 0.4 0.4 0.2 0.1 0.1 1.3 0.6 1.5 0.4 0.5 0.4 0.2 0.7 1.2 0.5 0.2 4.9 0.2 0.1 0.4 0.7 
252 0.54 octane 1.0 1.4 0.6 1.1 1.1 1.4 1.4 0.6 0.7 0.4 0.5 0.6 0.8 2.3 1.6 1.1 1.1 1.3 0.6 1.4 1.3 1.5 2.6 1.8 0.3 0.4 0.9 
276 0.55 2,2,4-trimethylhexane 0.2 0.3 0.1 0.1 0.8 0.3 0.2 0.1 0.1 0.0 0.1 3.5 2.4 3.9 3.3 0.7 1.4 1.9 3.1 1.4 1.9 1.7 4.1 3.3 0.1 1.8 1.7 
288 0.55 2,4-dimethylheptane  1.2 2.7 0.4 0.9 0.8 3.0 1.5 0.5 0.9 0.7 1.1 0.1 0.9 0.6 1.7 0.7 1.0 1.1 0.2 0.5 1.0 1.1 1.6 0.8 0.3 0.5 0.1 
318 0.56 4-ethyl-2-methylhexane 0.2 0.5 0.1 0.2 0.2 0.4 0.4 0.1 0.1 0.1 0.2 1.0 0.6 2.1 2.0 1.7 2.0 2.0 1.4 1.7 0.8 0.5 0.8 1.1 0.0 0.6 0.6 
366 0.58 alkane isomer (m/z 43, 57, 85) 0.5 0.9 0.3 0.5 0.3 1.1 1.1 0.0 0.0 0.0 0.0 0.7 0.4 0.7 0.6 1.3 1.2 1.3 0.9 0.4 0.3 0.4 0.0 1.2 0.2 0.4 0.4 
468 0.56 nonane  1.9 1.5 4.2 3.2 1.9 4.8 7.8 3.7 3.4 3.0 3.0 4.0 7.0 2.5 6.9 3.7 3.0 9.1 3.4 8.7 3.5 4.5 3.2 4.9 2.2 2.1 2.4 
504 0.55 alkane isomer (m/z 43, 57, 85) 0.2 0.2 0.3 0.3 0.1 0.6 0.8 0.3 0.1 0.1 0.1 2.0 0.5 0.6 0.5 1.3 1.6 1.0 1.2 0.5 0.3 0.7 0.5 2.0 0.1 0.5 2.8 
516 0.55 2,4-dimethyloctane  0.1 0.1 1.8 0.1 0.1 0.3 1.7 0.6 0.2 0.2 0.2 0.1 0.1 0.2 0.4 0.1 0.3 0.3 0.1 0.3 0.2 0.2 0.1 0.2 0.0 0.1 0.0 
528 0.56 3-ethyl-3-methylheptane  0.2 0.1 0.4 0.2 0.1 0.2 0.8 0.3 0.3 0.3 0.3 0.2 0.2 0.3 0.2 0.6 0.7 0.6 0.2 0.4 0.4 0.4 0.3 0.3 0.1 0.1 0.1 
540 0.55 2,6-dimethyloctane 0.6 0.3 1.0 0.9 0.4 1.5 2.0 0.3 0.5 0.5 3.1 0.9 0.8 0.7 0.7 1.3 1.3 0.6 0.9 0.6 0.5 1.6 1.0 1.1 0.6 0.8 0.7 
552 0.55 3-ethyl-2-methylheptane 0.5 0.2 0.8 0.6 0.2 1.1 1.6 0.7 1.3 0.7 2.1 0.4 0.4 0.3 0.4 0.3 0.3 0.3 0.2 0.1 0.5 0.5 0.4 0.3 0.1 0.2 0.3 
558 0.55 alkane isomer (m/z 57, 43, 71) 0.1 0.1 0.1 0.1 0.7 0.1 0.1 0.1 0.4 0.3 0.3 0.4 0.1 0.6 0.2 0.2 0.2 0.4 0.4 0.3 0.4 0.4 0.2 3.0 0.1 0.1 0.1 
564 0.55 alkane isomer (m/z 43, 57, 71) 0.3 0.1 0.6 0.4 0.2 0.6 1.1 0.1 0.1 0.1 0.1 0.2 0.3 0.2 0.2 0.3 0.2 0.3 0.3 0.2 0.3 0.5 0.3 0.4 0.1 0.3 0.1 
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1tR a (s) 2tR a (s) Compounds 
                           
                           
S29 S30 S31 S32 S33 S34 S35 S36 S37 S38 S39 S40 S41 S42 S43 S44 S45 S46 S47 S48 S49 S50 S51 S52 S53 S54 S55 
576 0.56 4-ethyloctane  0.2 0.1 0.3 0.2 0.1 0.3 0.4 0.2 0.0 0.0 0.0 0.3 0.2 0.2 0.2 0.3 0.4 0.3 0.3 0.2 0.2 0.3 0.2 0.4 0.1 0.3 0.3 
582 0.55 4-methylnonane  0.2 0.1 0.3 0.3 0.2 0.3 0.3 0.2 0.1 0.0 0.1 0.6 0.3 0.3 1.2 0.7 0.8 0.6 0.5 0.4 0.4 1.5 0.6 0.9 0.2 0.3 0.2 
588 0.54 alkane isomer (m/z 57, 43, 85) 0.4 0.2 1.2 0.2 0.1 0.8 1.8 1.1 0.5 0.4 0.4 0.4 0.1 0.7 0.1 0.5 0.3 0.5 0.5 0.7 0.1 0.4 0.4 0.4 0.1 0.1 0.1 
594 0.55 alkane isomer (m/z 57, 43, 71) 0.9 0.4 2.5 1.1 0.6 1.7 3.5 2.2 8.9 8.2 4.8 1.0 1.4 0.7 1.3 3.3 0.3 0.7 0.9 0.6 1.1 1.2 0.8 1.1 0.4 0.4 0.5 
600 0.55 2-methylnonane 0.6 0.3 1.1 0.8 0.4 1.0 1.5 0.9 1.1 0.9 0.9 0.9 2.4 0.7 0.6 2.9 1.0 1.5 0.9 0.6 0.6 1.0 0.6 0.9 0.4 1.5 0.5 
606 0.55 alkane isomer (m/z 57, 43, 41) 0.5 0.2 2.3 0.5 0.3 0.9 2.2 2.2 3.7 4.1 3.5 0.2 0.2 0.2 0.2 1.2 0.4 0.3 0.3 0.2 0.4 0.6 0.4 0.0 0.1 0.2 0.5 
612 0.55 3-methylnonane 0.5 0.2 0.2 0.7 0.3 0.8 0.8 0.6 0.7 2.4 0.6 1.1 0.9 0.6 0.7 1.2 1.3 1.0 0.9 0.7 0.5 0.9 0.8 0.8 0.4 0.5 0.7 
636 0.54 2,2,4,6,6-pentamethylheptane 6.6 3.0 4.6 19.3 9.4 3.8 7.4 3.4 4.5 3.6 3.9 2.6 3.7 3.9 3.0 2.9 3.9 2.8 0.9 2.8 3.8 1.3 2.3 1.4 0.2 0.6 2.7 
660 0.56 decane 4.6 3.3 6.8 7.2 3.9 5.0 8.6 6.9 5.5 3.6 5.4 3.4 5.2 3.3 3.2 7.6 6.1 6.9 4.0 3.4 4.1 4.5 3.4 4.4 3.5 2.9 3.4 
672 0.54 alkane isomer (m/z 57, 41, 71) 0.5 0.1 1.4 0.3 1.7 0.2 0.4 6.9 5.5 3.6 5.4 0.1 0.2 0.1 0.1 0.2 0.4 0.2 0.4 1.7 1.7 1.5 0.7 0.1 0.1 0.1 0.3 
720 0.54 3,9-dimethylnonane  0.5 0.1 1.3 1.2 0.3 0.5 0.7 1.2 0.6 0.5 0.5 7.0 6.5 6.3 9.7 0.5 0.7 1.1 0.5 0.1 0.1 0.1 0.1 0.1 0.7 7.9 0.1 
756 0.54 2-methyldecane 9.0 7.9 2.8 3.2 5.5 11.7 4.0 5.1 8.6 8.4 10.3 1.6 1.6 1.8 2.2 3.1 2.7 2.4 2.1 2.1 3.4 4.1 4.2 2.2 4.4 5.4 1.7 
768 0.54 alkane isomer (m/z 57, 43, 85) 0.5 0.4 3.0 0.9 0.6 0.6 0.7 5.1 5.4 5.4 6.3 1.5 0.4 0.5 0.5 1.1 1.3 1.5 0.6 0.3 1.0 0.5 0.3 0.4 0.3 0.9 0.4 
774 0.55 3-methyldecane 0.9 0.5 3.0 1.8 0.8 1.1 2.5 1.9 1.5 1.4 1.3 0.7 0.8 0.7 0.8 0.5 0.5 0.4 0.4 0.4 0.7 0.5 0.4 0.3 0.3 0.5 0.6 
786 0.55 alkane isomer (m/z 57, 43, 71)  0.9 0.2 1.4 1.0 1.0 0.9 1.0 0.5 0.5 0.4 0.6 0.2 0.2 0.2 0.3 0.2 0.2 0.2 0.1 0.2 0.1 0.2 0.2 0.1 0.1 0.1 0.2 
798 0.55 alkane isomer (m/z 57, 43, 71)  0.9 0.4 0.7 1.1 0.6 1.0 1.1 0.6 0.9 0.6 0.5 1.0 0.2 0.2 0.2 1.1 0.2 0.1 0.8 0.2 0.2 0.2 0.3 0.4 0.3 0.1 0.2 
804 0.55 alkane isomer (m/z 43, 71, 57) 0.8 0.4 0.5 1.0 0.4 0.9 0.9 0.5 0.4 0.5 0.4 0.1 0.1 0.2 0.5 0.4 0.2 0.2 0.1 0.1 0.2 0.2 0.2 0.1 0.2 0.1 0.1 
822 0.55 undecane 13.8 20.9 5.9 7.6 3.4 19.0 6.2 1.9 2.6 7.7 4.0 3.0 2.6 3.5 4.5 5.7 5.2 5.4 3.7 6.1 4.7 3.7 4.4 5.4 7.6 6.5 4.4 
864 0.56 2,3-dimethyldecane 0.4 0.3 0.7 0.7 0.4 0.4 0.4 1.0 0.4 0.4 0.0 0.2 0.6 0.2 0.0 0.4 0.2 0.1 1.6 0.2 0.2 0.2 0.2 0.3 0.6 0.4 0.4 
876 0.56 alkane isomer (m/z 57, 43, 71) 0.3 0.4 0.3 0.4 0.4 0.2 0.2 0.8 0.4 0.2 0.4 1.6 1.3 1.3 1.3 1.7 1.6 1.3 2.2 1.4 1.5 1.4 1.3 1.6 1.3 1.2 1.5 
894 0.55 5-methylundecane 0.7 0.5 0.7 1.1 0.0 0.7 0.6 1.2 1.3 1.0 1.4 1.0 0.8 0.4 0.4 0.4 0.4 0.9 0.7 0.5 0.4 0.2 0.7 0.3 0.5 0.6 0.7 
906 0.57 alkane isomer (m/z 57, 43, 71) 0.7 0.5 0.9 0.8 0.8 0.7 0.7 0.8 0.6 0.5 0.6 0.7 5.0 0.6 1.3 0.0 0.7 1.5 0.4 0.9 1.7 0.6 1.6 0.4 0.4 0.5 1.2 
912 0.57 3,9-dimethylundecane 0.5 0.3 0.7 0.6 0.5 0.6 0.5 0.6 0.5 0.5 0.5 0.5 0.6 0.7 0.5 0.7 0.8 0.7 1.0 0.8 0.6 0.8 0.4 0.9 0.8 1.0 0.9 
948 0.57 dodecane 10.6 9.2 3.7 6.3 6.6 8.7 7.7 3.2 5.2 3.6 7.6 2.4 2.6 2.5 2.5 2.7 3.0 2.7 2.9 2.3 2.8 2.5 2.4 2.8 2.9 2.8 3.1 
960 0.58 alkane isomer (m/z 57, 71, 43)  0.2 9.2 0.1 0.4 0.3 0.2 0.2 0.1 0.2 0.1 0.2 0.2 0.6 0.2 0.2 1.1 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.2 0.1 0.3 2.6 
966 0.57 alkane isomer (m/z 57, 43, 71) 0.4 0.3 0.4 0.4 0.5 0.4 0.3 0.3 0.3 0.3 0.3 2.2 1.9 1.5 1.5 2.4 0.9 1.1 1.2 1.6 2.2 1.9 2.0 2.4 1.8 2.1 2.6 
972 0.56 2,5,6-trimethyldecane 0.5 0.3 0.6 0.7 0.8 0.6 0.4 0.5 0.5 0.4 0.5 0.2 0.2 0.1 0.2 0.2 0.2 0.2 0.3 2.1 5.9 5.7 4.5 1.9 0.2 0.2 0.7 
978 0.57 alkane isomer (m/z 57, 43, 71) 0.3 0.1 0.2 0.1 0.4 0.2 0.2 0.6 0.2 0.5 0.2 1.0 0.4 0.7 0.7 0.4 2.9 0.4 3.3 0.4 0.4 0.7 0.3 0.7 0.0 0.7 0.2 
996 0.56 alkane isomer (m/z 57, 43, 71) 0.2 0.2 0.1 0.2 0.3 0.1 0.2 0.1 0.3 0.1 0.3 0.5 0.7 0.6 0.6 0.5 0.7 0.5 0.8 0.5 0.9 0.5 0.3 0.2 0.8 0.4 0.5 
1002 0.57 alkane isomer (m/z 57, 43, 71) 0.2 0.1 0.1 0.2 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.6 0.5 0.6 0.5 0.6 0.9 0.9 1.5 1.0 0.7 0.9 0.5 1.0 1.1 0.5 1.2 
1008 0.57 6-methyldodecane 0.2 0.2 0.2 0.2 0.4 0.2 0.0 0.1 0.2 0.1 0.2 2.6 0.7 2.6 0.5 1.5 2.4 1.5 2.2 1.4 0.6 1.8 1.4 1.5 1.6 1.5 1.9 
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1tR a (s) 2tR a (s) Compounds 
                           
                           
S29 S30 S31 S32 S33 S34 S35 S36 S37 S38 S39 S40 S41 S42 S43 S44 S45 S46 S47 S48 S49 S50 S51 S52 S53 S54 S55 
1056 0.57 alkane isomer (m/z 57, 43, 71) 0.2 0.1 0.1 0.2 0.5 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.9 0.8 0.8 0.3 0.6 0.5 0.4 0.4 0.6 0.5 0.4 0.3 0.8 0.6 0.3 
1062 0.55 alkane isomer (m/z 57, 71, 43) 1.0 0.8 0.4 0.6 1.1 1.0 0.8 0.4 1.0 1.2 0.7 0.3 0.2 0.3 0.4 0.5 0.3 0.5 0.4 0.5 0.5 0.4 0.3 0.4 0.6 0.6 0.3 
1068 0.56 alkane isomer (m/z 43, 57, 71) 0.9 0.6 0.3 0.7 1.4 0.9 0.7 0.3 1.0 0.5 0.4 0.4 0.5 0.4 0.3 0.8 0.4 0.5 0.1 0.5 0.4 0.5 0.8 0.4 0.5 0.8 0.3 
1074 0.57 tridecane 2.5 1.5 1.7 1.3 2.5 2.1 2.1 1.5 1.3 1.3 2.2 2.0 1.4 2.5 1.6 1.4 3.5 3.0 2.0 1.5 2.9 1.4 2.8 2.7 1.5 1.2 1.5 
1092 0.57 2,2-dimethyldodecane 0.3 0.3 0.8 0.3 1.0 0.3 0.3 0.9 0.8 0.3 0.3 0.4 0.3 0.8 0.5 0.5 0.6 0.5 1.1 0.4 0.4 0.4 0.4 0.4 0.9 0.8 0.5 
1104 0.57 alkane isomer (m/z 57, 43, 71) 4.9 5.0 1.4 3.6 5.0 4.3 3.4 1.8 3.8 6.4 6.0 1.9 2.3 1.6 1.7 7.3 4.0 4.6 2.8 3.9 2.4 2.9 3.7 4.0 5.3 4.7 4.7 
1110 0.57 alkane isomer (m/z 57, 43, 71) 0.4 0.5 0.2 0.4 0.9 0.3 0.3 0.2 0.2 0.2 0.3 0.4 0.4 0.5 0.4 0.5 0.4 0.4 0.4 0.5 0.4 0.4 0.4 0.3 0.4 0.4 0.2 
1116 0.57 alkane isomer (m/z 57, 71, 43) 3.6 2.2 1.1 3.6 4.9 3.3 1.8 0.9 1.8 2.0 1.4 1.8 3.4 1.9 1.0 2.1 2.0 2.3 1.4 2.0 1.8 1.6 1.2 2.2 4.9 5.6 2.4 
1128 0.57 3-ethyl-3-methylundecane 1.2 1.4 0.6 0.0 0.0 1.1 0.0 0.5 0.6 0.7 0.7 2.6 1.0 4.7 4.8 2.2 1.3 2.7 1.8 3.2 2.8 1.1 0.7 2.6 1.8 2.6 2.0 
1152 0.60 2-methyltridecane 0.5 0.3 0.5 0.6 0.0 0.4 0.4 0.5 0.4 0.3 0.3 0.8 0.7 1.0 0.9 1.4 2.3 1.5 1.6 0.8 0.9 0.9 0.6 0.8 1.2 1.1 1.1 
1158 0.59 alkane isomer (m/z 57, 43, 71)  0.5 0.3 0.6 0.8 0.6 0.4 0.7 0.5 0.4 0.4 0.3 1.1 0.6 0.7 0.7 1.0 1.1 1.1 0.8 1.0 1.2 0.6 1.0 0.6 1.2 0.8 0.8 
1170 0.61 alkane isomer (m/z 57, 43, 71) 0.2 0.2 0.3 0.2 0.5 0.2 0.2 0.2 0.2 0.2 0.1 0.8 0.5 1.8 0.6 0.6 1.2 0.5 0.8 0.3 0.5 0.2 1.4 1.0 1.0 0.3 1.0 
1188 0.61 tetradecane 3.5 3.2 3.0 2.6 4.3 2.2 3.2 2.6 2.3 1.6 1.9 3.9 1.8 2.5 2.6 2.2 3.4 3.1 2.4 1.9 3.1 2.6 3.4 2.6 3.3 3.8 5.5 
1284 0.58 alkane isomer (m/z 57, 43, 85) 0.4 0.3 0.3 0.3 0.3 0.4 0.4 0.3 0.3 0.2 0.2 0.3 0.3 0.3 0.2 0.3 0.3 0.3 0.5 0.3 0.3 0.3 0.3 0.3 0.6 0.4 0.5 
1290 0.58 6,6-diethyldodecane 1.7 1.8 1.2 1.8 1.6 1.8 1.5 1.1 1.3 1.3 1.1 1.2 1.6 0.9 1.1 1.2 1.1 1.2 0.6 1.2 1.5 1.2 1.1 1.8 2.4 0.4 1.6 
1296 0.64 pentadecane 0.7 0.6 1.0 0.9 1.0 0.6 0.7 0.9 0.7 0.4 0.5 0.2 0.4 0.3 1.0 0.3 0.3 0.3 0.5 1.1 1.1 0.3 0.6 0.4 2.9 1.9 0.5 
1302 0.59 5-ethyl-5-methyltridecane 0.4 2.5 0.3 0.2 0.5 0.2 0.2 0.3 0.2 0.1 0.2 0.9 0.9 0.7 0.7 0.5 0.2 0.3 0.4 0.7 0.7 0.3 0.3 0.8 0.3 1.7 0.6 
1338 0.61 3-ethyl-3-methyltridecane  2.6 2.3 2.0 2.5 2.0 3.0 2.4 1.9 1.5 1.5 1.7 1.2 0.3 1.5 0.5 0.3 0.4 0.4 0.5 0.9 0.9 1.1 1.0 0.5 0.8 0.8 1.8 
                              
  Cyclic                            
240 0.57 1,2,4-trimethylcyclopentane 0.5 0.5 0.4 0.3 0.4 0.2 0.2 0.2 0.1 0.0 0.0 0.2 0.2 0.5 0.6 0.4 0.5 0.4 0.7 0.3 0.3 0.5 0.5 0.3 0.1 0.2 0.1 
534 0.60 propylcyclohexane 0.1 0.3 0.3 0.2 0.3 0.2 0.4 0.1 0.3 0.3 0.2 1.6 1.2 0.7 1.7 1.9 2.7 1.7 1.3 1.0 1.0 2.2 1.6 2.5 0.5 0.8 0.7 
576 0.59 1,1,2,3-tetramethylcyclohexane 0.3 0.1 0.5 0.5 0.3 0.4 0.3 0.2 0.1 0.1 0.1 1.1 0.7 0.7 0.3 0.2 0.4 0.6 1.3 0.7 0.8 0.5 0.5 1.9 0.2 0.4 0.6 
618 0.60 2-ethyl-1,3-dimethylcyclohexane 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.4 0.1 0.3 0.4 0.3 0.3 0.3 0.5 0.7 0.4 0.5 0.3 0.3 0.5 0.3 0.5 0.1 0.2 0.2 
624 0.59 1-methyl-3-propylcyclohexane 0.4 0.2 0.3 0.7 0.3 0.6 1.2 1.0 0.7 0.8 0.6 0.5 0.4 0.4 0.4 0.5 0.8 0.6 0.6 0.4 0.5 1.6 0.5 0.5 0.3 0.2 0.2 
630 0.58 1-methyl-3-(2-methylpropyl)cyclopentane 0.6 0.5 1.1 1.0 0.7 0.5 1.3 1.4 1.1 1.2 0.9 1.7 0.7 0.9 0.6 0.7 1.0 0.8 0.8 0.5 1.1 2.6 0.5 0.7 0.4 0.6 0.4 
642 0.59 ethylpropylcyclopentane 0.1 0.1 0.4 0.2 0.1 0.2 0.4 0.3 0.2 0.3 0.2 0.3 0.4 0.2 0.4 0.2 0.6 0.8 0.5 0.2 0.2 0.5 0.2 0.3 0.1 0.1 0.1 
654 0.59 1-methyl-2-propylcyclohexane 0.4 0.2 0.6 0.6 0.4 0.4 0.7 0.3 0.2 0.3 0.2 0.4 0.4 0.3 0.3 0.3 0.5 0.4 0.4 0.3 0.3 0.8 0.3 0.3 1.4 0.3 0.2 
732 0.57 hexylcyclopentane 0.4 0.2 0.6 0.5 0.4 0.3 0.5 1.0 0.8 0.4 0.6 1.3 2.5 2.4 1.2 1.1 0.6 0.4 0.9 0.6 0.7 1.0 1.8 0.6 0.4 0.4 0.5 
792 0.57 1,4-dimethylcycloctane 0.6 0.5 2.9 1.3 0.6 0.5 0.9 3.5 2.2 2.6 0.8 1.6 2.4 2.9 3.0 0.7 0.7 0.7 1.0 1.4 0.9 0.6 0.7 0.9 0.7 0.7 0.8 
804 0.59 1-ethyl-2-propycylohexane 0.2 0.4 0.9 0.8 0.7 0.3 0.2 0.9 0.7 0.2 0.3 1.1 2.4 1.3 1.2 1.4 1.0 0.7 0.9 1.4 1.2 0.9 0.5 2.3 2.2 1.6 1.4 
996 0.62 hexylcyclohexane 0.2 0.1 0.2 0.2 0.3 0.2 0.1 0.2 0.1 0.1 0.1 0.6 0.6 0.7 0.7 0.4 0.5 0.3 0.7 0.6 0.6 0.3 0.2 0.9 0.4 0.3 0.8 
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1tR a (s) 2tR a (s) Compounds 
                           
                           
S29 S30 S31 S32 S33 S34 S35 S36 S37 S38 S39 S40 S41 S42 S43 S44 S45 S46 S47 S48 S49 S50 S51 S52 S53 S54 S55 
1068 0.65 1-hexyl-3-methylcyclohexane 0.4 0.2 0.3 0.2 1.3 0.3 0.2 0.3 0.2 0.2 0.2 1.3 1.2 1.3 1.3 1.0 1.8 1.2 1.8 1.2 1.1 1.2 0.9 1.1 0.2 0.3 1.8 
1080 0.60 1-butyl-2-propylcyclopentane 0.4 0.2 0.3 0.2 0.5 0.3 0.2 0.2 0.2 0.2 0.3 1.7 1.2 2.5 1.5 1.3 1.6 1.5 3.1 1.7 1.3 2.1 1.5 1.4 1.6 0.5 0.5 
  
 
                           
  
Alkenes                            
252 0.60 3-octene 0.2 0.4 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.0 0.2 0.5 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 
330 0.61 2,4-dimethyl-1-heptene 0.3 0.5 0.3 0.3 0.3 0.4 0.2 0.2 0.2 0.1 0.2 0.2 0.2 1.1 0.7 0.3 0.1 0.2 0.1 0.1 0.2 0.1 0.2 0.2 0.2 0.1 0.2 
450 0.61 1-nonene 0.2 0.2 0.2 0.1 0.3 0.2 0.1 0.2 0.2 0.1 0.2 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.5 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 
546 0.57 alkene isomer (m/z 55, 41, 69) 0.1 0.1 0.4 0.3 0.1 0.4 0.8 0.4 0.2 0.1 0.5 0.4 0.3 0.3 0.3 0.5 0.7 0.8 0.5 0.0 0.3 0.7 0.4 0.6 0.1 0.2 0.2 
552 0.57 3-methyl-1-nonene 0.3 0.1 0.5 0.4 0.3 0.1 0.8 0.4 1.3 0.5 0.6 1.5 0.7 0.7 0.7 0.8 0.7 0.6 0.6 0.5 0.7 1.1 0.9 0.3 0.2 0.3 0.3 
570 0.59  3,4-diethyl-2-hexene  0.1 0.1 0.1 0.2 0.1 0.2 0.2 0.1 0.5 1.6 0.6 0.7 0.4 0.4 0.4 0.3 0.4 0.4 0.8 0.4 0.3 0.4 0.4 0.9 0.1 0.4 0.6 
582 0.59 alkene isomer (m/z 69,41,56) 1.4 0.1 0.2 0.3 0.2 0.2 0.3 0.3 0.0 0.2 0.2 0.3 0.1 0.1 0.2 0.2 0.4 0.2 0.3 0.2 0.2 0.4 0.3 0.3 1.2 0.1 0.1 
606 0.59 alkene isomer (m/z 69,41,56) 0.4 0.1 0.4 0.7 0.4 0.4 0.7 0.6 0.5 0.4 0.4 0.5 0.5 1.4 0.4 0.1 0.1 0.1 0.7 0.4 0.5 1.1 0.8 0.7 0.1 0.1 0.1 
612 0.59 7-methyl-1-nonene 0.2 0.2 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.4 0.3 0.3 0.3 0.4 0.7 0.5 0.5 0.3 0.2 0.4 0.3 0.5 0.2 0.2 0.3 
648 0.59 4-decene 0.4 0.4 0.4 0.4 0.4 0.3 0.3 0.4 0.3 0.3 0.6 0.4 0.7 0.3 0.4 0.5 0.7 0.8 0.5 0.3 0.3 0.5 0.2 0.5 0.2 0.3 0.2 
762 0.55 alkene isomer (m/z 55, 69, 41) 0.0 0.0 0.2 0.3 0.1 0.2 0.2 2.9 3.2 3.0 4.0 0.9 1.1 1.1 0.9 1.4 1.8 1.8 1.3 1.1 1.6 2.4 1.6 1.3 1.5 1.5 0.9 
768 0.56 alkene isomer (m/z 55, 69, 41) 0.5 0.2 0.3 0.5 0.0 0.6 0.6 0.2 0.2 0.1 0.6 0.5 0.4 0.4 0.4 0.4 0.4 0.4 0.6 0.2 0.3 0.5 0.3 0.1 0.3 0.5 0.4 
780 0.56 (Z)-2-decene 0.5 0.2 0.6 0.5 0.3 0.4 0.4 0.8 1.4 0.4 0.4 2.4 1.0 0.6 0.8 0.7 0.6 0.6 1.0 0.6 1.0 0.6 0.6 2.6 0.4 0.5 0.6 
798 0.56 alkene isomer (m/z 55, 69, 41) 1.0 0.3 2.9 1.6 0.6 0.7 0.8 1.2 0.8 0.8 0.8 1.6 2.4 2.9 3.0 1.3 1.5 1.2 2.2 1.3 1.3 1.4 1.8 1.6 4.7 0.9 3.2 
810 0.55 alkene isomer (m/z 69, 55, 41) 0.7 0.3 0.8 0.6 0.3 0.6 0.4 0.7 0.5 0.6 0.5 0.8 0.6 0.8 0.7 0.8 0.7 0.8 1.2 1.6 3.0 2.3 1.9 0.8 0.6 0.7 0.7 
828 0.57 alkene isomer (m/z 55, 69, 41) 0.6 0.2 0.6 1.0 0.4 0.4 0.4 2.4 0.9 0.6 0.3 3.6 2.9 2.9 0.2 1.1 2.9 1.9 2.0 3.2 1.3 1.4 1.4 1.2 1.9 1.9 3.8 
870 0.59 2-methyl-1-undecene 0.2 0.2 0.5 0.7 0.3 0.4 0.3 0.2 2.3 0.6 1.5 1.4 1.2 1.4 1.7 2.3 1.3 1.2 1.9 1.1 2.2 1.2 1.7 1.3 1.3 1.3 1.3 
918 0.60 (E)-5-methyl-4-undecene 0.5 0.3 0.5 0.2 0.2 0.1 0.1 0.2 0.2 0.1 0.2 0.9 0.7 0.8 0.8 0.8 0.7 0.6 1.1 0.6 0.7 0.8 0.6 0.8 0.7 0.6 0.4 
924 0.60 (Z)-5-methyl-5-undecene 0.3 0.1 0.5 0.3 0.2 0.2 0.2 0.4 0.2 0.2 0.2 0.9 0.8 0.7 0.7 0.8 0.7 0.7 1.1 0.8 0.8 0.9 0.7 0.8 0.6 0.5 0.7 
942 0.60 1-dodecene 1.1 1.1 0.7 0.4 0.4 1.0 0.8 0.6 1.0 1.0 1.1 1.6 1.2 0.8 1.0 2.0 2.5 1.3 2.7 1.3 1.3 3.2 0.9 1.3 2.9 1.4 1.9 
960 0.62 alkene isomer (m/z 55, 69, 41) 0.4 0.4 0.3 0.4 0.4 0.4 0.3 0.3 0.3 0.2 0.3 1.6 0.7 1.5 1.4 2.3 3.0 2.9 2.3 4.7 1.9 1.6 2.0 1.9 1.8 0.3 2.3 
978 0.59 alkene isomer (m/z 55, 69, 43) 0.2 0.1 0.2 0.1 0.3 0.2 0.1 0.1 0.1 0.1 0.1 0.4 1.2 0.4 0.4 0.9 0.8 2.1 0.5 0.7 1.2 1.8 0.8 0.3 0.8 0.3 1.3 
1062 0.61 1-tridecene 0.4 0.4 0.3 0.3 0.7 0.7 0.3 0.5 0.6 0.5 0.8 2.8 2.5 3.1 2.8 2.4 3.9 3.3 3.2 3.1 2.6 2.1 2.4 2.0 4.3 3.5 2.6 
                              
  Aldehydes                            
144 0.78 butanal 0.2 0.3 0.1 0.1 0.3 0.0 0.0 0.1 0.3 0.1 0.3 0.2 0.2 0.8 0.5 0.9 0.2 0.2 0.1 0.4 0.2 0.2 0.4 0.2 0.3 0.3 0.2 
252 1.17 hexanal 1.3 1.8 5.6 1.2 1.6 0.6 1.0 5.1 1.0 3.3 1.0 0.6 0.7 0.4 0.5 0.7 0.4 0.6 0.8 0.8 0.7 0.5 0.4 0.5 1.5 1.8 2.1 
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1tR a (s) 2tR a (s) Compounds 
                           
                           
S29 S30 S31 S32 S33 S34 S35 S36 S37 S38 S39 S40 S41 S42 S43 S44 S45 S46 S47 S48 S49 S50 S51 S52 S53 S54 S55 
474 1.22 heptanal 0.6 0.8 2.1 1.1 1.0 0.4 0.5 1.8 0.5 1.3 0.5 0.3 0.4 0.3 0.4 0.3 0.3 0.4 0.4 0.5 0.4 0.3 0.4 0.4 0.7 0.5 0.4 
576 0.92 2-ethylhexanal 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 
588 3.58 benzaldehyde  1.3 1.8 1.1 1.4 1.5 1.0 0.8 0.9 0.8 0.7 0.9 1.1 1.1 1.0 1.2 1.1 0.9 1.1 1.1 1.0 0.9 0.7 0.9 0.8 1.1 1.2 1.1 
666 1.06 octanal 1.0 1.1 3.0 1.1 2.0 0.6 1.1 2.7 1.1 2.0 1.0 0.8 0.6 0.6 0.7 0.6 0.7 0.9 0.6 0.8 0.8 0.7 0.7 1.0 1.6 1.7 1.4 
822 1.00 nonanal  3.7 2.7 8.6 3.5 7.7 1.9 3.2 7.4 3.7 5.9 3.5 2.1 2.0 1.5 2.3 2.1 1.8 2.0 2.5 2.5 2.3 1.8 2.2 2.4 4.8 4.3 5.1 
900 1.28 (E)-2-nonenal 0.5 0.1 0.3 0.3 0.3 0.1 0.1 0.5 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.2 
960 0.97 decanal 3.2 3.4 5.3 3.8 7.4 1.8 3.1 4.6 2.9 3.4 2.5 1.7 1.6 1.1 2.3 1.7 1.5 1.8 2.0 2.4 1.9 1.8 1.9 2.9 5.9 5.0 4.9 
1038 1.03 aldehyde isomer (m/z 41, 55, 71) 0.2 0.1 0.1 0.2 0.3 0.0 0.2 0.1 0.2 0.1 0.1 0.3 0.3 0.4 0.4 0.3 0.3 0.5 0.4 0.3 0.3 0.3 0.5 0.7 1.0 1.1 0.7 
1086 1.02 undecanal 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.7 0.1 0.2 0.3 0.3 0.2 
1200 1.09 dodecanal 0.3 0.2 0.4 0.4 0.3 0.1 0.2 1.1 0.3 0.2 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.3 0.4 0.5 0.2 
                              
  Ketones                            
138 0.79 2-butanone 0.5 0.7 0.2 0.8 1.3 0.2 0.5 0.8 0.3 0.3 0.3 0.2 0.1 0.1 0.2 0.2 0.1 0.4 0.4 0.5 0.3 0.2 0.4 0.1 0.3 0.2 0.2 
240 1.16 2-hexanone 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
438 1.19 3-heptanone 0.1 0.1 0.4 0.0 0.0 0.1 0.2 0.3 0.1 0.3 0.1 0.3 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.2 0.0 2.3 
450 1.29 ketone isomer (m/z 43, 58, 71) 0.5 0.4 0.4 0.1 0.5 0.2 0.3 0.3 0.6 0.2 0.3 0.1 0.2 0.2 0.0 0.2 0.2 0.2 0.2 0.4 0.3 0.1 0.2 0.1 0.2 0.2 0.1 
450 2.07 ciclohexanone 1.6 1.1 0.1 0.0 0.3 0.2 0.1 1.3 0.9 1.0 0.9 0.7 0.3 0.2 0.2 0.4 0.3 0.2 0.5 1.1 1.3 0.7 1.2 0.7 0.2 0.2 0.4 
642 1.10 3-octanone 0.0 0.2 0.0 0.2 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 
642 1.33 6-methyl-5-hepten-2-one  2.3 2.9 2.4 2.7 7.1 1.0 2.1 2.1 1.8 2.0 2.8 0.2 0.2 0.2 0.2 0.2 0.1 0.2 2.7 1.5 1.8 1.5 2.3 2.0 5.2 5.5 3.0 
804 1.03 2-nonanone 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 
810 1.02 ketone isomer (m/z 43, 58, 71) 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 1.7 1.7 1.8 1.6 0.1 0.1 0.1 0.1 
                              
  Miscellaneous                            
630 2.13 1-octen-3-ol 0.2 1.1 0.1 0.2 0.6 0.2 0.2 0.1 0.3 0.1 0.2 0.3 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.2 0.2 0.2 0.2 0.3 0.4 0.2 
720 1.78 2-ethyl-1-hexanol 0.6 0.1 0.9 0.3 0.5 0.4 0.3 0.4 0.6 0.4 0.4 3.9 6.3 5.4 5.2 0.3 0.3 0.4 3.5 4.9 4.5 3.1 4.1 0.3 0.4 0.4 0.5 
774 0.99 2-nonen-1-ol 0.1 0.1 0.1 0.1 0.2 0.0 0.1 0.3 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.2 
780 1.86 1-octanol 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.2 0.2 
912 0.97 2-decen-1-ol 0.2 0.1 0.3 0.3 0.3 0.1 0.1 0.2 0.1 0.2 0.1 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.4 0.3 0.3 0.3 0.3 0.4 0.5 0.5 0.2 
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Table S1 continued 
1tR a (s) 2tR a (s) Compounds 
       
       
S56 S57 S58 S59 S60 S61 S62 
  Hydrocarbons        
  Alkanes        
138 0.48 hexane 0.7 0.7 1.2 0.4 0.3 0.4 0.6 
210 0.52 2,4-dimethylhexane 0.2 0.8 0.5 0.1 0.1 0.1 1.0 
252 0.54 octane 0.2 0.2 0.7 0.2 0.4 0.9 1.4 
276 0.55 2,2,4-trimethylhexane 2.4 2.7 1.1 0.7 0.2 1.2 2.7 
288 0.55 2,4-dimethylheptane  0.0 0.1 0.1 0.0 0.1 0.0 0.3 
318 0.56 4-ethyl-2-methylhexane 0.7 0.9 0.5 0.3 0.2 0.4 0.8 
366 0.58 alkane isomer (m/z 43, 57, 85) 1.8 1.6 2.3 1.7 1.3 1.5 0.8 
468 0.56 nonane  2.9 3.5 2.1 4.4 2.7 2.9 2.7 
504 0.55 alkane isomer (m/z 43, 57, 85) 3.6 4.2 0.5 0.8 0.6 1.1 0.9 
516 0.55 2,4-dimethyloctane  0.1 0.1 0.0 0.0 0.0 0.0 0.0 
528 0.56 3-ethyl-3-methylheptane  0.7 0.1 0.6 0.0 0.0 0.0 0.1 
540 0.55 2,6-dimethyloctane 0.6 0.7 0.5 0.4 0.5 0.5 0.5 
552 0.55 3-ethyl-2-methylheptane 0.2 0.4 0.2 0.2 0.2 0.2 0.3 
558 0.55 alkane isomer (m/z 57, 43, 71) 0.3 0.3 0.1 0.3 0.0 0.3 0.3 
564 0.55 alkane isomer (m/z 43, 57, 71) 0.1 0.1 0.1 0.0 0.1 0.0 0.1 
576 0.56 4-ethyloctane  0.3 0.4 0.1 0.2 0.2 0.2 0.2 
582 0.55 4-methylnonane  0.2 0.0 0.2 0.2 0.3 0.4 0.3 
588 0.54 alkane isomer (m/z 57, 43, 85) 0.2 0.1 0.2 0.0 0.0 0.0 0.1 
594 0.55 alkane isomer (m/z 57, 43, 71) 0.5 0.7 0.4 1.4 1.3 1.4 0.5 
600 0.55 2-methylnonane 0.5 0.6 0.4 0.4 0.4 0.5 0.5 
606 0.55 alkane isomer (m/z 57, 43, 41) 0.5 0.6 0.4 0.1 0.1 0.1 0.1 
612 0.55 3-methylnonane 1.7 0.7 2.0 0.4 0.4 0.5 0.5 
636 0.54 2,2,4,6,6-pentamethylheptane 5.6 1.1 0.6 1.0 0.6 2.1 1.0 
660 0.56 decane 2.7 5.1 4.6 4.5 5.1 4.1 4.7 
672 0.54 alkane isomer (m/z 57, 41, 71) 0.2 0.2 0.3 0.1 0.2 0.1 0.2 
720 0.54 3,9-dimethylnonane  0.0 0.1 0.1 0.3 0.2 0.2 0.4 
756 0.54 2-methyldecane 2.1 2.3 1.3 1.8 2.7 1.6 2.2 
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1tR a (s) 2tR a (s) Compounds 
       
       
S56 S57 S58 S59 S60 S61 S62 
768 0.54 alkane isomer (m/z 57, 43, 85) 0.4 0.8 0.4 0.4 0.5 0.5 0.4 
774 0.55 3-methyldecane 0.8 0.8 0.5 0.4 0.3 0.4 0.4 
786 0.55 alkane isomer (m/z 57, 43, 71)  0.2 0.2 0.1 0.1 0.1 0.1 0.1 
798 0.55 alkane isomer (m/z 57, 43, 71)  1.1 0.1 0.3 0.7 0.4 0.4 0.1 
804 0.55 alkane isomer (m/z 43, 71, 57) 0.2 0.1 0.1 0.2 0.1 0.1 0.1 
822 0.55 undecane 4.8 6.1 3.6 5.6 5.9 6.5 5.1 
864 0.56 2,3-dimethyldecane 0.1 0.2 0.2 0.1 0.1 0.4 0.1 
876 0.56 alkane isomer (m/z 57, 43, 71) 1.3 1.2 1.6 0.6 0.4 0.6 1.2 
894 0.55 5-methylundecane 0.3 0.4 0.7 0.3 0.5 0.4 0.2 
906 0.57 alkane isomer (m/z 57, 43, 71) 0.5 0.3 0.0 1.3 0.4 1.2 0.6 
912 0.57 3,9-dimethylundecane 0.6 0.5 0.7 0.1 0.1 0.2 1.0 
948 0.57 dodecane 3.1 2.7 3.7 2.8 3.4 3.4 2.9 
960 0.58 alkane isomer (m/z 57, 71, 43)  2.7 2.4 3.2 0.1 0.1 0.2 0.2 
966 0.57 alkane isomer (m/z 57, 43, 71) 2.1 2.1 3.2 2.2 2.5 1.0 2.4 
972 0.56 2,5,6-trimethyldecane 0.0 0.2 0.8 1.5 1.1 0.8 1.1 
978 0.57 alkane isomer (m/z 57, 43, 71) 0.0 0.0 1.6 1.2 1.2 1.4 1.3 
996 0.56 alkane isomer (m/z 57, 43, 71) 0.3 0.2 0.4 0.2 0.2 1.5 0.2 
1002 0.57 alkane isomer (m/z 57, 43, 71) 0.7 0.4 0.7 0.0 0.9 0.2 0.7 
1008 0.57 6-methyldodecane 1.6 1.6 2.4 1.9 2.1 0.9 1.9 
1020 0.57 alkane isomer (m/z 43, 57, 71) 0.2 0.3 0.5 0.4 0.1 0.2 0.3 
1044 0.55 alkane isomer (m/z 57, 43, 71) 0.5 0.6 0.6 1.7 2.1 2.3 1.9 
1050 0.55 4-ethylundecane  3.0 2.4 2.2 4.6 2.5 4.2 1.7 
1056 0.57 alkane isomer (m/z 57, 43, 71) 0.5 0.3 0.2 1.3 1.0 1.3 1.4 
1062 0.55 alkane isomer (m/z 57, 71, 43) 0.5 0.7 0.1 0.5 0.7 0.7 0.3 
1068 0.56 alkane isomer (m/z 43, 57, 71) 0.7 0.6 0.4 0.5 0.7 0.3 0.4 
1074 0.57 tridecane 1.4 1.2 1.8 1.2 1.1 1.5 1.1 
1092 0.57 2,2-dimethyldodecane 0.4 0.4 0.7 1.1 0.8 0.9 0.1 
1104 0.57 alkane isomer (m/z 57, 43, 71) 5.1 4.8 3.3 8.0 4.3 8.3 3.9 
1110 0.57 alkane isomer (m/z 57, 43, 71) 0.1 0.3 0.0 1.1 0.9 1.0 0.3 
1116 0.57 alkane isomer (m/z 57, 71, 43) 2.6 2.4 2.9 1.3 1.7 1.4 2.2 
1128 0.57 3-ethyl-3-methylundecane 1.7 1.5 2.6 1.1 1.2 1.3 1.4 
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1tR a (s) 2tR a (s) Compounds 
       
       
S56 S57 S58 S59 S60 S61 S62 
1152 0.60 2-methyltridecane 2.1 0.7 1.6 0.8 0.8 1.0 2.7 
1158 0.59 alkane isomer (m/z 57, 43, 71)  0.6 0.6 1.0 1.3 1.0 1.3 0.9 
1170 0.61 alkane isomer (m/z 57, 43, 71) 0.4 0.7 0.8 0.5 1.5 0.7 1.0 
1188 0.61 tetradecane 3.0 2.6 4.3 3.7 3.2 3.4 2.9 
1284 0.58 alkane isomer (m/z 57, 43, 85) 0.4 0.3 0.5 0.5 0.4 0.4 0.4 
1290 0.58 6,6-diethyldodecane 1.8 1.2 2.9 1.6 2.1 1.9 1.4 
1296 0.64 pentadecane 0.6 1.1 1.4 0.8 0.7 1.3 1.8 
1302 0.59 5-ethyl-5-methyltridecane 0.5 0.3 0.5 0.7 0.5 0.6 0.4 
1338 0.61 3-ethyl-3-methyltridecane  1.9 1.2 2.4 2.3 4.7 2.7 1.0 
          
  Cyclic        
240 0.57 1,2,4-trimethylcyclopentane 0.1 0.2 0.1 0.1 0.1 0.1 0.1 
534 0.60 propylcyclohexane 0.9 1.5 0.8 0.5 0.5 0.3 0.8 
576 0.59 1,1,2,3-tetramethylcyclohexane 0.7 0.7 0.4 0.7 0.6 0.7 0.7 
618 0.60 2-ethyl-1,3-dimethylcyclohexane 0.3 0.3 0.2 0.2 0.2 0.2 0.2 
624 0.59 1-methyl-3-propylcyclohexane 0.2 0.3 0.2 0.2 0.2 0.2 0.2 
630 0.58 1-methyl-3-(2-methylpropyl)cyclopentane 0.4 0.5 0.4 0.3 0.4 0.4 0.5 
642 0.59 ethylpropylcyclopentane 0.1 0.3 0.1 0.2 0.3 0.2 0.2 
654 0.59 1-methyl-2-propylcyclohexane 0.2 0.3 0.2 0.2 0.2 0.3 0.2 
732 0.57 hexylcyclopentane 0.4 0.4 0.4 0.1 0.3 0.0 0.1 
792 0.57 1,4-dimethylcycloctane 0.7 1.0 0.8 0.7 0.7 0.7 0.8 
804 0.59 1-ethyl-2-propycylohexane 1.5 1.8 1.6 0.9 0.8 0.8 0.4 
996 0.62 hexylcyclohexane 0.8 0.6 1.1 0.8 1.0 0.7 0.9 
1068 0.65 1-hexyl-3-methylcyclohexane 1.5 1.5 2.4 2.2 2.4 3.1 2.2 
1080 0.60 1-butyl-2-propylcyclopentane 0.4 0.3 0.3 0.8 0.5 0.2 0.5 
  
 
       
  
Alkenes        
252 0.60 3-octene 0.0 0.1 0.0 0.1 0.0 0.0 0.1 
330 0.61 2,4-dimethyl-1-heptene 0.6 0.0 0.0 0.0 0.3 0.1 0.1 
450 0.61 1-nonene 0.1 0.2 0.1 0.1 0.2 0.1 0.2 
546 0.57 alkene isomer (m/z 55, 41, 69) 0.4 0.3 0.2 0.2 0.2 0.2 0.2 
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1tR a (s) 2tR a (s) Compounds 
       
       
S56 S57 S58 S59 S60 S61 S62 
552 0.57 3-methyl-1-nonene 0.4 0.4 0.3 0.2 0.3 0.2 0.6 
570 0.59  3,4-diethyl-2-hexene  0.6 0.9 0.5 0.4 0.3 0.5 0.4 
582 0.59 alkene isomer (m/z 69,41,56) 0.1 0.2 0.4 0.1 0.1 0.1 0.1 
606 0.59 alkene isomer (m/z 69,41,56) 0.1 0.2 0.1 0.2 0.3 0.3 0.3 
612 0.59 7-methyl-1-nonene 0.2 0.4 0.1 0.2 0.3 0.3 0.3 
648 0.59 4-decene 0.2 0.3 0.2 0.2 0.3 0.4 0.3 
762 0.55 alkene isomer (m/z 55, 69, 41) 1.0 2.1 1.6 0.6 0.8 0.6 2.1 
768 0.56 alkene isomer (m/z 55, 69, 41) 0.4 0.8 0.9 0.6 0.6 0.7 0.4 
780 0.56 (Z)-2-decene 0.6 0.6 0.5 0.4 0.4 0.4 0.6 
798 0.56 alkene isomer (m/z 55, 69, 41) 1.2 3.6 1.7 0.8 2.8 1.1 1.3 
810 0.55 alkene isomer (m/z 69, 55, 41) 0.6 0.7 0.6 1.0 0.9 1.5 0.6 
828 0.57 alkene isomer (m/z 55, 69, 41) 0.9 1.4 1.2 1.0 1.0 1.0 1.2 
870 0.59 2-methyl-1-undecene 1.3 1.4 1.6 1.2 1.3 1.2 1.3 
918 0.60 (E)-5-methyl-4-undecene 0.5 0.9 0.9 0.8 0.9 1.0 0.9 
924 0.60 (Z)-5-methyl-5-undecene 0.6 0.7 0.8 0.5 0.6 0.6 0.6 
942 0.60 1-dodecene 1.8 1.8 2.8 1.2 1.2 1.7 0.7 
960 0.62 alkene isomer (m/z 55, 69, 41) 3.1 5.2 4.2 1.4 1.6 1.6 1.6 
978 0.59 alkene isomer (m/z 55, 69, 43) 1.0 1.0 0.5 0.9 0.8 1.1 0.2 
1062 0.61 1-tridecene 2.7 2.2 4.0 1.5 1.6 2.2 2.5 
          
  Aldehydes        
144 0.78 butanal 0.3 0.3 0.5 0.2 0.3 0.3 0.2 
252 1.17 hexanal 1.3 1.6 0.8 1.9 1.5 1.0 1.7 
474 1.22 heptanal 0.4 0.4 0.3 0.5 0.6 0.2 0.5 
576 0.92 2-ethylhexanal 0.0 0.0 0.0 0.1 0.1 0.1 0.1 
588 3.58 benzaldehyde  1.1 1.0 1.7 3.8 1.4 1.7 1.3 
666 1.06 octanal 1.6 0.5 0.5 1.6 1.6 1.9 1.9 
822 1.00 nonanal  4.9 5.2 4.9 5.9 6.5 4.7 6.4 
900 1.28 (E)-2-nonenal 0.1 0.2 0.2 0.3 0.3 0.3 0.3 
960 0.97 decanal 6.2 4.3 4.3 5.3 6.6 4.5 6.0 
1038 1.03 aldehyde isomer (m/z 41, 55, 71) 0.8 1.0 0.9 0.9 1.1 1.3 0.8 
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1tR a (s) 2tR a (s) Compounds 
       
       
S56 S57 S58 S59 S60 S61 S62 
1086 1.02 undecanal 0.3 0.2 0.2 0.5 0.6 0.4 0.5 
1200 1.09 dodecanal 0.3 0.3 0.3 0.7 0.7 0.6 0.7 
          
  Ketones        
138 0.79 2-butanone 0.3 0.0 0.3 0.4 0.2 0.2 0.2 
240 1.16 2-hexanone 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
438 1.19 3-heptanone 1.8 1.2 0.2 0.1 0.1 0.1 0.1 
450 1.29 ketone isomer (m/z 43, 58, 71) 0.2 0.1 0.2 0.2 0.1 0.1 0.2 
450 2.07 ciclohexanone 0.7 0.7 0.4 0.6 0.6 0.9 0.5 
642 1.10 3-octanone 0.2 0.1 0.1 0.1 0.1 0.1 0.1 
642 1.33 6-methyl-5-hepten-2-one  3.1 3.5 4.0 5.2 5.0 3.6 6.0 
804 1.03 2-nonanone 0.1 0.1 0.1 0.2 0.1 0.1 0.0 
810 1.02 ketone isomer (m/z 43, 58, 71) 0.1 0.1 0.1 0.0 0.0 0.0 0.1 
          
  Miscellaneous        
630 2.13 1-octen-3-ol 0.6 0.2 0.2 0.6 0.3 0.2 0.2 
720 1.78 2-ethyl-1-hexanol 0.5 0.5 0.4 4.9 5.9 4.4 6.3 
774 0.99 2-nonen-1-ol 0.2 0.2 0.1 0.2 0.3 0.2 0.3 
780 1.86 1-octanol 0.1 0.1 0.3 0.1 0.1 0.1 0.2 
912 0.97 2-decen-1-ol 0.2 0.5 0.4 0.2 0.2 0.2 0.5 
 
